

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

The role of patient preferences in clinical practice guidelines: a mixed method study using guidelines from oncology as a case

	I
Journal:	BMJ Open
Manuscript ID	bmjopen-2019-032483
Article Type:	Research
Date Submitted by the Author: 21-Jun-2019	
Complete List of Authors:	Gärtner , Fania; Leiden University Medical Center Portielje, Johanneke; Leiden University Medical Center, Clinical Oncology Langendam, Miranda; Academic Medical Center, Clinical Epidemiology, Biostatistics and Bioinformatics Hairwassers, Desiree; Breast Cancer Association the Netherlands Agoritsas, Thomas; University Hospitals of Geneva, Division of General Internal Medicine & Division of Clinical Epidemiology; McMaster University Faculty of Health Sciences, Department of Health Research Methods, Evidence, and Impact Gijsen, Brigitte; Netherlands Comprehensive Cancer Organisation Liefers, Gerrit-Jan; Leids Universitair Medisch Centrum, Surgery; Leids Universitair Medisch Centrum, Pieterse, A.H. ; Leids Universitair Medisch Centrum, Medical Decision Making Stiggelbout, Anne; Leiden University Medical Center
Keywords:	Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, shared decision making, evidence-based medicine, GRADE, patient preferences, choice awareness
	·

SCHOLARONE[™] Manuscripts

1		
2 3	1	The value of water to configure and in alterial superior still because without
4	1	The role of patient preferences in clinical practice guidelines: a mixed
5 6	2	method study using guidelines from oncology as a case
7	3	
8	4	FR Gärtner (1) (<u>https://orcid.org/0000-0002-0351-0204</u>), JEA Portielje (2) (<u>https://orcid.org/0000-</u>
9 10	5	<u>0002-5169-6306</u>), M Langendam (3) (<u>https://orcid.org/0000-0001-9038-3209</u>), D Hairwassers (4), T
11	6	Agoritsas (5,6) (<u>https://orcid.org/0000-0002-6182-9969</u>), BCM Gijsen (7) (<u>https://orcid.org/0000-</u>
12	7	0003-4578-0293), GJ Liefers (8) (<u>https://orcid.org/0000-0001-7326-8313</u>), AH Pieterse (1)
13 14	8	(<u>https://orcid.org/0000-0001-6395-0052</u>), AM Stiggelbout (1) (<u>https://orcid.org/0000-0002-6293-</u>
15	9	<u>4509)</u>
16	10	
17	11	1. Medical Decision Making, Department of Biomedical Data Sciences, Leiden University
18 19	12	Medical Center, Leiden, The Netherlands,
20	13	2. Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands
21	14	3. Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam UMC,
22 23	15 16	Amsterdam, The Netherlands
24		4. Breast Cancer Association The Netherlands (Borstkankervereniging Nederland), The
25	17 18	Netherlands
26 27	18 19	 Division General Internal Medicine, University Hospitals of Geneva, Geneva, Switzerland Department of Health Research Methods, Evidence, and Impact, McMaster University,
28	20	 Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, L8S 4K1, Canada
29	20 21	 The Netherlands Comprehensive Cancer Organisation (IKNL), Maastricht/Utrecht, The
30 31	21	Netherlands
32	22	8. Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands
33	23 24	8. Department of Surgery, Leiden Oniversity Medical Center, Leiden, The Nethenands
34 35	24 25	Word count: 4665
36	26	
37	20	Keywords: EBM, Clinical Practice Guidelines, Shared Decision Making, patient preferences, patient-
38 39	28	centred care, choice awareness
40	29	
41	30	
42 43	31	Corresponding author:
43 44	32	Corresponding author: AM Stiggelbout, A.M.Stiggelbout@lumc.nl
45		
46 47		
47		
49		
50 51		
52		
53		
54		
55 56		
57		
58 59		
59 60		

ABSTRACT (300 words) Objectives: Many treatment decisions are preference-sensitive, and call for shared decision-making, notably when benefits are limited or uncertain, and harms impact quality of life. We explored to what extent clinical practice guidelines (CPGs) acknowledge preference-sensitive decisions in how they motivate and phrase their recommendations. Design: Mixed-methods study, using CPG content analysis, verified in semi-structured interviews with CPG panel members. Setting: Dutch oncology CPGs issued in 2010 or later, concerning primary treatment with curative intent. Participants: 14 CPG panel members. Main outcomes: For treatment recommendations from six CPG modules, two researchers extracted: strength of recommendation in terms of GRADE and its consistency with the CPG text; completeness of presentation of benefits and harms; incorporation of patient preferences; statements on the the CPG panel's benefits-harm tradeoff underlying recommendation; advice on patient involvement in decision-making. Results: We identified 32 recommendations of which 18 were acknowledged preference-sensitive decisions. Three of 14 strong recommendations should have been weak based on the module text. The report of benefits and harms, and their probabilities, was sufficiently complete and clear to inform the strength of the recommendation in one of the six modules only. Absolute, numerical probabilities were seldom presented. None of the modules presented information on patient preferences. CPG panel's preferences were not made explicit, but appeared to have impacted 15 of 32 recommendations. Advice to involve patients and their preferences in decision-making was given for 20 recommendations (14 weak). Interviewees confirmed these findings. Explanations for lack of information were e.g. that clinicians know the information and that CPGs need to be short. Explanations for trade-offs made were cultural-historical preferences, compliance with daily care, the presumed role of CPGs, and lack of time. Conclusions: The motivation and phrasing of CPG recommendations do not stimulate choice awareness and a neutral presentation of options, thus hindering shared decision making.

1		
2		
3 4	1	SUMMARY BOX
5 6 7	2	Strengths and limitations of this study
7 8	3	• Strength of the study is that the content analysis of the guidelines uses GRADE, in which
9	4	preference sensitive decisions have a parallel in weak recommendations
10	5	• Strength of this study is the validation of the content analysis of the guidelines in in-depth
11 12	6	interviews with the guideline developers.
13	7	• Limitation of the study is that only oncology guidelines from one country were studied.
14	8	
15 16	U	
16 17	9	FUNDING
18		
19	10	This work was supported by the Dutch Cancer Society grant number UL 2015-7615. The funding
20	11	agreement ensured the authors' independence in designing the study, interpreting the data, writing,
21 22	12	and publishing the report.
23	12	
24	13	COMPETING INTERESTS
25	14	TA and ML are active members of the GRADE working group. BG is employed at The Netherlands
26 27	15	Comprehensive Cancer Organisation (IKNL), the organization responsible for development of the
28	16	CPGs that were analyzed. e data, writing, and publishing the report.
29		
30 31	17	DATA SHARING
31		
33	18	Anonymized transcripts of the interviews may be shared upon request to the corresponding author.
34		
35 36	19	
37	20	
38	20	
39		
40 41		
42		
43		
44		
45 46		
47		
48		
49		
50 51		
52		
53		
54		
55 56		
50 57		
58		
59		
60		

1. INTRODUCTION

Many decisions in healthcare are preference-sensitive, in particular when treatments are burdensome, benefits are limited or uncertain, and harms may impact quality of life.(1) Examples are decisions about adjuvant treatment in oncology (2-4) or about hip or knee arthroplasty for osteoarthritis. (5-7) Research shows that patients as well as clinicians often vary considerably in their evaluation of the balance of benefits and harms. Further, clinicians are not always able to predict their individual patients' preferences.(8, 9) Shared decision making (SDM) is therefore advocated particularly in preference-sensitive decisions, but is not yet common practice.(10, 11) Clinicians are not prone to fostering choice awareness in their patients, (12, 13) often present treatment options in unbalanced ways, e.g., by overestimating benefits and minimizing harms, (14) or steer in other ways, consciously or unconsciously.(15) Further, numerical probabilities needed to make a trade-off are seldom discussed, (16) and patient preferences infrequently elicited. (17, 18) This raises the question if clinicians perceive these decisions as preference-sensitive? Clinical practice guidelines (CPGs) could play a role in this perception, given the impact they have on what treatment options clinicians present to their patients. While CPGs may use wording that suggests that a decision is preference-sensitive, such as "we suggest" or "clinicians might", rather than "we recommend" or "clinicians should", clinicians may still not fully appreciate the importance of offering more than one option to their patients. It is unknown if recommendations in current CPGs identify preference-sensitive decisions and

demand a role for patient preferences in decision making. Two older studies showed that the relevance of preferences of individual patients was not acknowledged in many CPGs.(19, 20) CPG developers often assume "generally accepted" values in developing recommendations, but do not acknowledge this in the phrasing of the recommendation.(21) A request for a more systematic incorporation of patient preferences in CPGs has been expressed repeatedly in high impact journals since the publications of these studies. (22-25) The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) working group -whose approach is nowadays considered the standard in CPG development- has published a framework that acknowledges the integration of patients' values and preferences in the development of CPG recommendations.(26-31) In the GRADE approach, preference-sensitive decisions are reflected in so-called "weak", or "conditional" recommendations. These arise when benefits and harms are closely balanced, evidence is lacking or of uncertain quality, when patients' preferences are expected to vary substantially, but also when no evidence on patient preferences is available, even with moderate or strong evidence of high quality on the benefits of an option. (28) In such situations, GRADE still leads to weak recommendations, assuming that most informed patients would choose the recommended treatment, but a substantial number would not. (28, 29, 31) (see Box 1 for a summary of the role that GRADE proposes for patient values and preferences in CPG development)

Therefore, a key ingredient for the identification of preference-sensitive decisions is the acknowledgment of values and preferences in the rationale for CPG recommendations. The aim of our study was therefore to explore to what extent CPGs acknowledge preference-sensitive decisions in the way they support and phrase their recommendations. We further wished to assess if the CPGs facilitate the communication of the preference-sensitive nature of these decisions to patients.

1		
2		
3 4	1	>>> Insert Box 1 about here <<<
5	2	
6	3	2. METHODS
7 8	4	Using a mixed-methods approach, we first performed a content analysis of Dutch oncologic CPGs,
9	5	which we next verified and refined in semi-structured interviews with members of CPG development
10	6	panels. We assessed if the CPG acknowledges preference-sensitive decisions, and whether the user
11 12	7	is able to understand the strength of a recommendation, based on the information presented. We
13	8	evaluated five themes: 1) the strength of recommendations, and if this was supported by
14	9 10	information in the CPG, 2) if the balance of benefits and harms was made explicit, and informed by
15 16	10 11	the probabilities of these, 3) if evidence on patient preferences (or variation therein) had been
17	11	searched for and presented, 4) if there was a statement on the preferences that underlie the CPG
18	12	panel's weighing of the benefits and harms to derive a recommendation, and 5) if the CPG
19 20	13	recommends if and how patient preferences should be incorporated in decision making for the individual patient.
20 21	14	Individual patient.
22	15	We used Dutch oncologic CPGs as a case, because oncology is strongly guideline-driven, decisions
23	10	are often preference-sensitive, the guideline development process is organized nationally, and the
24 25	18	CPGs are open access. The Netherlands Comprehensive Cancer Organisation (IKNL) develops
26	19	guidelines "under responsibility of the most relevant professional or scientific society, usually
27	20	following evidence-based methodology" (www.oncoline.nl).
28 29	20	Tonowing evidence bused methodology (www.oncome.in/).
30	22	2.1 Content analysis of CPGs
31	23	2.1.1 Selected CPG modules
32 33	24	We selected three tumour-specific CPGs, and of each we selected two modules to include in our
34	25	analysis. (i.e., the sections of the CPGs that address specific treatments or patient groups). We
35	26	selected modules that we expected to contain at least one preference-sensitive decision, requiring a
36 37	27	weak recommendation. This expectation was based on views from the oncology experts on our
38	28	research team, or on the availability of literature on SDM and decision aids for the treatment in that
39	29	module. Each of the modules includes more than one recommendation.
40 41	30	Further criteria for selection of the CPGs and the modules were: published on www.oncoline.nl,
42	31	issued in 2010 or later, and concerning primary treatment with curative intent. Table 1 presents the
43	32	CPGs and modules we selected. For the breast cancer CPG, our contact person at the IKNL provided
44 45	33	us confidentially with the most recent revision of the two selected modules, which were not yet
46	34	published at the time of our analysis.
47	35	
48 49	36	2.1.2 Data extraction and analysis
50	37	We developed a coding scheme that consisted of five sections covering the themes described above.
51	38	
52 53	39	Ad 1. Strength of recommendations: First, we scored the strength of the recommendation for each
53 54	40	treatment option from the Recommendation section, based on the phrasing used (strongly in
55	41	favour/ weakly in favour/ neutral / weakly against/ strongly against a specific option). The
56 57	42	categories strong and weak are in line with GRADE. We added the 'neutral' category if a weak
57 58	43	recommendation for more than one option was given.
59	44	
60		

2		
3	1	Next, we assessed whether this strength of recommendation was supported by information
4	2	elsewhere in the guideline, including information about the certainty of the evidence, the balance
5 6	3	between benefits and harms and their probabilities, the variability or uncertainty in how patients
7	4	value the benefits and harms. If other criteria were provided, we coded these as well. We extracted
8	5	• •
9		all information that indicated a discrepancy with the strength of recommendation, and scored
10	6	whether or not textual discrepancies were identified (<i>yes/no</i>). We based this on the CPG text, and
11 12	7	did not resort to the supporting literature.
12	8	
14	9	Ad 2. Balance of benefits and harms (trade-offs): we defined a trade-off as a statement presenting
15	10	the balance of benefits and harms in the treatment decision, ideally based on the probability of
16	11	benefits and harms, the quality of the evidence, and on how much patients value the outcomes. We
17	12	extracted statements about the trade-offs made in the CPG or about the trade-offs to be made in
18 19	13	the clinical encounter with the individual patient (trade-offs made explicit/trade-offs not made
20	14	explicit). We also judged whether the presentation of outcomes was sufficiently complete and clear
21	15	to inform the trade-off (<i>sufficient/insufficient</i>).
22	16	
23	17	Ad 2. Detions professores: We accord if patient professores had been incorporated (vec(na)) and if
24 25		<u>Ad 3. Patient preferences:</u> We assessed if patient preferences had been incorporated (<i>yes/no</i>), and if
26	18	so, how (<i>literature search/data collection by CPG panel/other</i>). Also, we extracted whether explicit
27	19	assumptions were made regarding patient preferences (<i>yes/no</i>).
28	20	
29	21	Ad 4. CPG panel's values and preferences: We extracted information about the preferences that
30 21	22	supported the CPG panel's weighing of benefits and harms, and summarized per treatment
31 32	23	recommendation if these preferences were explicitly mentioned (yes/no). This theme does not
33	24	directly originate from the GRADE recommendations. We added it as we encountered statements
34	25	suggesting that CPG panel's values and preferences had influenced the development of
35	26	recommendations.
36 37	27	
38	28	Ad 5. Advice on how to involve the patient: We extracted statements that described how to involve
39	20 29	an individual patient or his/her preferences in the decision making process, and summarized per
40		recommendation if such statement was given (<i>yes, actively involving the patient or patient</i>
41	30	
42 43	31	preferences in the decision making/yes, informing the patient/no advice about patient involvement).
44	32	
45	33	Two coders (FG and AS) independently applied a first draft of the coding scheme to a CPG module
46	34	that would not be included in the final selection. They subsequently discussed the coding process
47	35	and any inconsistencies, and updated the coding scheme. They had not been involved in the
48 40	36	development of any CPG in oncology nor GRADE, and had no existing working relationship with the
49 50	37	members of the respective CPG panels. The coders independently applied the coding scheme to one
51	38	of the selected modules, and resolved any discrepancies by consensus. Based on this discussion no
52	39	further changes were made to the scheme. One researcher (FG) then coded the remaining modules,
53	40	and the second checked the extraction and scoring. They discussed any inconsistency between them
54 57	41	until agreement was reached. Data extracted was analysed descriptively.
55 56	42	and an abient was reached. But extracted was undrysed descriptively.
57	42 43	
58	J.	
59		
60		

Page 7 of 27

1

2		
3	1	2.2 Semi-structured interviews with CPG developers
4 5	2	2.2.1 Recruitment
6	3	We or our IKNL contact person invited the panel members involved in the development of the
7	4	selected modules for participation. Membership and size of the different CPG panels varied, not all
8	5	were multidisciplinary, and not all included a patient representative. We aimed to interview at least
9	6	one member of each specialty involved in the development of a module, the patient representative,
10 11	7	and the IKNL supervisor of the CPG. As patient representatives did not participate in this study based
12	8	on a paid position, the respective patient organizations received an incentive of 100 Euros. The study
13		
14	9	protocol did not require review from a medical ethics committee as no patients or lay people were
15	10	recruited.
16 17	11	
18	12	2.2.2 Data collection
19	13	In semi-structured interviews, we first checked whether the interviewee agreed with our
20	14	interpretation of the strength of recommendations, our extraction of the discrepancies found in the
21	15	CPG text, of the trade-offs, and the completeness and clarity of the presentation of the benefits and
22 23	16	harms, of the role of patient preferences, and of the preferences of the CPG panels that supported
24	17	the recommendations. For the benefits, harms, and trade-offs we asked them how the developers
25	18	selected which ones to present, and whether the presentation of benefits and harms aimed to
26	19	facilitate communication in the clinical encounter. Finally, we discussed the function of statements
27 28	20	concerning the involvement of patients and their preferences in decision making for the individual
29	21	patient.
30	22	We adapted the questions to the specific content of the module to be discussed. For each
31	23	subsequent interview we added or adapted questions based on earlier interviews. Interviews lasted
32 33	24	30 to 60 minutes, were audiotaped, and transcribed verbatim.
34	25	so to oo minutes, were dudiotaped, and transensed versatim.
35	23 26	2.2.3 Coding and analysis
36	20 27	
37 38		We adhered to the Framework Approach to code and analyse the interviews. (32, 33) The coding
30 39	28 20	scheme was based on the five themes of the CPG analysis described above. First, two researchers
40	29	(FG and AS) independently familiarized themselves with the data, and coded three interviews
41	30	deductively, to supplement our coding scheme with any additional emerging themes. Dissimilarities
42	31	in coding were discussed and codes were adapted based on consensus. Second, one researcher
43 44	32	applied deductive coding to all other interviews and refined, and reduced the codes in a process of
45	33	re-reading and constant comparison of codes. Third, categories of codes were clustered to generate
46	34	(sub)themes. Steps two and three were performed by one researcher and checked by the second.
47	35	Inconsistencies in interpretation of the data and formulation of codes and themes were discussed
48 49	36	until consensus was reached. Coding was performed using Atlas.ti software.(34)
49 50	37	
51	38	2.3 Patient involvement
52	39	The CPG committee involved patient representatives for two modules, and we interviewed these
53	40	patients. One patient (DH) took part in the writing of the manuscript. The article will be shared with
54 55	41	the Netherlands Federation of Cancer Patient Societies NFK.
56	42	
57	43	3. RESULTS
58	44	We present the results of the content analysis and the interviews together, structured around the
59 60	45	five themes mentioned above. We interviewed 14 CPG panel members: 10 clinicians, two patient
00	15	The atoms mentioned above. We interviewed 14 of 6 parter members, 10 clinicians, two patient

representatives, and two IKNL supervisors (Table 1). For one module (adjuvant endocrine therapy in
 breast cancer), none of the clinician panel members was willing to participate, therefore only the
 IKNL supervisor and the patient panel member were interviewed. Patients were not part of the CPG
 panel for the NSCLC modules. To illustrate our analyses we add examples of the extractions of the

5 CPG modules in Box 2-5.

3.1 Strength of CPG recommendations

8 In the six modules we identified 32 recommendations, of which 14 were phrased as strong and 18 as 9 weak or neutral. The proportion of weak or neutral recommendations was just over half for all 10 modules, except for that on adjuvant chemotherapy for colorectal carcinoma, which had fewer weak 11 recommendations (33%). For five of the recommendations, both strong (three) and weak (one) or 12 neutral (one), we found discrepancies between the strength of recommendation and extracted 13 sentences from the module text. Box 2 shows examples of such discrepancies. In two of the strong 14 recommendations, the discrepancy concerned evidence that was limited or of (very) low quality.

16 >>> Insert Box 2 about here <<<

The CPG panel members confirmed our interpretation of the strength of recommendations. They explained that the three strong recommendations in the case of limited evidence were based on a valuation of the outcomes by the CPG panel (see further under 3.4). One explanation for the discrepancies between the strength of recommendation and the extracted were the differences in the handling of low quality evidence between methodologists and clinicians. One clinician described methodologists as being more careful in drawing conclusions, while clinicians incorporate current standards of practice in the formulation of recommendations.

Panel member: I think that it is inherent to making recommendations, where clinicians and methodologists clash. I am currently preparing the revision of the guideline, and what one sees is that we simply clash immediately with the methodologists in the preparation of the revision. Those are very dogmatic in their methodologic thinking. And the problem is, that that does not work, particularly not for the medical literature, so to say. And that is why the GRADE methodology explicitly discusses that in their approach, that one can upgrade the recommendation if one agrees as professional group that something should or should not be done. (Interview 10, about T1 carcinoma in polyp)

3.2 Information supporting the balance of benefits and harms

Three of the modules (T1 carcinoma in polyp and adjuvant chemotherapy in colorectal cancer, stereotactic radiotherapy in NSCLC) included explicit trade-off statements (see Box 3). Probabilities of outcomes were mentioned in one of these, but for the benefits only. One trade-off statement substantiating a strong recommendation included the presentation of a value judgment, but it was unclear whose values it presented "it is agreed upon that it is safe ...," and "the risk of radiation pneumonitis seems acceptable". For one of the six modules, adjuvant chemotherapy for colorectal cancer, we rated the report of benefits and harms and their probabilities as sufficiently complete and clear to inform the strength of recommendation. In three modules information was lacking about benefits, in four about harms,

46 and harms were often only presented generically (e.g., "complications", "psychological impact").

1 Relative rather than absolute risk reduction was often presented, verbal labels rather than numbers 2 were used to convey risk, e.g., "The chance of eventually preserving the breast is higher if radiation 3 of the breast already takes place after the first excision". 4 >>>> Insert Box 3 about here << 6 Some interviewees found that transparency about the trade-offs in the CPG text could be improved, 7 Some interviewees found that transparency about the trade-offs in the CPG text could be improved, 8 while others found an explicit mention, including details about benefits and harms and their 9 probabilities, unnecessary. Reasons for the latter were time constraints, the aim to keep the CPG 10 short, the assumption that CPG-suers know the balance of benefits and harms, or that the weighting 11 of benefits and harms was acceptable to everyone. One interviewee, e.g., stated that not 12 recommending endocrine treatment in DCIS was "common knowledge" and that "we also could 13 howe chosen to just leave out the whole paragraph about this adjuvant theray, to just not mention it 14 at al." (interview 15) 15 The interviewees indicated that in none of the modules patients had been involved in the selection 16 The interviewees indicated that in none of the modules, evidence for long-term harms is	1 ว		
 were used to convey risk, e.g., "The chance of eventually preserving the breast is higher if radiation of the breast already takes place after the first excision". >>> Insert Box 3 about here << Some interviewees found that transparency about the trade-offs in the CPG text could be improved, while others found an explicit mention, including details about benefits and harms and their probabilities, unnecessary. Reasons for the latter were time constraints, the aim to keep the CPG of benefits and harms was acceptable to everyone. One interviewee, e.g., stated that not recommending endocrine treatment in DCIS was "common knowledge" and that "we also could have chosen to just leave out the whole paragraph about this adjuvant therapy. to just not mention it at all." (Interview 15) The interviewees indicated that in none of the modules patients had been involved in the selection of the outcomes described. Some acknowledged that outcomes and their probabilities an eccessary, using the following arguments: guidelines should be short, harms are assumed to be common knowledge for clinicians or might be presented in other modules, evidence for long-term harms is lacking, and probabilities from the literature are not applicable to the Dutch setting or would only be representative at the hospital level, not at that of the individual clinician (i.e., for mortality due to a surgery). Several interviewees were especially reticent to present probabilities in terms of absolute trick reduction, as those percentages would soon be dated, differed between patient groups, or would be too time-consuming to calculate. One stated to have argued to include Numbers Needed to Treat in the CPG, to no avail. Panel-member: the CPG is mostly written to, what we provide as recommendation towards the patient for the outcome of treatment. J don't know if the CPG is written at least, how ence there evertee to a sub it on the row of one stensive. And then the CPG, let's say, what's it called, all rists	2 3	1	Relative rather than absolute risk reduction was often presented, verbal labels rather than numbers
a of the breast already takes place after the first excision". b >>> Insert Box 3 about here <<			
 >>> Insert Box 3 about here << Some interviewees found that transparency about the trade-offs in the CPG text could be improved, while others found an explicit mention, including details about benefits and harms and their probabilities, unnecessary. Reasons for the latter were time constraints, the aim to keep the CPG short, the assumption that CPG-users know the balance of benefits and harms, or that the weighting of benefits and harms was acceptable to everyone. One interviewee, e.g., stated that not recommending endocrine treatment in DCIS was "common knowledge" and that' we also could have chosen to just leave out the whole paragraph about this adjuvant therapy, to just nor mention it at al." (Interview 15) The interviewees indicated that in none of the modules patients had been involved in the selection of the outcomes described. Some acknowledged that outcomes might be missing, but a substantial number did not regard a complete presentation of outcomes and their probabilities as necessary, using the following arguments: guidelines should be short, harms are assumed to be common knowledge for clinicians or might be presented in other modules, evidence for long-term harms is lacking, and probabilities from the literature are not applicable to the Dutch setting or would only be representative at the hospital level, not at that of the individual clinican (i.e., for mortality due to surgery). Several interviewees were especially retricent to present probabilities in terms of absolute treat in the CPG to no avail. Interviewer: and for what regord is the other side of the coin not mentioned in the CPG? you would be too time-consuming to calculate. One stated to have argued to include Numbers Needed to Treat in the CPG is mostly written to, what			
 >>> Insert Box 3 about here << Some interviewees found that transparency about the trade-offs in the CPG text could be improved, while others found an explicit mention, including details about benefits and harms and their probabilities, unnecessary. Reasons for the latter were time constraints, the aim to keep the CPG short, the assumption that CPG-users know the balance of benefits and harms, or that the weighting of benefits and harms was acceptable to everyone. One interviewee, e.g., stated that not recommending endocrine treatment in DCIS was "common knowledge" and that "we also could have chosen to just leave out the whole paragraph about this adjuvant therapy, to just not mention it at all." (Interview 15) The interviewees indicated that in none of the modules patients had been involved in the selection of the outcomes described. Some acknowledged that outcomes might be missing, but a substantial number did not regard a complete presented in other modules, evidence for long-term harms is lacking, and probabilities from the literature are not applicable to the Dutch setting or would only be representative at the hospital level, not at that of the individual clinican (i.e., for mortality due to surgery). Several interviewees were especially reticent to present probabilities in terms of absolute tacking, and probabilities for a vali. Panel-member: the CPG is mostly written to, what we provide as recommandation to Treat in the CPG, is no avail. Panel-member: the CPG is mostly written to, what we provide as recommandation to avait the hospital head and the individual clinican (in the CPG, let's say, what's it called, all reterture are sume. But that is also the baseline knowledge that every pacologist should have. (Interview 7, about adjuvant			
9 6 91 6 91 7 91 7 91 7 91 7 91 7 91 9 91 9 91 9 91 9 91 9 91 9 91 9 91 9 91 9 92 9 93 9 94 9 95 9 96 9 97 9 98 9 91 9 91 9 92 9 92 9 93 9 94 9 95 9 95 9 95 9 95 9 95 9 95 9 95 9 95 9 95			>>> Insert Box 2 about here <<<
7 Some interviewees found that transparency about the trade-offs in the CPG text could be improved, 8 while others found an explicit mention, including details about benefits and harms and their 9 probabilities, unnecessary. Reasons for the latter were time constraints, the aim to keep the CPG 9 short, the assumption that CPG-users know the balance of benefits and harms, or that the weighting 11 of benefits and harms was acceptable to everyone. One interviewee, e.g., stated that not 12 recommending endocrine treatment in DCIS was "common knowledge" and that" we also could 13 have chosen to just leave out the whole paragraph about this adjuvant therapy, to just aot mention it 14 at al." (Interview 15) 15 The interviewees indicated that in none of the modules patients had been involved in the selection 16 of the outcomes described. Some acknowledged that outcomes might be missine, but a substantial 18 number did not regard a complete presentation of outcomes and their probabilities as necessary, 19 using the following arguments: guidelines should be short, harms are assumed to be common 18 knowledge for clinicians or might be presented in other modules, evidence for long-term harms is 19 lacking, and probabilities from the literature are not applicable to the Dutch setting or would only be 20 re			
12 8 while others found an explicit mention, including details about benefits and harms and their 13 9 probabilities, unnecessary. Reasons for the latter were time constraints, the aim to keep the CPG 15 0 short, the assumption that CPG-users know the balance of benefits and harms, or that the weighting 16 0 benefits and harms was acceptable to everyone. One interviewee, e.g., stated that not 16 recommending endocrine treatment in DCIS was "common knowledge" and that "we also could 17 not echosen to just leave out the whole paragraph about this adjuvant therapy, to just out mention it 18 at all." (Interview 15) 19 The interviewees indicated that in none of the modules patients had been involved in the selection 10 of the outcomes described. Some acknowledged that outcomes and their probabilities as necessary, 118 number did not regard a complete presentation of outcomes and their probabilities as necessary, 118 number did not regard a complete presentation of outcomes and their probabilities as necessary, 118 number did not regard a complete presentation of outcomes and their probabilities as necessary, 119 using the following arguments: guidelines should be short, harms are assumed to be common 110 knowledge for clinicians or might be presented in other modules, evidence for long-t			Some intenviewees found that transportancy about the trade offs in the CPC toyt could be improved
 a probabilities, unnecessary. Reasons for the latter were time constraints, the aim to keep the CPG a short, the assumption that CPG-users know the balance of benefits and harms, or that the weighting of benefits and harms was acceptable to everyone. One interviewee, e.g., stated that not recommending endocrine treatment in DCIS was "common knowledge" and that "we also could have chosen to just leave out the whole paragraph about this adjuvant therapy, to just not mention it at all." (Interview 15) The interviewees indicated that in none of the modules patients had been involved in the selection of the outcomes described. Some acknowledged that outcomes might be missing, but a substantial number did not regard a complete presentation of outcomes and their probabilities as necessary, using the following arguments: guidelines should be short, harms are assumed to be common knowledge for clinicians or might be presented in other modules, evidence for long-term harms is lacking, and probabilities from the literature are not applicable to the Dutch setting or would only be representative at the hospital level, not at that of the individual clinician (i.e., for mortality due to surgery). Several interviewees were especially reticent to present probabilities in terms of absolute risk reduction, as those percentages would soon be dated, differed between patient groups, or would be too time-consuming to calculate. One stated to have argued to include Numbers Needed to Treat in the CPG, is mostly written to, what we provide as recommendation towards the patient, for the outcome of treatment. I don't know if one should put in the CPG, you indicated, oteray, that actually Panel-member: the CPG is mostly written to, what we provide as recommendation t			
 short, the assumption that CPG-users know the balance of benefits and harms, or that the weighting of benefits and harms was acceptable to everyone. One interviewee, e.g., stated that not recommending endocrine treatment in DCIS was "common knowledge" and that "we also could have chosen to just leve out the whole paragraph about this adjuvant therapy, to just not mention it at all." (Interview 15) The interviewees indicated that in none of the modules patients had been involved in the selection of the outcomes described. Some acknowledged that outcomes might be missing, but a substantial number did not regard a complete presentation of outcomes and their probabilities as necessary, using the following arguments: guidelines should be short, harms are assumed to be common knowledge for clinicians or might be presented in other modules, evidence for long-term harms is lacking, and probabilities from the literature are not applicable to the Dutch setting or would only be representative at the hospital level, not at that of the individual clinician (i.e., for mortality due to surgery). Several interviewees were especially reticent to present probabilities in terms of absolute risk reduction, as those percentages would soon be dated, differed between patient groups, or would be too time-consuming to calculate. One stated to have argued to include Numbers Needed to Treat in the CPG, to no avail. Interviewee: and for what reason is the other side of the coin not mentioned in the CPG? You indicated, already, that actually Panel-memer: the CPG is mostly written to, what we provide as recommendation towards the patient, for the outcome of treatment. If don't know if the CPG is written at least, have envire interpreted it as such, but I don't know if one should			
11 of benefits and harms was acceptable to everyone. One interviewee, e.g., stated that not 12 recommending endocrine treatment in DCIS was "common knowledge" and that "we also could 13 hove chosen to just leave out the whole paragraph about this adjuvant therapy, to just not mention it 14 at all." (Interview 15) 15 The interviewees indicated that in none of the modules patients had been involved in the selection 16 the outcomes described. Some acknowledged that outcomes might be missing, but a substantial 18 number did not regard a complete presented in other modules, evidence for long-term harms is 19 using the following arguments: guidelines should be short, harms are assumed to be common 10 knowledge for clinicians or might be presented in other modules, evidence for long-term harms is 11 lacking, and probabilities from the literature are not applicable to the Dutch setting or would only be 12 surgery). Several interviewees were especially reticent to present probabilities in terms of absolute 13 risk reduction, as those percentages would soon be dated, differed between patient groups, or 14 would be too time-consuming to calculate. One stated to have argued to include Numbers Needed 15 to Treat in the CPG, to no avail. 16 Panel-member: the CPG is mostly written to, what we provide as reco			
recommending endocrine treatment in DCIS was "common knowledge" and that "we also could have chosen to just leave out the whole paragraph about this adjuvant therapy, to just not mention it at all." (Interview 15) The interviewees indicated that in none of the modules patients had been involved in the selection of the outcomes described. Some acknowledged that outcomes might be missing, but a substantial number did not regard a complete presentation of outcomes and their probabilities as necessary, using the following arguments: guidelines should be short, harms are assumed to be common knowledge for clinicians or might be presented in other modules, evidence for long-term harms is lacking, and probabilities from the literature are not applicable to the Dutch setting or would only be representative at the hospital level, not at that of the individual clinician (i.e., for mortality due to surgery). Several interviewees were especially reticent to present probabilities in terms of absolute risk reduction, as those percentages would son be dated, differed between patient groups, or would be too time-consuming to calculate. One stated to have argued to include Numbers Needed to Treat in the CPG, to no avail. Interviewer: and for what reason is the other side of the coin not mentioned in the CPG? You indicated, already, that actually Panel-member: the CPG is mostly written to, what we provide as recommendation towar			
12 recommending endocrine treatment in DCIs was common knowledge and that we also could 13 have chosen to just leave out the whole paragraph about this adjuvant therapy, to just not mention it 14 at all." (Interview 15) 15 The interviewees indicated that in none of the modules patients had been involved in the selection 16 The interviewees indicated that in none of the modules patients had been involved in the selection 17 of the outcomes described. Some acknowledged that outcomes and their probabilities as necessary, 18 number did not regard a complete presentation of outcomes and their probabilities as necessary, 19 using the following arguments: guidelines should be short, harms are assumed to be common 10 knowledge for clinicians or might be presented in other modules, evidence for long-term harms is 10 lacking, and probabilities from the literature are not applicable to the Dutch's etting or would only be 11 representative at the hospital level, not at that of the individual clinician (i.e., for mortality due to 12 surgery). Several interviewees were especially reticent to present probabilities in terms of absolute 13 netwees were especially reticent to present probabilities in terms of absolute 14 risk reduction, as those percentages would son be dated, differed between patient groups, or 15			
14 at all." (Interview 15) 15 The interviewees indicated that in none of the modules patients had been involved in the selection 17 of the outcomes described. Some acknowledged that outcomes might be missing, but a substantial 18 number did not regard a complete presentation of outcomes and their probabilities as necessary, 19 using the following arguments: guidelines should be short, harms are assumed to be common 20 knowledge for clinicians or might be presented in other modules, evidence for long-term harms is 21 lacking, and probabilities from the literature are not applicable to the Dutch setting or would only be 21 representative at the hospital level, not at that of the individual clinician (i.e., for mortality due to 22 surgery). Several interviewees were especially reticent to present probabilities in terms of absolute 23 would be too time-consuming to calculate. One stated to have argued to include Numbers Needed 26 to Treat in the CPG, to no avail. 27 You indicated, already, that actually 28 Interviewer: and for what reason is the other side of the coin not mentioned in the CPG; 29 You indicated, already that actually 29 You indicated, all risks of treatment. I don't know if one should put in the CPG, 21 let's say, what's it cal			
151617181819191919191919101011121314151516171819191919101112121314151515161718181919191910101112121314151515161718181919191910101112121314151515161718181818181818191919 <td></td> <td></td> <td></td>			
1011111112121212131214131514151416151715181219121912191219121912191210121112121213121412151215121612171218121912191210121212121212121212121212121212121212121312141215 <td< td=""><td></td><td></td><td>at all." (Interview 15)</td></td<>			at all." (Interview 15)
16The interviewees indicated that in none of the modules patients had been involved in the selection17of the outcomes described. Some acknowledged that outcomes might be missing, but a substantial18number did not regard a complete presentation of outcomes and their probabilities as necessary,19using the following arguments: guidelines should be short, harms are assumed to be common20knowledge for clinicians or might be presented in other modules, evidence for long-term harms is21lacking, and probabilities from the literature are not applicable to the Dutch setting or would only be22representative at the hospital level, not at that of the individual clinical (i.e., for mortality due to23surgery). Several interviewees were especially reticent to present probabilities in terms of absolute24risk reduction, as those percentages would soon be dated, differed between patient groups, or26would be too time-consuming to calculate. One stated to have argued to include Numbers Needed26to Treat in the CPG, to no avail.27You indicated, already, that actually28Interviewer: and for what reason is the other side of the coin not mentioned in the CPG?29You indicated, neaver interpreted it as such, but I don't know if one should put in the CPG,29for the outcome of treatment. I don't know if the CPG is written at20least, I have never interpreted it as such, but I don't know if one should put in the CPG,29least, uhave interpreted it as such, but I don't know if one should put in the CPG,29least, i abale dui risks of treatment. I don't know if the CPG is k			
2518number did not regard a complete presentation of outcomes and their probabilities as necessary,2619using the following arguments: guidelines should be short, harms are assumed to be common20knowledge for clinicians or might be presented in other modules, evidence for long-term harms is21lacking, and probabilities from the literature are not applicable to the Dutch setting or would only be22representative at the hospital level, not at that of the individual clinician (i.e., for mortality due to23surgery). Several interviewees were especially reticent to present probabilities in terms of absolute24risk reduction, as those percentages would soon be dated, differed between patient groups, or25would be too time-consuming to calculate. One stated to have argued to include Numbers Needed26to Treat in the CPG, to no avail.2770indicated, already, that actually28Interviewer: and for what reason is the other side of the coin not mentioned in the CPG?29You indicated, already, that actually29Panel-member: the CPG is mostly written to, what we provide as recommendation40towards the patient, for the outcome of treatment. I don't know if one should put in the CPG,41let's say, what's it called, all risks of treatment. That differs per agent, have different42risks. And then the CPG becomes much more extensive. But that is also the baseline43knowledge that every oncologist should have.44(Interview 7, about adjuvant chemotherapy for colon carcinoma)453346Some intervi			
 using the following arguments: guidelines should be short, harms are assumed to be common knowledge for clinicians or might be presented in other modules, evidence for long-term harms is lacking, and probabilities from the literature are not applicable to the Dutch setting or would only be representative at the hospital level, not at that of the individual clinician (i.e., for mortality due to surgery). Several interviewees were especially reticent to present probabilities in terms of absolute risk reduction, as those percentages would soon be dated, differed between patient groups, or would be too time-consuming to calculate. One stated to have argued to include Numbers Needed to Treat in the CPG, to no avail. Interviewer: and for what reason is the other side of the coin not mentioned in the CPG? You indicated, already, that actually Panel-member: the CPG is mostly written to, what we provide as recommendation towards the patient, for the outcome of treatment. I don't know if the CPG is written at least, I have never interpreted it as such, but I don't know if one should put in the CPG, let's say, what's it called, all risks of treatment. That differs per agent, have different risks. And then the CPG becomes much more extensive. But that is also the baseline knowledge that every oncologist should have. (Interview 7, about adjuvant chemotherapy for colon carcinoma) 33.3 Patient preferences None of the modules stated that evidence about patient preferences, or about variation in patient preferences, either from the literature or assumed by the panel. Some interviewees acknowledged that patient preferences may vary and may differ from clinician preferences, and they stressed that the awareness of such variation sometimes motivated a weak recommendation. Reasons not to include information about patient preferences were: time and preferences, and they stressed that the awareness of such variation sometimes motivated a wea			of the outcomes described. Some acknowledged that outcomes might be missing, but a substantial
1718191920knowledge for clinicians or might be presented in other modules, evidence for long-term harms is20knowledge for clinicians or might be presented in other modules, evidence for long-term harms is21lacking, and probabilities from the literature are not applicable to the Dutch setting or would only be22representative at the hospital level, not at that of the individual clinician (i.e., for mortality due to23surgery). Several interviewees were especially reticent to present probabilities in terms of absolute24risk reduction, as those percentages would soon be dated, differed between patient groups, or25would be too time-consuming to calculate. One stated to have argued to include Numbers Needed26to Treat in the CPG, to no avail.27Panel-member: the CPG is mostly written to, what we provide as recommendation28towards the patient, for the outcome of treatment. I don't know if the CPG is written at29least, I have never interpreted it as such, but I don't know if one should put in the CPG,29least, what's it called, all risks of treatment. That differs per agent, have different20risks. And then the CPG becomes much more extensive. But that is also the baseline31knowledge that every oncologist should have.32Interviewes acknowledged that patient preferences had been searched for or33elicited. No information was presented about generic patient preferences, or about variation in33patient preferences34Some interviewees acknowledged that patient preferences may vary and may differ from clinician <td></td> <td></td> <td>number did not regard a complete presentation of outcomes and their probabilities as necessary,</td>			number did not regard a complete presentation of outcomes and their probabilities as necessary,
 knowledge for clinicians or might be presented in other modules, evidence for long-term harms is lacking, and probabilities from the literature are not applicable to the Dutch setting or would only be representative at the hospital level, not at that of the individual clinician (i.e., for mortality due to surgery). Several interviewees were especially reticent to present probabilities in terms of absolute risk reduction, as those percentages would soon be dated, differed between patient groups, or would be too time-consuming to calculate. One stated to have argued to include Numbers Needed to Treat in the CPG, to no avail. Interviewer: and for what reason is the other side of the coin not mentioned in the CPG? You indicated, already, that actually Panel-member: the CPG is mostly written to, what we provide as recommendation towards the patient, for the outcome of treatment. I don't know if the CPG is written at least, I have never interpreted it as such, but I don't know if one should put in the CPG, let's say, what's it called, all risks of treatment. That differs per agent, have different risks. And then the CPG becomes much more extensive. But that is also the baseline knowledge that every oncologist should have. (Interview 7, about adjuvant chemotherapy for colon carcinoma) 3.3 Patient preferences None of the modules stated that evidence about patient preferences had been searched for or elicited. No information was presented about generic patient preferences, or about variation in patient preferences, either from the literature or assumed by the panel. 		19	using the following arguments: guidelines should be short, harms are assumed to be common
 representative at the hospital level, not at that of the individual clinician (i.e., for mortality due to surgery). Several interviewees were especially reticent to present probabilities in terms of absolute risk reduction, as those percentages would soon be dated, differed between patient groups, or would be too time-consuming to calculate. One stated to have argued to include Numbers Needed to Treat in the CPG, to no avail. Interviewer: and for what reason is the other side of the coin not mentioned in the CPG? You indicated, already, that actually Panel-member: the CPG is mostly written to, what we provide as recommendation towards the patient, for the outcome of treatment. I don't know if the CPG is written at least, I have never interpreted it as such, but I don't know if one should put in the CPG, let's say, what's it called, all risks of treatment. That differs per agent, have different risks. And then the CPG becomes much more extensive. But that is also the baseline knowledge that every oncologist should have. (Interview 7, about adjuvant chemotherapy for colon carcinoma) 3.3 Patient preferences None of the modules stated that evidence about patient preferences, or about variation in patient preferences, either from the literature or assumed by the panel. Some interviewees acknowledged that patient preferences may vary and may differ from clinician preferences, and they stressed that the awareness of such variation sometimes motivated a weak recommendation. Reasons not to include information about patient preferences were: time and recommendation. Reasons not to include information about patient preferences were: time and 		20	knowledge for clinicians or might be presented in other modules, evidence for long-term harms is
 surgery). Several interviewees were especially reticent to present probabilities in terms of absolute risk reduction, as those percentages would soon be dated, differed between patient groups, or would be too time-consuming to calculate. One stated to have argued to include Numbers Needed to Treat in the CPG, to no avail. Interviewer: and for what reason is the other side of the coin not mentioned in the CPG? You indicated, already, that actually Panel-member: the CPG is mostly written to, what we provide as recommendation towards the patient, for the outcome of treatment. I don't know if the CPG is written at least, I have never interpreted it as such, but I don't know if one should put in the CPG, let's say, what's it called, all risks of treatment. That differs per agent, have different risks. And then the CPG becomes much more extensive. But that is also the baseline knowledge that every oncologist should have. (Interview 7, about adjuvant chemotherapy for colon carcinoma) 3.3 Patient preferences None of the modules stated that evidence about patient preferences had been searched for or elicited. No information was presented about generic patient preferences, or about variation in patient preferences, either from the literature or assumed by the panel. Some interviewees acknowledged that patient preferences may vary and may differ from clinician preferences, and they stressed that the awareness of such variation sometimes motivated a weak recommendation. Reasons not to include information about patient preferences were: time and 		21	lacking, and probabilities from the literature are not applicable to the Dutch setting or would only be
 surgery). Several interviewees were especially reticent to present probabilities in terms of absolute risk reduction, as those percentages would soon be dated, differed between patient groups, or would be too time-consuming to calculate. One stated to have argued to include Numbers Needed to Treat in the CPG, to no avail. Interviewer: and for what reason is the other side of the coin not mentioned in the CPG? You indicated, already, that actually Panel-member: the CPG is mostly written to, what we provide as recommendation towards the patient, for the outcome of treatment. I don't know if the CPG is written at least, I have never interpreted it as such, but I don't know if one should put in the CPG, let's say, what's it called, all risks of treatment. That differs per agent, have different risks. And then the CPG becomes much more extensive. But that is also the baseline knowledge that every oncologist should have. (Interview 7, about adjuvant chemotherapy for colon carcinoma) 3.3 Patient preferences None of the modules stated that evidence about patient preferences, or about variation in patient preferences, either from the literature or assumed by the panel. Some interviewees acknowledged that patient preferences may vary and may differ from clinician preferences, and they stressed that the awareness of such variation sometimes motivated a weak recommendation. Reasons not to include information about patient preferences were: time and 		22	representative at the hospital level, not at that of the individual clinician (i.e., for mortality due to
 risk reduction, as those percentages would soon be dated, differed between patient groups, or would be too time-consuming to calculate. One stated to have argued to include Numbers Needed to Treat in the CPG, to no avail. Interviewer: and for what reason is the other side of the coin not mentioned in the CPG? You indicated, already, that actually Panel-member: the CPG is mostly written to, what we provide as recommendation towards the patient, for the outcome of treatment. I don't know if the CPG is written at least, I have never interpreted it as such, but I don't know if one should put in the CPG, let's say, what's it called, all risks of treatment. That differs per agent, have different risks. And then the CPG becomes much more extensive. But that is also the baseline knowledge that every oncologist should have. (Interview 7, about adjuvant chemotherapy for colon carcinoma) 3.3 Patient preferences None of the modules stated that evidence about patient preferences, or about variation in patient preferences, either from the literature or assumed by the panel. Some interviewees acknowledged that patient preferences may vary and may differ from clinician preferences, and they stressed that the awareness of such variation sometimes motivated a weak recommendation. Reasons not to include information about patient preferences were: time and 		23	surgery). Several interviewees were especially reticent to present probabilities in terms of absolute
 to Treat in the CPG, to no avail. Interviewer: and for what reason is the other side of the coin not mentioned in the CPG? You indicated, already, that actually Panel-member: the CPG is mostly written to, what we provide as recommendation towards the patient, for the outcome of treatment. I don't know if the CPG is written at least, I have never interpreted it as such, but I don't know if one should put in the CPG, let's say, what's it called, all risks of treatment. That differs per agent, have different risks. And then the CPG becomes much more extensive. But that is also the baseline knowledge that every ancologist should have. (Interview 7, about adjuvant chemotherapy for colon carcinoma) 3.3 Patient preferences None of the modules stated that evidence about generic patient preferences, or about variation in patient preferences, either from the literature or assumed by the panel. Some interviewees acknowledged that patient preferences may vary and may differ from clinician preferences, and they stressed that the awareness of such variation sometimes motivated a weak recommendation. Reasons not to include information about patient preferences that the 		24	risk reduction, as those percentages would soon be dated, differed between patient groups, or
 to Treat in the CPG, to no avail. Interviewer: and for what reason is the other side of the coin not mentioned in the CPG? You indicated, already, that actually Panel-member: the CPG is mostly written to, what we provide as recommendation towards the patient, for the outcome of treatment. I don't know if the CPG is written at least, I have never interpreted it as such, but I don't know if one should put in the CPG, let's say, what's it called, all risks of treatment. That differs per agent, have different risks. And then the CPG becomes much more extensive. But that is also the baseline knowledge that every oncologist should have. (Interview 7, about adjuvant chemotherapy for colon carcinoma) 3.3 Patient preferences None of the modules stated that evidence about patient preferences, or about variation in patient preferences, either from the literature or assumed by the panel. Some interviewees acknowledged that patient preferences may vary and may differ from clinician preferences, and they stressed that the awareness of such variation sometimes motivated a weak recommendation. Reasons not to include information about patient preferences were: time and 		25	would be too time-consuming to calculate. One stated to have argued to include Numbers Needed
 Interviewer: and for what reason is the other side of the coin not mentioned in the CPG? You indicated, already, that actually Panel-member: the CPG is mostly written to, what we provide as recommendation towards the patient, for the outcome of treatment. I don't know if the CPG is written at least, I have never interpreted it as such, but I don't know if one should put in the CPG, let's say, what's it called, all risks of treatment. That differs per agent, have different risks. And then the CPG becomes much more extensive. But that is also the baseline knowledge that every oncologist should have. (Interview 7, about adjuvant chemotherapy for colon carcinoma) 37 3.3 Patient preferences None of the modules stated that evidence about patient preferences, or about variation in patient preferences, either from the literature or assumed by the panel. Some interviewees acknowledged that patient preferences may vary and may differ from clinician preferences, and they stressed that the awareness of such variation sometimes motivated a weak recommendation. Reasons not to include information about patient preferences were: time and 		26	
 Interviewer: and for what reason is the other side of the coin not mentioned in the CPG? You indicated, already, that actually Panel-member: the CPG is mostly written to, what we provide as recommendation towards the patient, for the outcome of treatment. I don't know if the CPG is written at least, I have never interpreted it as such, but I don't know if one should put in the CPG, let's say, what's it called, all risks of treatment. That differs per agent, have different risks. And then the CPG becomes much more extensive. But that is also the baseline knowledge that every oncologist should have. (Interview 7, about adjuvant chemotherapy for colon carcinoma) 3.3 Patient preferences None of the modules stated that evidence about patient preferences, or about variation in patient preferences, either from the literature or assumed by the panel. Some interviewees acknowledged that patient preferences may vary and may differ from clinician preferences, and they stressed that the awareness of such variation sometimes motivated a weak recommendation. Reasons not to include information about patient preferences were: time and recommendation. Reasons not to include information about patient preferences were: time and 			
 You indicated, already, that actually Panel-member: the CPG is mostly written to, what we provide as recommendation towards the patient, for the outcome of treatment. I don't know if the CPG is written at least, I have never interpreted it as such, but I don't know if one should put in the CPG, let's say, what's it called, all risks of treatment. That differs per agent, have different risks. And then the CPG becomes much more extensive. But that is also the baseline knowledge that every oncologist should have. (Interview 7, about adjuvant chemotherapy for colon carcinoma) 3.3 Patient preferences None of the modules stated that evidence about patient preferences, or about variation in patient preferences, either from the literature or assumed by the panel. Some interviewees acknowledged that patient preferences may vary and may differ from clinician preferences, and they stressed that the awareness of such variation sometimes motivated a weak recommendation. Reasons not to include information about patient preferences were: time and preferences were: time and preferences were: time and 		28	Interviewer: and for what reason is the other side of the coin not mentioned in the CPG?
 31 towards the patient, for the outcome of treatment. I don't know if the CPG is written at 32 least, I have never interpreted it as such, but I don't know if one should put in the CPG, 33 let's say, what's it called, all risks of treatment. That differs per agent, have different 34 risks. And then the CPG becomes much more extensive. But that is also the baseline 35 knowledge that every oncologist should have. 46 (Interview 7, about adjuvant chemotherapy for colon carcinoma) 37 33 Patient preferences 34 None of the modules stated that evidence about patient preferences had been searched for or 40 elicited. No information was presented about generic patient preferences, or about variation in 41 patient preferences, either from the literature or assumed by the panel. 42 43 Some interviewees acknowledged that patient preferences may vary and may differ from clinician 44 preferences, and they stressed that the awareness of such variation sometimes motivated a weak 45 recommendation. Reasons not to include information about patient preferences were: time and 	39		
 12 lowards the patient, for the obtcome of treatment. I addit know if the CPG is written at 12 least, I have never interpreted it as such, but I don't know if one should put in the CPG, 14 13 least, I have never interpreted it as such, but I don't know if one should put in the CPG, 14 13 least, I have never interpreted it as such, but I don't know if one should put in the CPG, 14 13 least, I have never interpreted it as such, but I don't know if one should put in the CPG, 14 13 least, I have never interpreted it as such, but I don't know if one should put in the CPG, 14 14 15 least, and then the CPG becomes much more extensive. But that is also the baseline 14 knowledge that every oncologist should have. 15 (Interview 7, about adjuvant chemotherapy for colon carcinoma) 16 37 17 36 (Interview 7, about adjuvant chemotherapy for colon carcinoma) 18 37 19 38 3.3 Patient preferences 19 None of the modules stated that evidence about patient preferences had been searched for or 10 elicited. No information was presented about generic patient preferences, or about variation in 10 patient preferences, either from the literature or assumed by the panel. 10 patient preferences, and they stressed that the awareness of such variation sometimes motivated a weak 11 preferences, and they stressed that the awareness of such variation sometimes motivated a weak 12 recommendation. Reasons not to include information about patient preferences were: time and 14 or preferences were: time and 15 description of the stressed that the awareness of such variation sometimes that the interviewees acknowledged that patient patient preferences were: time and 14 preferences were: time and 15 description of the stressed that the awareness of such variation sometimes motivated a weak 16 recommendation. Reasons not to include informati		30	Panel-member: the CPG is mostly written to, what we provide as recommendation
 <i>least, I have never interpreted it as such, but I don't know if one should put in the CPG,</i> <i>let's say, what's it called, all risks of treatment. That differs per agent, have different</i> <i>risks. And then the CPG becomes much more extensive. But that is also the baseline</i> <i>knowledge that every oncologist should have.</i> (Interview 7, about adjuvant chemotherapy for colon carcinoma) 3.3 Patient preferences None of the modules stated that evidence about patient preferences had been searched for or elicited. No information was presented about generic patient preferences, or about variation in patient preferences, either from the literature or assumed by the panel. Some interviewees acknowledged that patient preferences may vary and may differ from clinician preferences, and they stressed that the awareness of such variation sometimes motivated a weak recommendation. Reasons not to include information about patient preferences were: time and 			
 34 risks. And then the CPG becomes much more extensive. But that is also the baseline knowledge that every oncologist should have. 47 36 (Interview 7, about adjuvant chemotherapy for colon carcinoma) 37 38 3.3 Patient preferences 39 None of the modules stated that evidence about patient preferences had been searched for or elicited. No information was presented about generic patient preferences, or about variation in patient preferences, either from the literature or assumed by the panel. 42 56 43 Some interviewees acknowledged that patient preferences may vary and may differ from clinician preferences, and they stressed that the awareness of such variation sometimes motivated a weak recommendation. Reasons not to include information about patient preferences were: time and 			
 <i>knowledge that every oncologist should have.</i> (Interview 7, about adjuvant chemotherapy for colon carcinoma) 37 3.3 Patient preferences None of the modules stated that evidence about patient preferences had been searched for or elicited. No information was presented about generic patient preferences, or about variation in patient preferences, either from the literature or assumed by the panel. Some interviewees acknowledged that patient preferences may vary and may differ from clinician preferences, and they stressed that the awareness of such variation sometimes motivated a weak recommendation. Reasons not to include information about patient preferences were: time and 			
 36 (Interview 7, about adjuvant chemotherapy for colon carcinoma) 37 39 3.3 Patient preferences 39 None of the modules stated that evidence about patient preferences had been searched for or elicited. No information was presented about generic patient preferences, or about variation in patient preferences, either from the literature or assumed by the panel. Some interviewees acknowledged that patient preferences may vary and may differ from clinician preferences, and they stressed that the awareness of such variation sometimes motivated a weak recommendation. Reasons not to include information about patient preferences were: time and 			
 37 38 3.3 Patient preferences 39 None of the modules stated that evidence about patient preferences had been searched for or 40 elicited. No information was presented about generic patient preferences, or about variation in patient preferences, either from the literature or assumed by the panel. 42 Some interviewees acknowledged that patient preferences may vary and may differ from clinician preferences, and they stressed that the awareness of such variation sometimes motivated a weak recommendation. Reasons not to include information about patient preferences were: time and 			
 38 3.3 Patient preferences 39 None of the modules stated that evidence about patient preferences had been searched for or 40 elicited. No information was presented about generic patient preferences, or about variation in patient preferences, either from the literature or assumed by the panel. 42 56 43 Some interviewees acknowledged that patient preferences may vary and may differ from clinician preferences, and they stressed that the awareness of such variation sometimes motivated a weak recommendation. Reasons not to include information about patient preferences were: time and 			(interview y, about adjuvant chemotherapy for colon carcinoma)
 None of the modules stated that evidence about patient preferences had been searched for or elicited. No information was presented about generic patient preferences, or about variation in patient preferences, either from the literature or assumed by the panel. Some interviewees acknowledged that patient preferences may vary and may differ from clinician preferences, and they stressed that the awareness of such variation sometimes motivated a weak recommendation. Reasons not to include information about patient preferences were: time and 	49		3 3 Patient preferences
 40 elicited. No information was presented about generic patient preferences, or about variation in 41 patient preferences, either from the literature or assumed by the panel. 42 42 56 43 Some interviewees acknowledged that patient preferences may vary and may differ from clinician 57 44 preferences, and they stressed that the awareness of such variation sometimes motivated a weak 45 recommendation. Reasons not to include information about patient preferences were: time and 46 recommendation. Reasons not to include information about patient preferences were: time and 			•
 patient preferences, either from the literature or assumed by the panel. 42 54 56 43 56 Some interviewees acknowledged that patient preferences may vary and may differ from clinician preferences, and they stressed that the awareness of such variation sometimes motivated a weak 45 45 46 46 			
 42 43 56 43 56 43 56 57 44 58 45 58 45 59 46 47 48 49 49 40 41 41 42 43 54 56 43 57 58 45 59 46 47 48 49 49 40 41 41 42 43 44 45 45 46 46 47 48 49 49 49 40 41 41 42 42 44 45 46 47 48 49 49 49 49 40 41 41 42 42 44 45 46 47 48 49 4			
 Some interviewees acknowledged that patient preferences may vary and may differ from clinician preferences, and they stressed that the awareness of such variation sometimes motivated a weak recommendation. Reasons not to include information about patient preferences were: time and and the awareness of such variation about patient preferences were: time and 	54		patient preferences, ethier nom the interature of assumed by the patien.
57 44 preferences, and they stressed that the awareness of such variation sometimes motivated a weak 58 45 recommendation. Reasons not to include information about patient preferences were: time and 59 46 recommendation about patient preferences were: time and			Some interviewage acknowledged that nations professores may year and may differ from all sizes
58 59 46 recommendation. Reasons not to include information about patient preferences were: time and 46 recommendation that the eccurrentiate the eccurrentiate that the eccurrentiate that the eccurrentiate that the eccurrentiate the eccurrentiate that the eccurrentiate that the eccurrentiate that the eccurrentiate the eccurrentiate the eccurrentiate the eccurrentiate that the eccurrentiate th			
59			
60 40 capacity constraints, the assumption that no evidence exists, or lack of awareness that this	59		
	60	40	capacity constraints, the assumption that no evidence exists, or lack of awareness that this

1		
2 3		
4	1	information is to be included. Others were reluctant to include information about preference
5	2	variation, because it could threaten the relationship between specialties (if this information would
6	3	lead to patients choosing against the generally accepted treatment modality). Numerous
7	4	assumptions about patient preferences were voiced, such as that patients prefer lumpectomy to
8 9	5	mastectomy, length of life to quality of life, and active treatment to refraining from treatment.
10	6	Interviewees also stressed that if patients have a strong preference, they will express it anyway.
11	7	
12	8	3.4 CPG panels' values and preferences
13	9	None of the modules explicitly labelled statements as presenting the CPG panel's values and
14 15	10	preferences that underlie their weighing of the benefits and harms. We found implicit reference to
16	11	CPG panels' preferences, having influenced the development of the recommendation in 15/32
17	12	recommendations (see Box 4). These preferences concerned 9/14 strong recommendations and
18	13	6/18 weak recommendations (see Table 2).
19 20	14	
20	15	>>> Insert Box 4 about here <<<
22	16	
23	17	As described under 3.1, the interviewees sometimes explained discrepancies between the strength
24 25		
25 26	18	of recommendation and the extracted information by the CPG panel's valuation of the outcomes.
27	19	Explanations for the panel members' preferences beyond the evidence were: compliance with daily
28	20	practice; the organisation of care; culture (a preference for radiotherapy seemed more culturally
29	21	and historically determined than evidence-based); and concerns about keeping a good relationship
30	22	between specialties when their treatments compete.
31 32	23	Some interviewees found that CPG panels' preferences underlying the weighing of benefits and
33	24	harms should be made explicit. One interviewee stated that having an external party critically
34	25	reviewing the CPGs before publication would foster this. The panel members often expressed their
35	26	own preference for active treatment versus refraining from (further) treatment or active
36 37	27	surveillance, even at the expense of over-treating a substantial part of the patient population.
38	28	
39	29	Panel member: That is watertight, radiotherapy does have an effect. Not for everyone,
40	30	far from it, but for some. And we cannot sufficiently select for whom it does, so we say,
41	31	give radiation to all.
42 43	32	(Interview 4, about radiotherapy for DCIS patients)
44	33	
45	34	Their motivation was mostly a strong belief in survival gain for a subgroup that cannot be identified
46	35	as of yet. In these instances, panel preferences for active treatment had influenced the balancing of
47	36	benefits and harms, such that a recommendation for active treatment would not be a weak one.
48 49	37	This was argued e.g. for treatment aimed at reducing local recurrence rates without concomitant
50	38	survival gain. Concerning this example, an interviewee argued in one instance that it was preferable
51	39	simply to not include survival as an outcome, as no survival gain was possible given the already high
52	40	survival (Interview 2, about radiotherapy for DCIS).
53 54	41	
54 55	42	Band members but I find it a bit of a bromide to say that DCIS or rather that
56	42 43	Panel member: but I find it a bit of a bromide to say that DCIS, or rather that radiotherapy for DCIS yields no survival benefit and therefore we shouldn't do it. Because
57	44	one cannot improve upon 99 % survival benefit. The important thing is, in which sub-
58	45	groups those recurrences occur that might not be such nice recurrences, that call for a lot
59 60	46	more treatment and the like

2		
3	1	(Interview 2, about radiotherapy for DCIS patients)
4 5	2	
6	3	At the same time, others voiced opinions against over-treatment and pointed out that the paradigm
7	4	in favour of over-treatment to avoid under-treatment is shifting, particularly in patients diagnosed
8	5	by population screening (DCIS, T1 carcinoma in polyp).
9	6	
10 11	7	3.5 Advice about patient involvement in decision-making
12	8	Five modules included in total 20 statements about the patient's role in decision-making (see Box 5).
13	9	Relatively more statements (14) were seen for the weak than for the strong (6) recommendations.
14		
15	10	All statements recommended to include the patient's preferences in making the decision except for
16 17	11	two, relating to weak recommendations, that recommended to inform the patient about the trade-
18	12	off. One of the three CPGs included a separate chapter about decision-making, in which it was
19	13 14	recommended to elicit the preferences of the patient in an SDM process.
20 21		
21	15	Interviewees disagreed on the necessity of recommendations about patient involvement in decision-
23	16	making. Several stressed that these statements were included only because the patient
24	17	representative asked for it. Others mentioned that the inclusion was based on the opinion of
25	18	individual panel members.
26 27	19	
28	20	>>> Insert Box 5 about here <<<
29	21	
30	22	
31 22	22	4. DISCUSSION
32 33	23	Healthcare is increasingly guideline-driven, which promotes quality of care and reduces unwarranted
34	24	practice variation. But guidelines may be a barrier to SDM if they do not acknowledge the
35	25	preference-sensitive nature of many treatment decisions. (1, 30) The aim of this study was to explore
36	26	to what extent CPGs acknowledge preference-sensitive decisions in their recommendations. Our
37 38	27	analysis showed that the guidelines involved incomplete and unclear presentation of benefits,
39	28	harms, and the probabilities thereof. This makes it difficult for the users not only to judge the
40	29	appropriateness of the strength of the recommendation, but also to inform patients about the
41	30	trade-offs as part of an SDM process. Whether or not clinicians have complete knowledge about all
42	31	benefits and harms and their probabilities is questionable, and from an earlier study we know that at
43 44	32	least many clinicians do not share this information with their patients during the decision making
45	33	process.(14, 15) Complete and clear presentation in CPGs of the benefits and harms help to fill
46	34	knowledge gaps in CPG users, and acknowledge the importance of the information for the trade-offs
47	35	to be made with the individual patient in preference-sensitive decisions.
48 49	36	
49 50	37	Furthermore, information on patient preferences or the variation therein, was not included in any
51	38	
52		of the six modules analysed. If GRADE were to be followed, this lack of evidence on patient
53	39	preferences should have led to more weak recommendations than seen. Additionally, we found
54 55	40	indications that panel members' assumptions about patient preferences as well as their own
55 56	41	preferences, determined the recommendations. This corroborates findings of De Kort et al. (21) on
57	42	the role of value judgements in guideline formulation in palliative oncology. They found that
58	43	preferences, such as those for intervening and prolonging life, were not mentioned in the guidelines
59	44	but had played an important role in determining final recommendations. In line with a study by
60		

Alexander et al. (35), it appeared that panel members find it difficult to refrain from providing a clear recommendation in a case of limited or conflicting evidence. CPG panel preferences for active treatment had influenced the way the panel had balanced benefits and harms, such that a recommendation for active treatment would be strong and overtreatment likely. The strong belief in survival gain for a subgroup that cannot be identified as of yet fosters the so-called therapeutic illusion, in which both physicians and patients overestimate the benefits of treatment, since patients are seemingly cured by treatment while they might have had the same outcome without treatment.(36) Rather than routinely resort to active treatment in these instances, the discussion should be opened on how to deal with such uncertainties. Little research is available yet on how best to communicate uncertainty, (37) but this does not relieve us from the obligation to discuss matters honestly with patients. Such openness would contribute to reducing unnecessary treatment, addressing unacceptable variation, and delivering more appropriate, personalised care.(38) Guidelines can facilitate this discussion by acknowledging preference-sensitive decisions, and encouraging users to become more aware of choice and presenting multiple options to patients.

A limitation of the format of GRADE, is that it asks for a dichotomous categorization (weak vs. strong) and a recommendation either for or against. This categorization makes it difficult to explicitly state that multiple options are medically reasonable. Furthermore, information on patient preferences should be more often sought in guideline development. Oncologist experts are invited in guideline panels because of their content expertise, but this involves a risk when more evidence is available for benefits than for harms, and when there is no evidence on patient preferences. Then chances increase that that panel members resort to their own preferences, often favouring active treatment and neglecting harms.(39) The guideline development process, while aiming at achieving EBM, may threaten it by its reliance on expert judgment at the expense of involving patient preferences. GRADE publications accede that panels' judgements of patient preferences often relies on their interactions with patients, but how well such judgements correspond to typical values and preferences is uncertain.

We do not know to what extent our analysis will hold for CPGs from other countries than the Netherlands. Dutch healthcare is likely less paternalistic than that in many other countries, and the Netherlands are leading in the implementation of SDM(40). We therefore expect more discrepancies between evidence and recommendations to arise elsewhere. De Kort et al.,(21) analysed a sample of evidence-based oncology guidelines from other countries, and found that recommendations were rarely explained and value judgements were not made explicit either. Further, we do not know if, but have no reason to expect that our findings will be different for other specialties. We urge researchers in other countries and other fields to evaluate their guidelines with preference-sensitivity in mind as well.

An analysis like the one performed runs the risk of subjectivity, as the data extraction and coding requires interpretation. We therefore checked our results with the developers of the guidelines we studied. This provided a validation of our analysis. The aim of this endeavour was to highlight an issue that is a major barrier to patient-centred care and SDM in particular.(41) With the strong current call for patient involvement, worldwide, it is important to establish to what extent guidelines potentially hinder such involvement, and our study may be seen as a first step in that direction.

1		
2 3	1	
4	1	In sum, our analysis points out a lack of transparency in the CPG development process. Being more
5	2	transparent about benefits and harms and their probabilities, as well as about the preferences of the
6	3	guideline panel members, and their assumptions about patient preferences, will help avoid what
7 8	4	McCartney feared in his 2016 Analysis in the BMJ: "there is the danger of guideline
8 9	5	recommendations being applied to people who do not place the same values on those
10	6	recommendations as their clinician ()".(23)
11	7	
12	8	
13 14	9	
15	10	ACKNOWLEDGEMENTS
16	11	We thank all interviewees for their participation in this study.
17	12	
18 19	13	AUTHORS CONTRIBUTION
20		
21	14	FRG, AP, and AMS designed the study. FRG and AMS conducted the data extraction. FRG, AMS,
22	15	wrote the first draft of the manuscript. All authors were involved in interpreting the results. All
23 24	16	authors have read the manuscript and made improvement of the content and wording and have
24 25	17	agreed to the final version. The corresponding author attests that all listed authors meet authorship
26	18	criteria and that no others meeting the criteria have been omitted.
27		
28	19	
29 30	20	
31	21	EXCLUSIVE LICENCE STATEMENT
32	22	The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of
33	23	all authors, a worldwide licence to the Publishers and its licensees in perpetuity, in all forms, formats
34 35	24	and media (whether known now or created in the future), to i) publish, reproduce, distribute, display
36	25	and store the Contribution, ii) translate the Contribution into other languages, create adaptations,
37	26	reprints, include within collections and create summaries, extracts and/or, abstracts of the
38	27	Contribution and convert or allow conversion into any format including without limitation audio, iii)
39 40	28	create any other derivative work(s) based in whole or part on the on the Contribution, iv) to exploit
41	29	all subsidiary rights to exploit all subsidiary rights that currently exist or as may exist in the future in
42	30	the Contribution, v) the inclusion of electronic links from the Contribution to third party material
43	31	where-ever it may be located; and, vi) licence any third party to do any or all of the above.
44 45	32	
46		
47		
48		
49 50		
51		
52		
53		
54 55		
56		
57		
58		
59 60		
00		

Box 1: The GRADE approach and GRADE's proposed role of patient values and preferences in CPG recommendation development:

GRADE offers an approach to rate the certainty in the evidence and strength of recommendations, in which strong and weak (also known as conditional) recommendations are distinguished. Consideration of patient preferences is a crucial step in deciding on the strength of the recommendation. According to the GRADE approach, first, the best estimates of effect for the interventions and the certainty in this evidence (quality of the evidence) is assessed, using up-todate systematic reviews. Further, the CPG panel should consider a number of criteria that influence the strength of recommendations, such as variability or uncertainty in how patients value the main outcomes (both benefits and harms), the balance between benefits and harms, and considerations of resource use, health equity, feasibility and acceptability (from both stakeholder and patient perspective) of an intervention. (26-30) Based on an overall assessment across these criteria, CPG panels reach a conclusion about the direction of their recommendation (for or against the intervention) and the strength of their recommendation: strong or weak. (26) A high level of certainty across the criteria (such as high quality evidence, clear balance between benefits and harms, no uncertainty in patient preferences) allows for strong recommendations. A high level of uncertainty, i.e., preference-sensitive decisions, leads to weak recommendations: there is more than one single best option available, there is important uncertainty or variability in patient preferences, or the benefits and harms are closely balanced.

To guarantee the acknowledgement of patient preferences in the development of recommendations, the GRADE strategy asks to clearly present i) how substantial benefits and harms are, what their balance is, and what the overall certainty of the evidence on these outcomes is, and ii) if there is uncertainty about or variability in how much patients value the important outcomes. (26, 27, 47) In other papers GRADE recommends guideline developers to make transparent and explicit statements iii) about the (variability in) patient values and preferences, as well as CPG panel assumptions of these values and preferences on which decisions on the strength of recommendations are based, in order to be able to judge the applicability of recommendations for decision making with the individual patient. (28, 29)

 Box 2. Examples of textual discrepancies between strength of recommendation and statements in
 other parts of the CPG module

1. Strongly phrased recommendation for adjuvant radiotherapy after lumpectomy in DCIS patients, combined with a statement about the relevance of patient involvement in the decision: <u>Recommendation</u>

"After complete excision of DCIS, radiotherapy of the whole chest wall (with or without boost) is recommended." (Section: Recommendations, module 1)

Statement about patient involvement

"Individual risk assessment and good deliberation with the informed patient determine whether radiotherapy is applied, with or without boost." (Section: Recommendations, module 1)

2. Strongly-phrased recommendation for adjuvant chemotherapy for patients with an MSI colon carcinoma, combined with a statement about very low-quality evidence.

Recommendation

"It is recommended that patients with an MSI carcinoma are offered only fluoropyrimidineoxaliplatin-based chemotherapy." (Section: Recommendations, module 4) <u>Statement about the evidence</u>

"The limited evidence concerning the value of oxaliplatin-based chemotherapy in this group shows no difference compared to patients with MSS tumours, so for patients with stage III MSI tumours, oxaliplatin-based chemotherapy remains recommended for now." (Section: Literature review, module 4)

1 Box 3: Extracted trade-off statements

Trade-off statement for a <u>strong</u> recommendation:

• It is generally agreed upon that a dose of 45–60 Gy in 3 fractions is safe and can achieve good (> 80%) local tumour control. The risk of radiation pneumonitis appears to be acceptable. However, long-term data on the late toxicity of SBRT is lacking, especially for T2 tumours. Evidence pertaining to quality of life is likewise sparse. (Conclusions, module 3a)

Trade-off statements for weak recommendations:

- Additional surgical resection after endoscopic removal of a malignant polyp should always be a balanced decision because of the relative high number needed to treat, for which the patient should always be fully informed about the potential oncologic benefit on the one hand and the risk of complications on the other (Recommendations, module 2a, used for <u>weak</u> recommendations)
- In various case-series, the incidence of local lymph node metastases in T1 colorectal carcinoma varies from 8 to 14 %. ^{654 1082 1259} There is also a large chance that surgical (segmental) resection of the colon has no therapeutic benefits, while being associated with morbidity and even mortality. Hence, it is important to make a well-considered choice for the treatment of malignant polyps." (Section: Literature review, module 2a)
- For high risk malignant colon polyps the oncologic benefit of additional resection should be balanced against the risk of morbidity and possibly even mortality. In this trade-off the age, tumor location, comorbidity of the patient, and the preference of the patient should be taken into account. All patients should be discussed in the multidisciplinary team. (Section: Considerations, module 2a, used for <u>weak</u> recommendations)
- A retrospective subgroup analysis of the MOSAIC studying patients with Stage II colon carcinoma has shown that adding oxaliplatin to a fluoropyrimidine does not convey significant gain in dFS and OS. It seems useful to educate patients with high risk Stage II colon carcinoma about the possible advantages of adjuvant chemotherapy and the concomitant side effects. (Section: literature review, module 2b, used for weak recommendation)]
- Treatment of centrally-located tumours is still under debate, given its high toxicity (Conclusions, module 3a, used for <u>weak</u> recommendation)

3 4	1 Box 4: Examples of CPG panels' va	lues or preferences reflected in the CPG modules	
5 6 7 8 9	CPG statement on which the interpretation of the panel's preference is based.	Description of the identified CPG panel's preference	Concerning what type of recommendation
9 10 11 12	If breast-conserving surgery is not feasible or desirable, there is an indication for mastectomy. (Section: Literature review, module 1)	The panel appears to prefer breast-sparing surgery to mastectomy; mastectomy is considered only when breast-sparing surgery is not feasible or desirable.	2 weak
13 14 15 16 17 18 19 20 21 22 23	DCIS is often discovered based on calcifications on the mammogram that, when biopsied, turn out to be associated with this DCIS. DCIS does not metastasize, and patients with DCIS hence have an excellent prognosis with adequate local treatment. (Section: Introduction, module 1)	The panel prefers local treatment and therefore has a more positive attitude about radiotherapy and a less positive attitude about endocrine therapy for DCIS from the outset. (Supplemental note: no survival benefit has been demonstrated for either radiotherapy or endocrine therapy. It is, however, suspected that a subgroup of the radiotherapy group does indeed have improved survival. Radiotherapy also has an effect on the risk reduction of an invasive recurrence, which appears to be more limited with endocrine therapy. This could be a reason for the more positive attitude toward radiotherapy compared to endocrine therapy)	1 strong
24 25 26 27 28	The risk of radiation pneumonitis seems to be acceptable (Section: Conclusions, module 5)	The panel finds the risk of radiation pneumonitis acceptable. In the literature, this risk is only represented in chance words: the risk is "very low" and "generally low". The reader is shown neither the absolute risk or patient preferences relevant to this trade-off.	1 strong and 1 weak
29 30 31 32 33 34 35 36 37	Radiotherapy hence appears to be effective, considering that without adjuvant radiotherapy the risk of recurrence is expected to be higher and the chance of cure to be lower. (Section: Literature review, module 6)	In case of positive surgical margins, there is a strong recommendation in favour of adjuvant radiotherapy, arising from the assumption that the benefits outweigh the disadvantages. The phrase "appears to be effective" is used, but the guideline does not state the absolute survival gain and does not address side effects, short term or long term. Furthermore, we do not know if patients differ in how they weigh these considerations.	1 strong
38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	2345		

1 Box 5: Examples of phrasings about the patient role

Statements that propose to inform the patient:

- 1. Additional surgical resection after endoscopic removal of a malignant polyp should always be a considered decision, given the relatively high 'number needed to treat', in which the patient must be fully informed about the possible oncological benefit on the one hand and the risk of complications on the other. (Section: Recommendations, module 3)
- 2. It appears worthwhile to inform patients with a high-risk stage II colorectal carcinoma about the possible advantages of adjuvant chemotherapy and the associated side-effects. (Section: Literature review, module 4)

Statements that propose to include the patient's preferences in making the decision:

- 1. Side-effects and effectiveness of both endocrine therapy and radiotherapy should be weighed together with the patient. (Section: Recommendations, module 1)
- **2.** For high-risk malignant colon polyps, the oncological benefit of additional colon resection should always be weighed against the risk of morbidity and even mortality. Age, tumour location, comorbidity, and the patient's preference should be included in this trade-off. (Section: Considerations, module 3)

Localisation	Module	Publication date	Approach	Number of options discussed in recommendations	Strength of recommendations					Role and specialty of interviewees ^s
					In favou	r	Neutral	Against		
		\sim			Strong	Weak		Weak	strong	
Breast cancer	DCIS	Unpublished concept (27 th February 2017)	GRADE	5	1	0	3	0	1	Surgeon (N=2) Radiotherapist (N=2)
	Endocrine therapy	Unpublished concept (27 th March 2017)	GRADE	11	4	7	0	0	0	None
			201							IKNL Supervisor (N=1)* Patien representative (N=1)
Colorectal cancer	T1 carcinoma in polyp	16 th April 2014 (version 3)	Evidence-based	3	1	2	0	0	0	Surgeon (N=1) Gastroenterologist (N=1)
	Adjuvant chemotherapy	16 th April 2014 (version 3)	Evidence-based	6	4	2	0	0	0	Oncologist (N=1)
										IKNL Supervisor (N=1)* Patient representative (N=1)
Resectable non- small cell lung cancer	Stereotactic radiotherapy	16 th April 2014 (version 3)	Evidence-based (2011) and Consensus-based (2013)	3	1	1	0	1	0	Radiotherapist (N=3)**
	(Neo) adjuvant radiotherapy	16 th April 2014 (version 3)	Evidence-based (2011) and Consensus-based (2013)	4	1	2	0	0	1	Radiotherapist (N=1)**
										IKNL Supervisor (N=1)
N=3	N=6			N=32	N=12	N=14	N=3	N=1	N=2	IKNL Supervisors N=2; Patient representatives N=2; Radiotherapists N=5; Surgeon

N=3; Oncologists N=1; Gastroenterologist N=1

And the colorectal carcinoma guidely. Lout two modules of the NSCLC CPG. IKNL, Netherlands Comprehensive Cancer Organisation *interviewed once, both about the breast cancer and the colorectal carcinoma guidelines

** one radiotherapist was interviewed once about two modules of the NSCLC CPG.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Table 2. Quantitative overview of the results of the CPG analysis

		Strength of recommendation		
		Strong N (%)	Weak or neutral N (%)	Total N (%)
		14 (44)	18 (56)	32
Trade-offs mentioned	Yes	7 (50)	11 (61)	18 (56)
	No	7 (50)	7 (39)	14 (44)
Patient preferences assessed	Yes	0	0	0
CPG panel's preferences mentioned	Yes, explicitly	0	0	0
	Yes, implicitly	10 (71)	7 (39)	17 (53)
	No	4 (29)	11 (61)	15 (47)
Statements about patient involvement included	Yes, to actively involve the patient	6 (43)	12 (67)	18 (56)
	Yes, to inform the patient	0	2 (11)	2 (6)
	No	8 (57)	4 (22)	12 (38)

REFERENCES

1. O'Connor AM, Legare F, Stacey D. Risk communication in practice: the contribution of decision aids. BMJ. 2003;327(7417):736-40.

2. Burstein HJ, Lacchetti C, Griggs JJ. Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression Summary. Journal of Oncology Practice. 2016;12(4):390-3.

3. Early Breast Cancer Trialists' Collaborative G, Peto R, Davies C, Godwin J, Gray R, Pan HC, et al. Comparisons between different polychemotherapy regimens for early breast cancer: metaanalyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379(9814):432-44.

4. Whelan T, Sawka C, Levine M, Gafni A, Reyno L, Willan A, et al. Helping patients make informed choices: a randomized trial of a decision aid for adjuvant chemotherapy in lymph node-negative breast cancer. J Natl Cancer Inst. 2003;95(8):581-7.

5. Shue J, Karia RJ, Cardone D, Samuels J, Shah M, Slover JD. A Randomized Controlled Trial of Two Distinct Shared Decision-Making Aids for Hip and Knee Osteoarthritis in an Ethnically Diverse Patient Population. Value Health. 2016;19(4):487-93.

6. Stacey D, Hawker G, Dervin G, Tugwell P, Boland L, Pomey M-P, et al. Decision aid for patients considering total knee arthroplasty with preference report for surgeons: a pilot randomized controlled trial. BMC Musculoskeletal Disorders. 2014;15(1):54.

7. Stacey D, Taljaard M, Dervin G, Tugwell P, O'Connor AM, Pomey MP, et al. Impact of patient decision aids on appropriate and timely access to hip or knee arthroplasty for osteoarthritis: a randomized controlled trial. Osteoarthritis Cartilage. 2016;24(1):99-107.

8. Hamelinck VC, Bastiaannet E, Pieterse AH, Jannink I, van de Velde CJ, Liefers GJ, et al. Patients' preferences for surgical and adjuvant systemic treatment in early breast cancer: a systematic review. Cancer Treat Rev. 2014;40(8):1005-18.

9. Pieterse AH, Stiggelbout AM, Baas-Thijssen MC, van de Velde CJ, Marijnen CA. Benefit from preoperative radiotherapy in rectal cancer treatment: disease-free patients' and oncologists' preferences. Br J Cancer. 2007;97(6):717-24.

10. Couet N, Desroches S, Robitaille H, Vaillancourt H, Leblanc A, Turcotte S, et al. Assessments of the extent to which health-care providers involve patients in decision making: a systematic review of studies using the OPTION instrument. Health Expect. 2015;18(4):542-61.

11. Snijders HS, Kunneman M, Bonsing BA, de Vries AC, Tollenaar RA, Pieterse AH, et al. Preoperative risk information and patient involvement in surgical treatment for rectal and sigmoid cancer. Colorectal Dis. 2014;16(2):O43-9.

12. Kunneman M, Branda ME, Hargraves I, Pieterse AH, Montori VM. Fostering Choice Awareness for Shared Decision Making: A Secondary Analysis of Video-Recorded Clinical Encounters. Mayo Clin Proc Innov Qual Outcomes. 2018;2(1):60-8.

13. Kunneman M, Engelhardt EG, Ten Hove FL, Marijnen CA, Portielje JE, Smets EM, et al. Deciding about (neo-)adjuvant rectal and breast cancer treatment: Missed opportunities for shared decision making. Acta Oncol. 2016;55(2):134-9.

14. Kunneman M, Marijnen CA, Rozema T, Ceha HM, Grootenboers DA, Neelis KJ, et al. Decision consultations on preoperative radiotherapy for rectal cancer: large variation in benefits and harms that are addressed. Br J Cancer. 2015;112(1):39-43.

15. Engelhardt EG, Pieterse AH, van der Hout A, de Haes HJ, Kroep JR, Quarles van Ufford-Mannesse P, et al. Use of implicit persuasion in decision making about adjuvant cancer treatment: A potential barrier to shared decision making. Eur J Cancer. 2016;66:55-66.

16. Kunneman M, Stiggelbout AM, Marijnen CA, Pieterse AH. Probabilities of benefit and harms of preoperative radiotherapy for rectal cancer: What do radiation oncologists tell and what do patients understand? Patient Educ Couns. 2015;98(9):1092-8.

Page 23 of 27

BMJ Open

17. Kunneman M, Marijnen CA, Baas-Thijssen MC, van der Linden YM, Rozema T, Muller K, et al. Considering patient values and treatment preferences enhances patient involvement in rectal cancer treatment decision making. Radiother Oncol. 2015;117(2):338-42.

18. Pieterse AH, Kunneman M, Engelhardt EG, Brouwer NJ, Kroep JR, Marijnen CAM, et al. Oncologist, patient, and companion questions during pretreatment consultations about adjuvant cancer treatment: a shared decision-making perspective. Psychooncology. 2017;26(7):943-50.

19. Chong CA, Chen IJ, Naglie G, Krahn MD. How well do guidelines incorporate evidence on patient preferences? J Gen Intern Med. 2009;24(8):977-82.

20. McCormack JP, Loewen P. Adding "value" to clinical practice guidelines. Can Fam Physician. 2007;53(8):1326-7.

21. de Kort SJ, Burgers JS, Willems DL. Value judgements that matter to patients remain implicit in oncology guidelines: an observational study. Neth J Med. 2009;67(2):62-8.

22. Krahn M, Naglie G. The next step in guideline development: incorporating patient preferences. JAMA. 2008;300(4):436-8.

23. McCartney M, Treadwell J, Maskrey N, Lehman R. Making evidence based medicine work for individual patients. BMJ. 2016;353:i2452.

24. Montori VM, Brito JP, Murad MH. The optimal practice of evidence-based medicine: incorporating patient preferences in practice guidelines. JAMA. 2013;310(23):2503-4.

25. Shaneyfelt TM, Centor RM. Reassessment of clinical practice guidelines: go gently into that good night. JAMA. 2009;301(8):868-9.

26. Alonso-Coello P, Oxman AD, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines. BMJ. 2016;353:i2089.

27. Alonso-Coello P, Schunemann HJ, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction. BMJ. 2016;353:i2016.

28. Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, et al. GRADE guidelines:
14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol. 2013;66(7):719-25.

29. Andrews JC, Schunemann HJ, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, et al. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength. J Clin Epidemiol. 2013;66(7):726-35.

30. Stiggelbout AM, Van der Weijden T, De Wit MP, Frosch D, Legare F, Montori VM, et al. Shared decision making: really putting patients at the centre of healthcare. BMJ. 2012;344:e256.

31. Zhang Y, Coello PA, Brozek J, Wiercioch W, Etxeandia-Ikobaltzeta I, Akl EA, et al. Using patient values and preferences to inform the importance of health outcomes in practice guideline development following the GRADE approach. Health Qual Life Outcomes. 2017;15(1):52.

32. Gale NK, Heath G, Cameron E, Rashid S, Redwood S. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. BMC Med Res Methodol. 2013;13:117.

33. Pope C, Ziebland S, Mays N. Qualitative research in health care. Analysing qualitative data. BMJ. 2000;320(7227):114-6.

34. Friese S. Atlas.ti 7 User manual. Berlin: Atlas.ti Scientific Software Development; 2012.

35. Alexander PE, Li SA, Gionfriddo MR, Stoltzfus RJ, Neumann I, Brito JP, et al. Senior GRADE methodologists encounter challenges as part of WHO guideline development panels: an inductive content analysis. J Clin Epidemiol. 2016;70:123-8.

36. Casarett D. The Science of Choosing Wisely--Overcoming the Therapeutic Illusion. N Engl J Med. 2016;374(13):1203-5.

37. Engelhardt EG, Pieterse AH, Han PK, van Duijn-Bakker N, Cluitmans F, Maartense E, et al. Disclosing the Uncertainty Associated with Prognostic Estimates in Breast Cancer. Med Decis Making. 2017;37(3):179-92.

38. Christie B. Catherine Calderwood: champion of "realistic medicine". BMJ. 2016;355:i5455.
39. Ioannidis JPA. Hijacked evidence-based medicine: stay the course and throw the pirates overboard. J Clin Epidemiol. 2017;84:11-3.

40. Coulter A. The global reach of shared decision making 2017 [Available from: https://blogs.bmj.com/bmj/2017/07/13/angela-coulter-the-global-reach-of-shared-decision-

making/.

41. van der Weijden T, Pieterse AH, Koelewijn-van Loon MS, Knaapen L, Legare F, Boivin A, et al. How can clinical practice guidelines be adapted to facilitate shared decision making? A qualitative key-informant study. BMJ Qual Saf. 2013;22(10):855-63.

42. Agoritsas T, Merglen A, Heen AF, Kristiansen A, Neumann I, Brito JP, et al. UpToDate adherence to GRADE criteria for strong recommendations: an analytical survey. BMJ Open. 2017;7(11):e018593.

43. Agoritsas T, Neumann I, Mendoza C, Guyatt GH. Guideline conflict of interest management and methodology heavily impacts on the strength of recommendations: comparison between two iterations of the American College of Chest Physicians Antithrombotic Guidelines. J Clin Epidemiol. 2017;81:141-3.

44. Moreira T, May C, Mason J, Eccles M. A new method of analysis enabled a better understanding of clinical practice guideline development processes. J Clin Epidemiol. 2006;59(11):1199-206.

45. Shaneyfelt TM, Mayo-Smith MF, Rothwangl J. Are guidelines following guidelines? The methodological quality of clinical practice guidelines in the peer-reviewed medical literature. JAMA. 1999;281(20):1900-5.

46. Wollersheim H. Beyond the evidence of guidelines. Neth J Med. 2009;67(2):39-40.

47. Schunemann HJ, Wiercioch W, Brozek J, Etxeandia-Ikobaltzeta I, Mustafa RA, Manja V, et al. GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT. J Clin Epidemiol. 2017;81:101-10.

Standards for Reporting Qualitative Research (SRQR)*

http://www.equator-network.org/reporting-guidelines/srqr/

Page/line no(s).

Title and abstract

Title - Concise description of the nature and topic of the study Identifying the study as qualitative or indicating the approach (e.g., ethnography, grounded	
theory) or data collection methods (e.g., interview, focus group) is recommended	Page 1
Abstract - Summary of key elements of the study using the abstract format of the intended publication; typically includes background, purpose, methods, results,	
and conclusions	Page 2

Introduction

tro	oduction	
	Problem formulation - Description and significance of the problem/phenomenon studied; review of relevant theory and empirical work; problem statement	Page 4
	Purpose or research question - Purpose of the study and specific objectives or questions	Page 4, lines 39- 43

Methods

	Page 4, lines 2
Qualitative approach and research paradigm - Qualitative approach (e.g.,	37
ethnography, grounded theory, case study, phenomenology, narrative research)	Page 5, lines 4
and guiding theory if appropriate; identifying the research paradigm (e.g.,	14
postpositivist, constructivist/ interpretivist) is also recommended; rationale**	Page 7, line 27
Researcher characteristics and reflexivity - Researchers' characteristics that may	
influence the research, including personal attributes, qualifications/experience,	
relationship with participants, assumptions, and/or presuppositions; potential or	
actual interaction between researchers' characteristics and the research	Page 6, lines 3
questions, approach, methods, results, and/or transferability	37
	Page 5, lines 1
Context - Setting/site and salient contextual factors; rationale**	20
Sampling strategy - How and why research participants, documents, or events	Page 5, lines 2
were selected; criteria for deciding when no further sampling was necessary (e.g.,	34
sampling saturation); rationale**	Page 7, lines 5
Ethical issues pertaining to human subjects - Documentation of approval by an	
appropriate ethics review board and participant consent, or explanation for lack	Page 7, lines 8
thereof; other confidentiality and data security issues	10
Data collection methods - Types of data collected; details of data collection	Page 5, line 39
procedures including (as appropriate) start and stop dates of data collection and	page 6, line 31
analysis, iterative process, triangulation of sources/methods, and modification of	Page 7, lines 1
procedures in response to evolving study findings; rationale**	24

Page 5, lines 37; Page 6. Lines 33-

Page 7, lines 22-

Page 5, lines 24-

Page 7, line 45-

Page 7, line 27-

Page 6, line 41 Page 7, line 33-

Page 7, lines 13-

Pages 7, Ine 44--page 11, line 18 Idem (including Boxes and

Page 11, line 22

– page 13, line 6 Page 12, lines

Page 3, lines 12-

Page 3, lines 8-

29-44

14

11

Tables)

page 8, line 4

41

24

25

36

44

17

1 2 3 4 5	Data collection instruments and technologies - Description of instruments (e.g., interview guides, questionnaires) and devices (e.g., audio recorders) used for data collection; if/how the instrument(s) changed over the course of the study
6 7 8 9	Units of study - Number and relevant characteristics of participants, documents, or events included in the study; level of participation (could be reported in results)
10 11 12 13	Data processing - Methods for processing data prior to and during analysis, including transcription, data entry, data management and security, verification of data integrity, data coding, and anonymization/de-identification of excerpts
14 15 16 17	Data analysis - Process by which inferences, themes, etc., were identified and developed, including the researchers involved in data analysis; usually references a specific paradigm or approach; rationale**
18 19 20 21	Techniques to enhance trustworthiness - Techniques to enhance trustworthiness and credibility of data analysis (e.g., member checking, audit trail, triangulation); rationale**
22 23 Res	ults/findings
24 25 26 27	Synthesis and interpretation - Main findings (e.g., interpretations, inferences, and themes); might include development of a theory or model, or integration with prior research or theory
28 29 30 31	Links to empirical data - Evidence (e.g., quotes, field notes, text excerpts, photographs) to substantiate analytic findings
51	
32 33 Disc	cussion
32	Integration with prior work, implications, transferability, and contribution(s) to the field - Short summary of main findings; explanation of how findings and conclusions connect to, support, elaborate on, or challenge conclusions of earlier scholarship; discussion of scope of application/generalizability; identification of unique contribution(s) to scholarship in a discipline or field
32 33 Disc 34 35 36 37 38 39 40 41	Integration with prior work, implications, transferability, and contribution(s) to the field - Short summary of main findings; explanation of how findings and conclusions connect to, support, elaborate on, or challenge conclusions of earlier scholarship; discussion of scope of application/generalizability; identification of
32 33 Disc 34 35 36 37 38 39 40 41 42 43	Integration with prior work, implications, transferability, and contribution(s) to the field - Short summary of main findings; explanation of how findings and conclusions connect to, support, elaborate on, or challenge conclusions of earlier scholarship; discussion of scope of application/generalizability; identification of unique contribution(s) to scholarship in a discipline or field Limitations - Trustworthiness and limitations of findings
32 33 Disc 34 35 36 37 38 39 40 41 42 43	Integration with prior work, implications, transferability, and contribution(s) to the field - Short summary of main findings; explanation of how findings and conclusions connect to, support, elaborate on, or challenge conclusions of earlier scholarship; discussion of scope of application/generalizability; identification of unique contribution(s) to scholarship in a discipline or field Limitations - Trustworthiness and limitations of findings er Conflicts of interest - Potential sources of influence or perceived influence on
32 33 Disc 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49	Integration with prior work, implications, transferability, and contribution(s) to the field - Short summary of main findings; explanation of how findings and conclusions connect to, support, elaborate on, or challenge conclusions of earlier scholarship; discussion of scope of application/generalizability; identification of unique contribution(s) to scholarship in a discipline or field Limitations - Trustworthiness and limitations of findings
32 33 Disc 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50	Integration with prior work, implications, transferability, and contribution(s) to the field - Short summary of main findings; explanation of how findings and conclusions connect to, support, elaborate on, or challenge conclusions of earlier scholarship; discussion of scope of application/generalizability; identification of unique contribution(s) to scholarship in a discipline or field Limitations - Trustworthiness and limitations of findings er Conflicts of interest - Potential sources of influence or perceived influence on study conduct and conclusions; how these were managed Funding - Sources of funding and other support; role of funders in data collection,
32 33 Disc 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49	Integration with prior work, implications, transferability, and contribution(s) to the field - Short summary of main findings; explanation of how findings and conclusions connect to, support, elaborate on, or challenge conclusions of earlier scholarship; discussion of scope of application/generalizability; identification of unique contribution(s) to scholarship in a discipline or field Limitations - Trustworthiness and limitations of findings er Conflicts of interest - Potential sources of influence or perceived influence on study conduct and conclusions; how these were managed Funding - Sources of funding and other support; role of funders in data collection,

Reference:

DOI: 10.1097/ACM.00000000000388

**The rationale should briefly discuss the justification for choosing that theory, approach,

method, or technique rather than other options available, the assumptions and limitations

transferability. As appropriate, the rationale for several items might be discussed together.

O'Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative

research: a synthesis of recommendations. Academic Medicine, Vol. 89, No. 9 / Sept 2014

implicit in those choices, and how those choices influence study conclusions and

BMJ Open

The role of patient preferences in clinical practice guidelines: a multiple methods study using guidelines from oncology as a case

Journal:	BMJ Open
Manuscript ID	bmjopen-2019-032483.R1
Article Type:	Original research
Date Submitted by the Author:	13-Sep-2019
Complete List of Authors:	Gärtner , Fania; Leiden University Medical Center Portielje, Johanneke; Leiden University Medical Center, Clinical Oncology Langendam, Miranda; Academic Medical Center, Clinical Epidemiology, Biostatistics and Bioinformatics Hairwassers, Desiree; Breast Cancer Association the Netherlands Agoritsas, Thomas; University Hospitals of Geneva, Division of General Internal Medicine & Division of Clinical Epidemiology; McMaster University Faculty of Health Sciences, Department of Health Research Methods, Evidence, and Impact Gijsen, Brigitte; Netherlands Comprehensive Cancer Organisation Liefers, Gerrit-Jan; Leids Universitair Medisch Centrum, Surgery; Leids Universitair Medisch Centrum, Pieterse, A.H. ; Leids Universitair Medisch Centrum, Medical Decision Making Stiggelbout, Anne; Leiden University Medical Center
Primary Subject Heading :	Health services research
Secondary Subject Heading:	Communication, Ethics, Evidence based practice, Oncology, Qualitative research
Keywords:	Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, shared decision making, evidence-based medicine, GRADE, patient preferences, choice awareness

SCHOLARONE[™] Manuscripts

1		
2 3	1	The role of nationt proforences in clinical practice guidelines: a multiple
4		The role of patient preferences in clinical practice guidelines: a multiple
5 6	2	methods study using guidelines from oncology as a case
7	3	
8 9	4	FR Gärtner (1) (<u>https://orcid.org/0000-0002-0351-0204</u>), JEA Portielje (2) (<u>https://orcid.org/0000-</u>
9 10	5	<u>0002-5169-6306</u>), M Langendam (3) (<u>https://orcid.org/0000-0001-9038-3209</u>), D Hairwassers (4), T
11	6	Agoritsas (5,6) (<u>https://orcid.org/0000-0002-6182-9969</u>), BCM Gijsen (7) (<u>https://orcid.org/0000-</u>
12	7	0003-4578-0293), GJ Liefers (8) (<u>https://orcid.org/0000-0001-7326-8313</u>), AH Pieterse (1)
13 14	8 9	(<u>https://orcid.org/0000-0001-6395-0052</u>), AM Stiggelbout (1) (<u>https://orcid.org/0000-0002-6293-</u>
15	9 10	<u>4509</u>)
16	10	1 Medical Decision Melving Department of Diamedical Data Calendary Laiden University
17 18	11	1. Medical Decision Making, Department of Biomedical Data Sciences, Leiden University
19	12	Medical Center, Leiden, The Netherlands
20	13	2. Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands
21 22	14	 Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam UMC, Amsterdam, The Netherlands
23	16	 Breast Cancer Association The Netherlands (Borstkankervereniging Nederland), The
24	17	Netherlands
25 26	18	5. Division General Internal Medicine, University Hospitals of Geneva, Geneva, Switzerland
20	19	 Department of Health Research Methods, Evidence, and Impact, McMaster University,
28	20	Hamilton, L8S 4K1, Canada
29 30	20	7. The Netherlands Comprehensive Cancer Organisation (IKNL), Maastricht/Utrecht, The
31	22	Netherlands
32	23	8. Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands
33	24	
34 35	25	Word count: 4797
36	26	
37	27	Keywords: EBM, Clinical Practice Guidelines, Shared Decision Making, patient preferences, patient-
38 39	28	centred care, choice awareness
40	29	
41	30	
42 43	31	Corresponding author:
44	32	Corresponding author: AM Stiggelbout, A.M.Stiggelbout@lumc.nl
45		
46 47		
48		
49		
50 51		
52		
53		
54 55		
56		
57		
58 59		
60		

ABSTRACT (299 words) Objectives: Many treatment decisions are preference-sensitive, and call for shared decision-making, notably when benefits are limited or uncertain, and harms impact quality of life. We explored if clinical practice guidelines (CPGs) acknowledge preference-sensitive decisions in how they motivate and phrase their recommendations. Design: We performed a qualitative analysis of the content of CPGs, and verified the results in semi-structured interviews with CPG panel members. Setting: Dutch oncology CPGs issued in 2010 or later, concerning primary treatment with curative intent. Participants: 14 CPG panel members. Main outcomes: For treatment recommendations from six CPG modules, two researchers extracted: strength of recommendation in terms of GRADE and its consistency with the CPG text; completeness of presentation of benefits and harms; incorporation of patient preferences; statements on the panel's benefits-harm tradeoff underlying recommendation; advice on patient involvement in decision-making. Results: We identified 32 recommendations, 18 were acknowledged preference-sensitive decisions. Three of 14 strong recommendations should have been weak based on the module text. The reporting of benefits and harms, and their probabilities, was sufficiently complete and clear to inform the strength of the recommendation in one of the six modules only. Numerical probabilities were seldom presented. None of the modules presented information on patient preferences. CPG panel's preferences were not made explicit, but appeared to have impacted 15 of 32 recommendations. Advice to involve patients and their preferences in decision-making was given for 20 recommendations (14 weak). Interviewees confirmed these findings. Explanations for lack of information were e.g. that clinicians know the information and that CPGs must be short. Explanations for trade-offs made were cultural-historical preferences, compliance with daily care, presumed role of CPGs, and lack of time. Conclusions: The motivation and phrasing of CPG recommendations do not stimulate choice awareness and a neutral presentation of options, thus hindering shared decision making.

2		
3	1	SUMMARY BOX
4	-	
5	C	Churchester and limitations of this study.
6	2	Strengths and limitations of this study
7		
8	3	• Strength of the study is that we used GRADE for the qualitative analysis of the guidelines, as
9	4	weak recommendations in GRADE reflect preference-sensitive decisions.
10		
11	5	• Strength of the study is the validation of the qualitative analysis of the guidelines in in-depth
12	6	interviews with the guideline developers.
13	7	• Limitation of the study is that we studied oncology guidelines from one country only .
14	8	
15	0	
16	_	
17	9	FUNDING
18		
19	10	This work was supported by the Dutch Cancer Society grant number UL 2015-7615. The funding
20	11	agreement ensured the authors' independence in designing the study, interpreting the data, writing,
21	12	and publishing the report.
22	14	and publishing the report.
23	10	
24	13	COMPETING INTERESTS
25		
26	14	TA and ML are active members of the GRADE working group. BG is employed at The Netherlands
27	15	Comprehensive Cancer Organisation (IKNL), the organization responsible for development of the
28	16	CPGs that were analyzed. e data, writing, and publishing the report.
29		
30	17	DATA SHARING
31	17	
32	10	
33	18	Anonymized transcripts of the interviews and extraction forms (in Dutch) may be shared upon
34	19	reasonable request to the corresponding author.
35		
36	20	
37		
38		
39		
40		
41		
42		
43		
44		
45		
46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		
60		

1. INTRODUCTION

Many decisions in healthcare are preference-sensitive, in particular when treatments are burdensome, benefits are limited or uncertain, and harms may impact quality of life.(1) Examples are decisions about adjuvant treatment in oncology (2-4) or about hip or knee arthroplasty for osteoarthritis. (5-7) Research shows that patients as well as clinicians often vary considerably in their evaluation of the balance of benefits and harms. Further, clinicians are not always able to predict their individual patients' preferences for treatments or outcomes of treatment.(8, 9) Shared decision making (SDM) is therefore advocated particularly in preference-sensitive decisions, but is not yet common practice.(10, 11) Clinicians are not prone to fostering choice awareness in their patients, (12, 13) often present treatment options in unbalanced ways, e.g., by overestimating benefits and minimizing harms, (14) or steer in other ways, consciously or unconsciously. (15) Further, numerical probabilities needed to make a trade-off are seldom discussed, (16) and patient preferences infrequently elicited.(17, 18) This raises the question if clinicians perceive these decisions as preference-sensitive? Clinical practice guidelines (CPGs) could play a role in this perception, given the impact they have on what treatment options clinicians present to their patients. While CPGs may use wording that suggests that a decision is preference-sensitive, such as "we suggest" or "clinicians might", rather than "we recommend" or "clinicians should", clinicians may still not fully appreciate the importance of offering more than one option to their patients. It is unknown if recommendations in current CPGs identify preference-sensitive decisions and demand a role for patient preferences in decision making. Two older studies showed that the relevance of preferences of individual patients was not acknowledged in many CPGs.(19, 20) CPG developers often assume "generally accepted" values in developing recommendations, but do not acknowledge this in the phrasing of the recommendation.(21) A request for a more systematic incorporation of patient preferences in CPGs has been expressed repeatedly in high impact journals since the publications of these studies. (22-25) The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) working group -whose approach is nowadays considered the standard in CPG development- has published a framework that acknowledges the integration of patients' values and preferences in the development of CPG recommendations.(26-31) In the GRADE approach, preference-sensitive decisions are reflected in so-called "weak", or "conditional" recommendations. These arise when benefits and harms are closely balanced, evidence is lacking or of uncertain quality, when patients' preferences are expected to vary substantially, but also when no evidence on patient preferences is available, even with moderate or strong evidence of high quality on the benefits of an option. (28) In such situations, GRADE still leads to weak recommendations, assuming that most informed patients would choose the recommended treatment, but a substantial number would not. (28, 29, 31) (see Box 1 for a summary of the role that GRADE proposes for patient values and preferences in CPG development)

Therefore, a key ingredient for the identification of preference-sensitive decisions is the acknowledgment of values and preferences in the rationale for CPG recommendations. The aim of our study was therefore to explore to what extent CPGs acknowledge preference-sensitive decisions in the way they support and phrase their recommendations. We further wished to assess if the CPGs facilitate the communication of the preference-sensitive nature of these decisions to patients.

1		
2		
3	1	>>> Insert Box 1 about here <<<
4 5	2	
6	3	2. METHODS
7	4	We performed a qualitative analysis of Dutch oncologic CPGs, which we next verified and refined in
8 9	5	semi-structured interviews with members of CPG development panels.
10	6	
11	7	
12	8	2.1 Qualitative analysis of CPGs
13 14	9	2.1.1 Selected CPG modules
15	10	We used Dutch oncologic CPGs as a case, because oncology is strongly guideline-driven, decisions
16	11	are often preference-sensitive, the guideline development process is organized nationally, and the
17 18	12	CPGs are open access. The Netherlands Comprehensive Cancer Organisation (IKNL) develops
19	13	guidelines "under responsibility of the most relevant professional or scientific society, usually
20	14	following evidence-based methodology" (<u>www.oncoline.nl</u>). We selected three tumour-specific
21	15	CPGs, and of each we selected all content of two modules to include in our analysis (i.e., the sections
22 23	16	of the CPGs that address specific treatments or patient groups). We selected a convenience sample
24	17	of modules for prevalent cancers that we expected to contain at least one preference-sensitive
25	18	decision, calling for a weak recommendation. This expectation was based on earlier research from
26 27	19	our group (e.g., (11, 13, 15)), views from the oncology experts on our research team, and/or on the
28	20	availability of literature on SDM and decision aids for the treatment in that module. Each of the
29	21	modules included more than one recommendation.
30 31	22	Further criteria for selection of the CPGs and the modules were: published on www.oncoline.nl,
32	23	issued in 2010 or later, and concerning primary treatment with curative intent. Table 1 presents the
33	24	CPGs and modules we selected. For the breast cancer CPG, our contact person at the IKNL provided
34	25	us confidentially with the most recent revision of the two selected modules, which were not yet
35 36	26	published at the time of our analysis. In none of the modules explicit reference was made to GRADE.
37	27	
38	28	2.1.2 Data extraction and analysis
39 40	29	We assessed if the CPG acknowledges preference-sensitive decisions, and whether the user is to
41	30	understand the strength of a recommendation, based on the information presented. To this aim we
42	31	developed a coding scheme that consisted of the five following themes, based on the GRADE
43	32	framework ((28)).
44 45	33	
46	33 34	<u>1. Strength of recommendations:</u> First, we scored the strength of the recommendation (strongly in
47	34 35	
48 49	35 36	favour/ weakly in favour/ neutral / weakly against/ strongly against a specific option) for each
50	30 37	treatment option described in the Recommendation section of the CPG. Scoring was solely based on
51	37	the phrasing used in that section The categories strong and weak that we used are in line with
52	38 39	GRADE. We added the 'neutral' category if a weak recommendation for more than one option was
53 54	39 40	given.
55	40 41	Next, we accord whether this strength of recommendation was supported by information
56	41 42	Next, we assessed whether this strength of recommendation was supported by information
57 58	42 43	elsewhere in the guideline, including information about the certainty of the evidence, the balance
59	43 44	between benefits and harms and their probabilities, the variability or uncertainty in how patients
60	44	value the benefits and harms, or the absence of evidence on patient preferences, even with

moderate or strong evidence of high quality on the benefits of an option. If other criteria were provided, we coded these as well. We extracted all information that indicated a discrepancy with the strength of recommendation, and scored whether or not textual discrepancies were identified (yes/no). We based this on the CPG text, and did not resort to the supporting literature. 2. Balance of benefits and harms (trade-offs): We defined a trade-off as a statement presenting the balance of benefits and harms in the treatment decision, ideally based on the probability of benefits and harms, the quality of the evidence, and on how much patients value the outcomes. We extracted statements about the trade-offs made in the CPG or about the trade-offs to be made in the clinical encounter with the individual patient (trade-offs made explicit/trade-offs not made explicit). We also judged whether the presentation of outcomes was sufficiently complete and clear to inform the trade-off (*sufficient/insufficient*). 3. Patient preferences: We assessed if patient preferences had been incorporated (yes/no), and if so, how (*literature search/data collection by CPG panel/other*). Also, we extracted whether explicit assumptions were made regarding patient preferences (yes/no). 4. CPG panel's values and preferences: We extracted information about the preferences that supported the CPG panel's weighing of benefits and harms, and summarized per treatment recommendation if these preferences were explicitly mentioned (yes/no). This theme does not directly originate from the GRADE recommendations. We added it as we encountered statements suggesting that CPG panel's values and preferences had influenced the development of recommendations. Finally, we assessed if the CPGs facilitated discussion of patient preferences for weak recommendations, as for the latter "clinicians and other health care providers need to devote more time to the process of shared decision making by which they ensure that the informed choice reflects individual values".((28)) 5. Advice on how to involve the patient: We extracted statements that described how to involve an individual patient or his/her preferences in the decision making process, and summarized per recommendation if such statement was given (yes, actively involving the patient or patient preferences in the decision making/yes, informing the patient/no advice about patient involvement). Two coders (FG and AS) independently applied a first draft of the coding scheme to a CPG module that would not be included in the final selection. They subsequently discussed the coding process and any inconsistencies, and updated the coding scheme. They had not been involved in the development of any CPG in oncology nor GRADE, and had no existing working relationship with the members of the respective CPG panels. The coders independently applied the coding scheme to one of the selected modules, and resolved any discrepancies by consensus. Based on this discussion no further changes were made to the scheme. One researcher (FG) then coded the remaining modules, and the second checked the extraction and scoring. They discussed any inconsistency between them until agreement was reached. Data extracted was analysed descriptively. 2.2 Semi-structured interviews with CPG developers 2.2.1 Sampling

Page 7 of 27

BMJ Open

We or our IKNL contact person invited all panel members involved in the development of the selected modules for participation. Membership and size of the different CPG panels varied, not all were multidisciplinary, and not all included a patient representative. We aimed to interview at least one member of each specialty involved in the development of a module, the patient representative, and the IKNL supervisor of the CPG.. As patient representatives did not participate in this study based on a paid position, the respective patient organizations received an incentive of 100 Euros. The study protocol did not require review from a medical ethics committee as no patients or lay people were recruited. 2.2.2 Data collection In semi-structured interviews, we first checked whether the interviewee agreed with our interpretation of the strength of recommendations, our extraction of the discrepancies found in the CPG text, of the trade-offs, and the completeness and clarity of the presentation of the benefits and harms, of the role of patient preferences, and of the preferences of the CPG panels that supported the recommendations. For the benefits, harms, and trade-offs we asked them how the developers selected which ones to present, and whether the presentation of benefits and harms aimed to facilitate communication in the clinical encounter. Finally, we discussed the function of statements concerning the involvement of patients and their preferences in decision making for the individual patient. We adapted the questions to the specific content of the module to be discussed. For each subsequent interview we added or adapted questions based on earlier interviews. Interviews lasted 30 to 60 minutes, were audiotaped, and transcribed verbatim. One interviewer (FG) trained in qualitative research methods and highly experienced in interviewing carried out all interviews. 2.2.3 Coding and analysis We adhered to the Framework Approach to code and analyse the interviews.(32, 33) The coding scheme was based on the five themes of the CPG analysis described above. First, two researchers (FG and AS) independently familiarized themselves with the data, and coded three interviews deductively, to supplement our coding scheme with any additional emerging themes. Dissimilarities in coding were discussed and codes were adapted based on consensus. Second, one researcher applied deductive coding to all other interviews and refined, and reduced the codes in a process of re-reading and constant comparison of codes. Third, categories of codes were clustered to generate (sub)themes. Steps two and three were performed by one researcher and checked by the second. Inconsistencies in interpretation of the data and formulation of codes and themes were discussed until consensus was reached. Coding was performed using Atlas.ti software.(34) 2.3 Patient involvement The CPG committee involved patient representatives for two modules, and we interviewed these patients. One patient (DH) took part in the writing of the manuscript. The article will be shared with the Netherlands Federation of Cancer Patient Societies NFK. **3. RESULTS** We present the results of the qualitative analysis and the interviews together, structured around the five themes mentioned above. We interviewed 14 CPG panel members: 10 clinicians, two patient representatives, and two IKNL supervisors (Table 1). For one module (adjuvant endocrine therapy in

breast cancer), only one of the clinician panel members indicated to have time to participate. After an interruption due to a clinical urgency she did not want to resume the interview because she found the questions too critical. Therefore only the IKNL supervisor and the patient panel member were interviewed. Patients were not part of the CPG panel for the NSCLC modules. To illustrate our

5 analyses we add examples of the extractions of the CPG modules in Box 2-5.

3.1 Strength of CPG recommendations

8 In the six modules we identified 32 recommendations, of which 14 were phrased as strong and 18 as 9 weak or neutral. The proportion of weak or neutral recommendations was just over half for all 10 modules, except for that on adjuvant chemotherapy for colorectal carcinoma, which had fewer weak 11 recommendations (33%). For five of the recommendations, both strong (three) and weak (one) or 12 neutral (one), we found discrepancies between the strength of recommendation and extracted 13 sentences from the module text. Box 2 shows examples of such discrepancies. In two of the strong 14 recommendations, the discrepancy concerned evidence that was limited or of (very) low quality.

16 >>> Insert Box 2 about here <<<

The CPG panel members confirmed our interpretation of the strength of recommendations. They explained that the three strong recommendations in the case of limited evidence were based on a valuation of the outcomes by the CPG panel (see further under 3.4). One explanation for the discrepancies between the strength of recommendation and the extracted were the differences in the handling of low quality evidence between methodologists and clinicians. One clinician described methodologists as being more careful in drawing conclusions, while clinicians incorporate current standards of practice in the formulation of recommendations.

Panel member: I think that it is inherent to making recommendations, where clinicians and methodologists clash. I am currently preparing the revision of the guideline, and what one sees is that we simply clash immediately with the methodologists in the preparation of the revision. Those are very dogmatic in their methodologic thinking. And the problem is, that that does not work, particularly not for the medical literature, so to say. And that is why the GRADE methodology explicitly discusses that in their approach, that one can upgrade the recommendation if one agrees as professional group that something should or should not be done. (Interview 10, about T1 carcinoma in polyp)

3.2 Information supporting the balance of benefits and harms

Three of the modules (T1 carcinoma in polyp and adjuvant chemotherapy in colorectal cancer, stereotactic radiotherapy in NSCLC) included explicit trade-off statements (see Box 3). Probabilities of outcomes were mentioned in one of these, but for the benefits only. One trade-off statement substantiating a strong recommendation included the presentation of a value judgment, but it was unclear whose values it presented "it is agreed upon that it is safe ...," and "the risk of radiation pneumonitis seems acceptable". For one of the six modules, adjuvant chemotherapy for colorectal cancer, we rated the report of benefits and harms and their probabilities as sufficiently complete and clear to inform the strength of recommendation. In three modules information was lacking about benefits, in four about harms,

46 and harms were often only presented generically (e.g., "complications", "psychological impact").

1 Relative rather than absolute risk reduction was often presented, verbal labels rather than numbers 2 were used to convey risk, e.g., "The chance of eventually preserving the breast is higher if radiation 3 of the breast already takes place after the first excision". 4 >>>> Insert Box 3 about here << 6 Some interviewees found that transparency about the trade-offs in the CPG text could be improved, 7 Some interviewees found that transparency about the trade-offs in the CPG text could be improved, 8 while others found an explicit mention, including details about benefits and harms and their 9 probabilities, unnecessary. Reasons for the latter were time constraints, the aim to keep the CPG 10 short, the assumption that CPG-suers know the balance of benefits and harms, or that the weighting 11 of benefits and harms was acceptable to everyone. One interviewee, e.g., stated that not 12 recommending endocrine treatment in DCIS was "common knowledge" and that "we also could 13 howe chosen to just leave out the whole paragraph about this adjuvant theray, to just not mention it 14 at al." (interview 15) 15 The interviewees indicated that in none of the modules patients had been involved in the selection 16 The interviewees indicated that in none of the modules, evidence for long-term harms is	1 ว		
 were used to convey risk, e.g., "The chance of eventually preserving the breast is higher if radiation of the breast already takes place after the first excision". >>> Insert Box 3 about here << Some interviewees found that transparency about the trade-offs in the CPG text could be improved, while others found an explicit mention, including details about benefits and harms and their probabilities, unnecessary. Reasons for the latter were time constraints, the aim to keep the CPG of benefits and harms was acceptable to everyone. One interviewee, e.g., stated that not recommending endocrine treatment in DCIS was "common knowledge" and that "we also could have chosen to just leave out the whole paragraph about this adjuvant therapy. to just not mention it at all." (Interview 15) The interviewees indicated that in none of the modules patients had been involved in the selection of the outcomes described. Some acknowledged that outcomes and their probabilities an eccessary, using the following arguments: guidelines should be short, harms are assumed to be common knowledge for clinicians or might be presented in other modules, evidence for long-term harms is lacking, and probabilities from the literature are not applicable to the Dutch setting or would only be representative at the hospital level, not at that of the individual clinician (i.e., for mortality due to a surgery). Several interviewees were especially reticent to present probabilities in terms of absolute trick reduction, as those percentages would soon be dated, differed between patient groups, or would be too time-consuming to calculate. One stated to have argued to include Numbers Needed to Treat in the CPG, to no avail. Panel-member: the CPG is mostly written to, what we provide as recommendation towards the patient for the outcome of treatment. J don't know if the CPG is written at least, how ence there evertee to a sub it on the row of one stensive. And then the CPG, let's say, what's it called, all rists	2 3	1	Relative rather than absolute risk reduction was often presented, verbal labels rather than numbers
a of the breast already takes place after the first excision". b >>> Insert Box 3 about here <<			
 >>> Insert Box 3 about here << Some interviewees found that transparency about the trade-offs in the CPG text could be improved, while others found an explicit mention, including details about benefits and harms and their probabilities, unnecessary. Reasons for the latter were time constraints, the aim to keep the CPG short, the assumption that CPG-users know the balance of benefits and harms, or that the weighting of benefits and harms was acceptable to everyone. One interviewee, e.g., stated that not recommending endocrine treatment in DCIS was "common knowledge" and that' we also could have chosen to just leave out the whole paragraph about this adjuvant therapy, to just nor mention it at al." (Interview 15) The interviewees indicated that in none of the modules patients had been involved in the selection of the outcomes described. Some acknowledged that outcomes might be missing, but a substantial number did not regard a complete presentation of outcomes and their probabilities as necessary, using the following arguments: guidelines should be short, harms are assumed to be common knowledge for clinicians or might be presented in other modules, evidence for long-term harms is lacking, and probabilities from the literature are not applicable to the Dutch setting or would only be representative at the hospital level, not at that of the individual clinican (i.e., for mortality due to surgery). Several interviewees were especially retricent to present probabilities in terms of absolute treat in the CPG to no avail. Interviewer: and for what regord is the other side of the coin not mentioned in the CPG? you would be too time-consuming to calculate. One stated to have argued to include Numbers Needed to Treat in the CPG is mostly written to, what			
 >>> Insert Box 3 about here << Some interviewees found that transparency about the trade-offs in the CPG text could be improved, while others found an explicit mention, including details about benefits and harms and their probabilities, unnecessary. Reasons for the latter were time constraints, the aim to keep the CPG short, the assumption that CPG-users know the balance of benefits and harms, or that the weighting of benefits and harms was acceptable to everyone. One interviewee, e.g., stated that not recommending endocrine treatment in DCIS was "common knowledge" and that "we also could have chosen to just leave out the whole paragraph about this adjuvant therapy, to just not mention it at all." (Interview 15) The interviewees indicated that in none of the modules patients had been involved in the selection of the outcomes described. Some acknowledged that outcomes might be missing, but a substantial number did not regard a complete presented in other modules, evidence for long-term harms is lacking, and probabilities from the literature are not applicable to the Dutch setting or would only be representative at the hospital level, not at that of the individual clinican (i.e., for mortality due to surgery). Several interviewees were especially reticent to present probabilities in terms of absolute tacking, and probabilities for a vali. Panel-member: the CPG is mostly written to, what we provide as recommandation to Treat in the CPG, is no avail. Panel-member: the CPG is mostly written to, what we provide as recommandation to avait the hospital head and the individual clinican (in the CPG, let's say, what's it called, all reterture are sume. But that is also the baseline knowledge that every pacologist should have. (Interview 7, about adjuvant			
9 6 91 6 91 7 91 7 91 7 91 7 91 7 91 9 91 9 91 9 91 9 91 9 91 9 91 9 91 9 91 9 92 9 93 9 94 9 95 9 96 9 97 9 98 9 91 9 91 9 92 9 92 9 93 9 94 9 95 9 95 9 95 9 95 9 95 9 95 9 95 9 95 9 95			>>> Insert Box 2 about here <<<
7 Some interviewees found that transparency about the trade-offs in the CPG text could be improved, 8 while others found an explicit mention, including details about benefits and harms and their 9 probabilities, unnecessary. Reasons for the latter were time constraints, the aim to keep the CPG 9 short, the assumption that CPG-users know the balance of benefits and harms, or that the weighting 11 of benefits and harms was acceptable to everyone. One interviewee, e.g., stated that not 12 recommending endocrine treatment in DCIS was "common knowledge" and that" we also could 13 have chosen to just leave out the whole paragraph about this adjuvant therapy, to just aot mention it 14 at al." (Interview 15) 15 The interviewees indicated that in none of the modules patients had been involved in the selection 16 of the outcomes described. Some acknowledged that outcomes might be missine, but a substantial 18 number did not regard a complete presentation of outcomes and their probabilities as necessary, 19 using the following arguments: guidelines should be short, harms are assumed to be common 18 knowledge for clinicians or might be presented in other modules, evidence for long-term harms is 19 lacking, and probabilities from the literature are not applicable to the Dutch setting or would only be 20 re			
12 8 while others found an explicit mention, including details about benefits and harms and their 13 9 probabilities, unnecessary. Reasons for the latter were time constraints, the aim to keep the CPG 15 0 short, the assumption that CPG-users know the balance of benefits and harms, or that the weighting 16 0 benefits and harms was acceptable to everyone. One interviewee, e.g., stated that not 16 recommending endocrine treatment in DCIS was "common knowledge" and that "we also could 17 not echosen to just leave out the whole paragraph about this adjuvant therapy, to just out mention it 18 at all." (Interview 15) 19 The interviewees indicated that in none of the modules patients had been involved in the selection 10 of the outcomes described. Some acknowledged that outcomes and their probabilities as necessary, 118 number did not regard a complete presentation of outcomes and their probabilities as necessary, 118 number did not regard a complete presentation of outcomes and their probabilities as necessary, 118 number did not regard a complete presentation of outcomes and their probabilities as necessary, 119 using the following arguments: guidelines should be short, harms are assumed to be common 110 knowledge for clinicians or might be presented in other modules, evidence for long-t			Some intenviewees found that transportancy about the trade offs in the CPC toyt could be improved
 a probabilities, unnecessary. Reasons for the latter were time constraints, the aim to keep the CPG a short, the assumption that CPG-users know the balance of benefits and harms, or that the weighting of benefits and harms was acceptable to everyone. One interviewee, e.g., stated that not recommending endocrine treatment in DCIS was "common knowledge" and that "we also could have chosen to just leave out the whole paragraph about this adjuvant therapy, to just not mention it at all." (Interview 15) The interviewees indicated that in none of the modules patients had been involved in the selection of the outcomes described. Some acknowledged that outcomes might be missing, but a substantial number did not regard a complete presentation of outcomes and their probabilities as necessary, using the following arguments: guidelines should be short, harms are assumed to be common knowledge for clinicians or might be presented in other modules, evidence for long-term harms is lacking, and probabilities from the literature are not applicable to the Dutch setting or would only be representative at the hospital level, not at that of the individual clinician (i.e., for mortality due to surgery). Several interviewees were especially reticent to present probabilities in terms of absolute risk reduction, as those percentages would soon be dated, differed between patient groups, or would be too time-consuming to calculate. One stated to have argued to include Numbers Needed to Treat in the CPG, is mostly written to, what we provide as recommendation towards the patient, for the outcome of treatment. I don't know if one should put in the CPG, you indicated, oteray, that actually Panel-member: the CPG is mostly written to, what we provide as recommendation t			
 short, the assumption that CPG-users know the balance of benefits and harms, or that the weighting of benefits and harms was acceptable to everyone. One interviewee, e.g., stated that not recommending endocrine treatment in DCIS was "common knowledge" and that "we also could have chosen to just leve out the whole paragraph about this adjuvant therapy, to just not mention it at all." (Interview 15) The interviewees indicated that in none of the modules patients had been involved in the selection of the outcomes described. Some acknowledged that outcomes might be missing, but a substantial number did not regard a complete presentation of outcomes and their probabilities as necessary, using the following arguments: guidelines should be short, harms are assumed to be common knowledge for clinicians or might be presented in other modules, evidence for long-term harms is lacking, and probabilities from the literature are not applicable to the Dutch setting or would only be representative at the hospital level, not at that of the individual clinician (i.e., for mortality due to surgery). Several interviewees were especially reticent to present probabilities in terms of absolute risk reduction, as those percentages would soon be dated, differed between patient groups, or would be too time-consuming to calculate. One stated to have argued to include Numbers Needed to Treat in the CPG, to no avail. Interviewee: and for what reason is the other side of the coin not mentioned in the CPG? You indicated, already, that actually Panel-memer: the CPG is mostly written to, what we provide as recommendation towards the patient, for the outcome of treatment. If don't know if the CPG is written at least, have envire interpreted it as such, but I don't know if one should			
11 of benefits and harms was acceptable to everyone. One interviewee, e.g., stated that not 12 recommending endocrine treatment in DCIS was "common knowledge" and that "we also could 13 hove chosen to just leave out the whole paragraph about this adjuvant therapy, to just not mention it 14 at all." (Interview 15) 15 The interviewees indicated that in none of the modules patients had been involved in the selection 16 the outcomes described. Some acknowledged that outcomes might be missing, but a substantial 18 number did not regard a complete presented in other modules, evidence for long-term harms is 19 using the following arguments: guidelines should be short, harms are assumed to be common 10 knowledge for clinicians or might be presented in other modules, evidence for long-term harms is 11 lacking, and probabilities from the literature are not applicable to the Dutch setting or would only be 12 surgery). Several interviewees were especially reticent to present probabilities in terms of absolute 13 risk reduction, as those percentages would soon be dated, differed between patient groups, or 14 would be too time-consuming to calculate. One stated to have argued to include Numbers Needed 15 to Treat in the CPG, to no avail. 16 Panel-member: the CPG is mostly written to, what we provide as reco			
recommending endocrine treatment in DCIS was "common knowledge" and that "we also could have chosen to just leave out the whole paragraph about this adjuvant therapy, to just not mention it at all." (Interview 15) The interviewees indicated that in none of the modules patients had been involved in the selection of the outcomes described. Some acknowledged that outcomes might be missing, but a substantial number did not regard a complete presentation of outcomes and their probabilities as necessary, using the following arguments: guidelines should be short, harms are assumed to be common knowledge for clinicians or might be presented in other modules, evidence for long-term harms is lacking, and probabilities from the literature are not applicable to the Dutch setting or would only be representative at the hospital level, not at that of the individual clinician (i.e., for mortality due to surgery). Several interviewees were especially reticent to present probabilities in terms of absolute risk reduction, as those percentages would son be dated, differed between patient groups, or would be too time-consuming to calculate. One stated to have argued to include Numbers Needed to Treat in the CPG, to no avail. Interviewer: and for what reason is the other side of the coin not mentioned in the CPG? You indicated, already, that actually Panel-member: the CPG is mostly written to, what we provide as recommendation towar			
12 recommending endocrine treatment in DCIs was common knowledge and that we also could 13 have chosen to just leave out the whole paragraph about this adjuvant therapy, to just not mention it 14 at all." (Interview 15) 15 The interviewees indicated that in none of the modules patients had been involved in the selection 16 The interviewees indicated that in none of the modules patients had been involved in the selection 17 of the outcomes described. Some acknowledged that outcomes and their probabilities as necessary, 18 number did not regard a complete presentation of outcomes and their probabilities as necessary, 19 using the following arguments: guidelines should be short, harms are assumed to be common 10 knowledge for clinicians or might be presented in other modules, evidence for long-term harms is 10 lacking, and probabilities from the literature are not applicable to the Dutch's etting or would only be 11 representative at the hospital level, not at that of the individual clinician (i.e., for mortality due to 12 surgery). Several interviewees were especially reticent to present probabilities in terms of absolute 13 netwees were especially reticent to present probabilities in terms of absolute 14 risk reduction, as those percentages would son be dated, differed between patient groups, or 15			
14 at all." (Interview 15) 15 The interviewees indicated that in none of the modules patients had been involved in the selection 17 of the outcomes described. Some acknowledged that outcomes might be missing, but a substantial 18 number did not regard a complete presentation of outcomes and their probabilities as necessary, 19 using the following arguments: guidelines should be short, harms are assumed to be common 20 knowledge for clinicians or might be presented in other modules, evidence for long-term harms is 21 lacking, and probabilities from the literature are not applicable to the Dutch setting or would only be 21 representative at the hospital level, not at that of the individual clinician (i.e., for mortality due to 22 surgery). Several interviewees were especially reticent to present probabilities in terms of absolute 23 would be too time-consuming to calculate. One stated to have argued to include Numbers Needed 26 to Treat in the CPG, to no avail. 27 You indicated, already, that actually 28 Interviewer: and for what reason is the other side of the coin not mentioned in the CPG; 29 You indicated, already that actually 29 You indicated, all risks of treatment. I don't know if one should put in the CPG, 21 let's say, what's it cal			
151617181819191919191919101011121314151516171819191919101112121314151515161718181919191910101112121314151515161718181919191910101112121314151515161718181818181818191919 <td></td> <td></td> <td></td>			
1011111112121212131214131514151416151715181219121912191219121912191210121112121213121412151215121612171218121912191210121212121212121212121212121212121212121312141215 <td< td=""><td></td><td></td><td>at all." (Interview 15)</td></td<>			at all." (Interview 15)
16The interviewees indicated that in none of the modules patients had been involved in the selection17of the outcomes described. Some acknowledged that outcomes might be missing, but a substantial18number did not regard a complete presentation of outcomes and their probabilities as necessary,19using the following arguments: guidelines should be short, harms are assumed to be common20knowledge for clinicians or might be presented in other modules, evidence for long-term harms is21lacking, and probabilities from the literature are not applicable to the Dutch setting or would only be22representative at the hospital level, not at that of the individual clinical (i.e., for mortality due to23surgery). Several interviewees were especially reticent to present probabilities in terms of absolute24risk reduction, as those percentages would soon be dated, differed between patient groups, or26would be too time-consuming to calculate. One stated to have argued to include Numbers Needed26to Treat in the CPG, to no avail.27You indicated, already, that actually28Interviewer: and for what reason is the other side of the coin not mentioned in the CPG?29You indicated, neaver interpreted it as such, but I don't know if one should put in the CPG,29for the outcome of treatment. I don't know if the CPG is written at20least, I have never interpreted it as such, but I don't know if one should put in the CPG,29least, uhave interpreted it as such, but I don't know if one should put in the CPG,29least, i abale dui risks of treatment. I don't know if the CPG is k			
2518number did not regard a complete presentation of outcomes and their probabilities as necessary,2619using the following arguments: guidelines should be short, harms are assumed to be common20knowledge for clinicians or might be presented in other modules, evidence for long-term harms is21lacking, and probabilities from the literature are not applicable to the Dutch setting or would only be22representative at the hospital level, not at that of the individual clinician (i.e., for mortality due to23surgery). Several interviewees were especially reticent to present probabilities in terms of absolute24risk reduction, as those percentages would soon be dated, differed between patient groups, or25would be too time-consuming to calculate. One stated to have argued to include Numbers Needed26to Treat in the CPG, to no avail.2770indicated, already, that actually28Interviewer: and for what reason is the other side of the coin not mentioned in the CPG?29You indicated, already, that actually29Panel-member: the CPG is mostly written to, what we provide as recommendation40towards the patient, for the outcome of treatment. I don't know if one should put in the CPG,41let's say, what's it called, all risks of treatment. That differs per agent, have different42risks. And then the CPG becomes much more extensive. But that is also the baseline43knowledge that every oncologist should have.44(Interview 7, about adjuvant chemotherapy for colon carcinoma)453346Some intervi			
 using the following arguments: guidelines should be short, harms are assumed to be common knowledge for clinicians or might be presented in other modules, evidence for long-term harms is lacking, and probabilities from the literature are not applicable to the Dutch setting or would only be representative at the hospital level, not at that of the individual clinician (i.e., for mortality due to surgery). Several interviewees were especially reticent to present probabilities in terms of absolute risk reduction, as those percentages would soon be dated, differed between patient groups, or would be too time-consuming to calculate. One stated to have argued to include Numbers Needed to Treat in the CPG, to no avail. Interviewer: and for what reason is the other side of the coin not mentioned in the CPG? You indicated, already, that actually Panel-member: the CPG is mostly written to, what we provide as recommendation towards the patient, for the outcome of treatment. I don't know if the CPG is written at least, I have never interpreted it as such, but I don't know if one should put in the CPG, let's say, what's it called, all risks of treatment. That differs per agent, have different risks. And then the CPG becomes much more extensive. But that is also the baseline knowledge that every oncologist should have. (Interview 7, about adjuvant chemotherapy for colon carcinoma) 33.3 Patient preferences None of the modules stated that evidence about patient preferences, or about variation in patient preferences, either from the literature or assumed by the panel. Some interviewees acknowledged that patient preferences may vary and may differ from clinician preferences, and they stressed that the awareness of such variation sometimes motivated a weak recommendation. Reasons not to include information about patient preferences were: time and preferences, and they stressed that the awareness of such variation sometimes motivated a wea			of the outcomes described. Some acknowledged that outcomes might be missing, but a substantial
1718191920knowledge for clinicians or might be presented in other modules, evidence for long-term harms is20knowledge for clinicians or might be presented in other modules, evidence for long-term harms is21lacking, and probabilities from the literature are not applicable to the Dutch setting or would only be22representative at the hospital level, not at that of the individual clinician (i.e., for mortality due to23surgery). Several interviewees were especially reticent to present probabilities in terms of absolute24risk reduction, as those percentages would soon be dated, differed between patient groups, or25would be too time-consuming to calculate. One stated to have argued to include Numbers Needed26to Treat in the CPG, to no avail.27Panel-member: the CPG is mostly written to, what we provide as recommendation28towards the patient, for the outcome of treatment. I don't know if the CPG is written at29least, I have never interpreted it as such, but I don't know if one should put in the CPG,29least, what's it called, all risks of treatment. That differs per agent, have different20risks. And then the CPG becomes much more extensive. But that is also the baseline31knowledge that every oncologist should have.32Interviewes acknowledged that patient preferences had been searched for or33elicited. No information was presented about generic patient preferences, or about variation in33patient preferences34Some interviewees acknowledged that patient preferences may vary and may differ from clinician <td></td> <td></td> <td>number did not regard a complete presentation of outcomes and their probabilities as necessary,</td>			number did not regard a complete presentation of outcomes and their probabilities as necessary,
 knowledge for clinicians or might be presented in other modules, evidence for long-term harms is lacking, and probabilities from the literature are not applicable to the Dutch setting or would only be representative at the hospital level, not at that of the individual clinician (i.e., for mortality due to surgery). Several interviewees were especially reticent to present probabilities in terms of absolute risk reduction, as those percentages would soon be dated, differed between patient groups, or would be too time-consuming to calculate. One stated to have argued to include Numbers Needed to Treat in the CPG, to no avail. Interviewer: and for what reason is the other side of the coin not mentioned in the CPG? You indicated, already, that actually Panel-member: the CPG is mostly written to, what we provide as recommendation towards the patient, for the outcome of treatment. I don't know if the CPG is written at least, I have never interpreted it as such, but I don't know if one should put in the CPG, let's say, what's it called, all risks of treatment. That differs per agent, have different risks. And then the CPG becomes much more extensive. But that is also the baseline knowledge that every oncologist should have. (Interview 7, about adjuvant chemotherapy for colon carcinoma) 3.3 Patient preferences None of the modules stated that evidence about patient preferences had been searched for or elicited. No information was presented about generic patient preferences, or about variation in patient preferences, either from the literature or assumed by the panel. 		19	using the following arguments: guidelines should be short, harms are assumed to be common
 representative at the hospital level, not at that of the individual clinician (i.e., for mortality due to surgery). Several interviewees were especially reticent to present probabilities in terms of absolute risk reduction, as those percentages would soon be dated, differed between patient groups, or would be too time-consuming to calculate. One stated to have argued to include Numbers Needed to Treat in the CPG, to no avail. Interviewer: and for what reason is the other side of the coin not mentioned in the CPG? You indicated, already, that actually Panel-member: the CPG is mostly written to, what we provide as recommendation towards the patient, for the outcome of treatment. I don't know if the CPG is written at least, I have never interpreted it as such, but I don't know if one should put in the CPG, let's say, what's it called, all risks of treatment. That differs per agent, have different risks. And then the CPG becomes much more extensive. But that is also the baseline knowledge that every oncologist should have. (Interview 7, about adjuvant chemotherapy for colon carcinoma) 3.3 Patient preferences None of the modules stated that evidence about patient preferences, or about variation in patient preferences, either from the literature or assumed by the panel. Some interviewees acknowledged that patient preferences may vary and may differ from clinician preferences, and they stressed that the awareness of such variation sometimes motivated a weak recommendation. Reasons not to include information about patient preferences were: time and recommendation. Reasons not to include information about patient preferences were: time and 		20	knowledge for clinicians or might be presented in other modules, evidence for long-term harms is
 surgery). Several interviewees were especially reticent to present probabilities in terms of absolute risk reduction, as those percentages would soon be dated, differed between patient groups, or would be too time-consuming to calculate. One stated to have argued to include Numbers Needed to Treat in the CPG, to no avail. Interviewer: and for what reason is the other side of the coin not mentioned in the CPG? You indicated, already, that actually Panel-member: the CPG is mostly written to, what we provide as recommendation towards the patient, for the outcome of treatment. I don't know if the CPG is written at least, I have never interpreted it as such, but I don't know if one should put in the CPG, let's say, what's it called, all risks of treatment. That differs per agent, have different risks. And then the CPG becomes much more extensive. But that is also the baseline knowledge that every oncologist should have. (Interview 7, about adjuvant chemotherapy for colon carcinoma) 3.3 Patient preferences None of the modules stated that evidence about patient preferences had been searched for or elicited. No information was presented about generic patient preferences, or about variation in patient preferences, either from the literature or assumed by the panel. Some interviewees acknowledged that patient preferences may vary and may differ from clinician preferences, and they stressed that the awareness of such variation sometimes motivated a weak recommendation. Reasons not to include information about patient preferences were: time and 		21	lacking, and probabilities from the literature are not applicable to the Dutch setting or would only be
 surgery). Several interviewees were especially reticent to present probabilities in terms of absolute risk reduction, as those percentages would soon be dated, differed between patient groups, or would be too time-consuming to calculate. One stated to have argued to include Numbers Needed to Treat in the CPG, to no avail. Interviewer: and for what reason is the other side of the coin not mentioned in the CPG? You indicated, already, that actually Panel-member: the CPG is mostly written to, what we provide as recommendation towards the patient, for the outcome of treatment. I don't know if the CPG is written at least, I have never interpreted it as such, but I don't know if one should put in the CPG, let's say, what's it called, all risks of treatment. That differs per agent, have different risks. And then the CPG becomes much more extensive. But that is also the baseline knowledge that every oncologist should have. (Interview 7, about adjuvant chemotherapy for colon carcinoma) 3.3 Patient preferences None of the modules stated that evidence about patient preferences, or about variation in patient preferences, either from the literature or assumed by the panel. Some interviewees acknowledged that patient preferences may vary and may differ from clinician preferences, and they stressed that the awareness of such variation sometimes motivated a weak recommendation. Reasons not to include information about patient preferences were: time and 		22	representative at the hospital level, not at that of the individual clinician (i.e., for mortality due to
 risk reduction, as those percentages would soon be dated, differed between patient groups, or would be too time-consuming to calculate. One stated to have argued to include Numbers Needed to Treat in the CPG, to no avail. Interviewer: and for what reason is the other side of the coin not mentioned in the CPG? You indicated, already, that actually Panel-member: the CPG is mostly written to, what we provide as recommendation towards the patient, for the outcome of treatment. I don't know if the CPG is written at least, I have never interpreted it as such, but I don't know if one should put in the CPG, let's say, what's it called, all risks of treatment. That differs per agent, have different risks. And then the CPG becomes much more extensive. But that is also the baseline knowledge that every oncologist should have. (Interview 7, about adjuvant chemotherapy for colon carcinoma) 3.3 Patient preferences None of the modules stated that evidence about patient preferences, or about variation in patient preferences, either from the literature or assumed by the panel. Some interviewees acknowledged that patient preferences may vary and may differ from clinician preferences, and they stressed that the awareness of such variation sometimes motivated a weak recommendation. Reasons not to include information about patient preferences were: time and 		23	surgery). Several interviewees were especially reticent to present probabilities in terms of absolute
 to Treat in the CPG, to no avail. Interviewer: and for what reason is the other side of the coin not mentioned in the CPG? You indicated, already, that actually Panel-member: the CPG is mostly written to, what we provide as recommendation towards the patient, for the outcome of treatment. I don't know if the CPG is written at least, I have never interpreted it as such, but I don't know if one should put in the CPG, let's say, what's it called, all risks of treatment. That differs per agent, have different risks. And then the CPG becomes much more extensive. But that is also the baseline knowledge that every ancologist should have. (Interview 7, about adjuvant chemotherapy for colon carcinoma) 3.3 Patient preferences None of the modules stated that evidence about generic patient preferences, or about variation in patient preferences, either from the literature or assumed by the panel. Some interviewees acknowledged that patient preferences may vary and may differ from clinician preferences, and they stressed that the awareness of such variation sometimes motivated a weak recommendation. Reasons not to include information about patient preferences that the 		24	risk reduction, as those percentages would soon be dated, differed between patient groups, or
 to Treat in the CPG, to no avail. Interviewer: and for what reason is the other side of the coin not mentioned in the CPG? You indicated, already, that actually Panel-member: the CPG is mostly written to, what we provide as recommendation towards the patient, for the outcome of treatment. I don't know if the CPG is written at least, I have never interpreted it as such, but I don't know if one should put in the CPG, let's say, what's it called, all risks of treatment. That differs per agent, have different risks. And then the CPG becomes much more extensive. But that is also the baseline knowledge that every oncologist should have. (Interview 7, about adjuvant chemotherapy for colon carcinoma) 3.3 Patient preferences None of the modules stated that evidence about patient preferences, or about variation in patient preferences, either from the literature or assumed by the panel. Some interviewees acknowledged that patient preferences may vary and may differ from clinician preferences, and they stressed that the awareness of such variation sometimes motivated a weak recommendation. Reasons not to include information about patient preferences were: time and 		25	would be too time-consuming to calculate. One stated to have argued to include Numbers Needed
 Interviewer: and for what reason is the other side of the coin not mentioned in the CPG? You indicated, already, that actually Panel-member: the CPG is mostly written to, what we provide as recommendation towards the patient, for the outcome of treatment. I don't know if the CPG is written at least, I have never interpreted it as such, but I don't know if one should put in the CPG, let's say, what's it called, all risks of treatment. That differs per agent, have different risks. And then the CPG becomes much more extensive. But that is also the baseline knowledge that every oncologist should have. (Interview 7, about adjuvant chemotherapy for colon carcinoma) 37 3.3 Patient preferences None of the modules stated that evidence about patient preferences, or about variation in patient preferences, either from the literature or assumed by the panel. Some interviewees acknowledged that patient preferences may vary and may differ from clinician preferences, and they stressed that the awareness of such variation sometimes motivated a weak recommendation. Reasons not to include information about patient preferences were: time and 		26	
 Interviewer: and for what reason is the other side of the coin not mentioned in the CPG? You indicated, already, that actually Panel-member: the CPG is mostly written to, what we provide as recommendation towards the patient, for the outcome of treatment. I don't know if the CPG is written at least, I have never interpreted it as such, but I don't know if one should put in the CPG, let's say, what's it called, all risks of treatment. That differs per agent, have different risks. And then the CPG becomes much more extensive. But that is also the baseline knowledge that every oncologist should have. (Interview 7, about adjuvant chemotherapy for colon carcinoma) 3.3 Patient preferences None of the modules stated that evidence about patient preferences, or about variation in patient preferences, either from the literature or assumed by the panel. Some interviewees acknowledged that patient preferences may vary and may differ from clinician preferences, and they stressed that the awareness of such variation sometimes motivated a weak recommendation. Reasons not to include information about patient preferences were: time and recommendation. Reasons not to include information about patient preferences were: time and 			
 You indicated, already, that actually Panel-member: the CPG is mostly written to, what we provide as recommendation towards the patient, for the outcome of treatment. I don't know if the CPG is written at least, I have never interpreted it as such, but I don't know if one should put in the CPG, let's say, what's it called, all risks of treatment. That differs per agent, have different risks. And then the CPG becomes much more extensive. But that is also the baseline knowledge that every oncologist should have. (Interview 7, about adjuvant chemotherapy for colon carcinoma) 3.3 Patient preferences None of the modules stated that evidence about patient preferences, or about variation in patient preferences, either from the literature or assumed by the panel. Some interviewees acknowledged that patient preferences may vary and may differ from clinician preferences, and they stressed that the awareness of such variation sometimes motivated a weak recommendation. Reasons not to include information about patient preferences were: time and preferences were: time and preferences were: time and 		28	Interviewer: and for what reason is the other side of the coin not mentioned in the CPG?
 31 towards the patient, for the outcome of treatment. I don't know if the CPG is written at 32 least, I have never interpreted it as such, but I don't know if one should put in the CPG, 33 let's say, what's it called, all risks of treatment. That differs per agent, have different 34 risks. And then the CPG becomes much more extensive. But that is also the baseline 35 knowledge that every oncologist should have. 46 (Interview 7, about adjuvant chemotherapy for colon carcinoma) 37 33 Patient preferences 34 None of the modules stated that evidence about patient preferences had been searched for or 40 elicited. No information was presented about generic patient preferences, or about variation in 41 patient preferences, either from the literature or assumed by the panel. 42 43 Some interviewees acknowledged that patient preferences may vary and may differ from clinician 44 preferences, and they stressed that the awareness of such variation sometimes motivated a weak 45 recommendation. Reasons not to include information about patient preferences were: time and 	39		
 12 lowards the patient, for the obtcome of treatment. I addit know if the CPG is written at 12 least, I have never interpreted it as such, but I don't know if one should put in the CPG, 14 13 least, I have never interpreted it as such, but I don't know if one should put in the CPG, 14 13 least, I have never interpreted it as such, but I don't know if one should put in the CPG, 14 13 least, I have never interpreted it as such, but I don't know if one should put in the CPG, 14 13 least, I have never interpreted it as such, but I don't know if one should put in the CPG, 14 14 15 least, and then the CPG becomes much more extensive. But that is also the baseline 14 knowledge that every oncologist should have. 15 (Interview 7, about adjuvant chemotherapy for colon carcinoma) 16 37 17 36 (Interview 7, about adjuvant chemotherapy for colon carcinoma) 18 37 19 38 3.3 Patient preferences 19 None of the modules stated that evidence about patient preferences had been searched for or 10 elicited. No information was presented about generic patient preferences, or about variation in 10 patient preferences, either from the literature or assumed by the panel. 10 patient preferences, and they stressed that the awareness of such variation sometimes motivated a weak 11 preferences, and they stressed that the awareness of such variation sometimes motivated a weak 12 recommendation. Reasons not to include information about patient preferences were: time and 14 or preferences were: time and 15 description of the stressed that the awareness of such variation sometimes that the interviewees acknowledged that patient patient preferences were: time and 14 preferences were: time and 15 description of the stressed that the awareness of such variation sometimes motivated a weak 16 recommendation. Reasons not to include informati		30	Panel-member: the CPG is mostly written to, what we provide as recommendation
 <i>least, I have never interpreted it as such, but I don't know if one should put in the CPG,</i> <i>let's say, what's it called, all risks of treatment. That differs per agent, have different</i> <i>risks. And then the CPG becomes much more extensive. But that is also the baseline</i> <i>knowledge that every oncologist should have.</i> (Interview 7, about adjuvant chemotherapy for colon carcinoma) 3.3 Patient preferences None of the modules stated that evidence about patient preferences had been searched for or elicited. No information was presented about generic patient preferences, or about variation in patient preferences, either from the literature or assumed by the panel. Some interviewees acknowledged that patient preferences may vary and may differ from clinician preferences, and they stressed that the awareness of such variation sometimes motivated a weak recommendation. Reasons not to include information about patient preferences were: time and 			
 34 risks. And then the CPG becomes much more extensive. But that is also the baseline knowledge that every oncologist should have. 47 36 (Interview 7, about adjuvant chemotherapy for colon carcinoma) 37 38 3.3 Patient preferences 39 None of the modules stated that evidence about patient preferences had been searched for or elicited. No information was presented about generic patient preferences, or about variation in patient preferences, either from the literature or assumed by the panel. 42 56 43 Some interviewees acknowledged that patient preferences may vary and may differ from clinician preferences, and they stressed that the awareness of such variation sometimes motivated a weak recommendation. Reasons not to include information about patient preferences were: time and 			
 <i>knowledge that every oncologist should have.</i> (Interview 7, about adjuvant chemotherapy for colon carcinoma) 37 3.3 Patient preferences None of the modules stated that evidence about patient preferences had been searched for or elicited. No information was presented about generic patient preferences, or about variation in patient preferences, either from the literature or assumed by the panel. Some interviewees acknowledged that patient preferences may vary and may differ from clinician preferences, and they stressed that the awareness of such variation sometimes motivated a weak recommendation. Reasons not to include information about patient preferences were: time and 			
 36 (Interview 7, about adjuvant chemotherapy for colon carcinoma) 37 39 3.3 Patient preferences 39 None of the modules stated that evidence about patient preferences had been searched for or elicited. No information was presented about generic patient preferences, or about variation in patient preferences, either from the literature or assumed by the panel. Some interviewees acknowledged that patient preferences may vary and may differ from clinician preferences, and they stressed that the awareness of such variation sometimes motivated a weak recommendation. Reasons not to include information about patient preferences were: time and 			
 37 38 3.3 Patient preferences 39 None of the modules stated that evidence about patient preferences had been searched for or 40 elicited. No information was presented about generic patient preferences, or about variation in patient preferences, either from the literature or assumed by the panel. 42 Some interviewees acknowledged that patient preferences may vary and may differ from clinician preferences, and they stressed that the awareness of such variation sometimes motivated a weak recommendation. Reasons not to include information about patient preferences were: time and 			
 38 3.3 Patient preferences 39 None of the modules stated that evidence about patient preferences had been searched for or 40 elicited. No information was presented about generic patient preferences, or about variation in patient preferences, either from the literature or assumed by the panel. 42 56 43 Some interviewees acknowledged that patient preferences may vary and may differ from clinician preferences, and they stressed that the awareness of such variation sometimes motivated a weak recommendation. Reasons not to include information about patient preferences were: time and 			(interview y, about adjuvant chemotherapy for colon carcinoma)
 None of the modules stated that evidence about patient preferences had been searched for or elicited. No information was presented about generic patient preferences, or about variation in patient preferences, either from the literature or assumed by the panel. Some interviewees acknowledged that patient preferences may vary and may differ from clinician preferences, and they stressed that the awareness of such variation sometimes motivated a weak recommendation. Reasons not to include information about patient preferences were: time and 	49		3 3 Patient preferences
 40 elicited. No information was presented about generic patient preferences, or about variation in 41 patient preferences, either from the literature or assumed by the panel. 42 42 56 43 Some interviewees acknowledged that patient preferences may vary and may differ from clinician 57 44 preferences, and they stressed that the awareness of such variation sometimes motivated a weak 45 recommendation. Reasons not to include information about patient preferences were: time and 46 recommendation. Reasons not to include information about patient preferences were: time and 			•
 patient preferences, either from the literature or assumed by the panel. 42 54 56 43 56 Some interviewees acknowledged that patient preferences may vary and may differ from clinician preferences, and they stressed that the awareness of such variation sometimes motivated a weak 45 45 46 46 			
 42 43 56 43 56 43 56 57 44 58 45 58 45 59 46 47 48 49 49 40 41 41 42 43 54 56 43 57 58 45 59 46 47 48 49 49 40 41 41 42 43 44 45 45 46 46 47 48 49 49 49 40 41 41 42 42 44 45 46 47 48 49 49 49 49 40 41 41 42 42 44 45 46 47 48 49 4			
 Some interviewees acknowledged that patient preferences may vary and may differ from clinician preferences, and they stressed that the awareness of such variation sometimes motivated a weak recommendation. Reasons not to include information about patient preferences were: time and and the awareness of such variation about patient preferences were: time and 	54		patient preferences, ethier nom the interature of assumed by the patien.
57 44 preferences, and they stressed that the awareness of such variation sometimes motivated a weak 58 45 recommendation. Reasons not to include information about patient preferences were: time and 59 46 recommendation about patient preferences were: time and			Some interviewage acknowledged that nations professores may year and may differ from all sizes
58 59 46 recommendation. Reasons not to include information about patient preferences were: time and 46 recommendation that the eccurrentiate the eccurrentiate that the eccurrentiate that the eccurrentiate that the eccurrentiate the eccurrentiate that the eccurrentiate that the eccurrentiate that the eccurrentiate the eccurrentiate the eccurrentiate the eccurrentiate that the eccurrentiate th			
59			
60 40 capacity constraints, the assumption that no evidence exists, or lack of awareness that this	59		
	60	40	capacity constraints, the assumption that no evidence exists, or lack of awareness that this

1		
2 3		
4	1	information is to be included. Others were reluctant to include information about preference
5	2	variation, because it could threaten the relationship between specialties (if this information would
6	3	lead to patients choosing against the generally accepted treatment modality). Numerous
7	4	assumptions about patient preferences were voiced, such as that patients prefer lumpectomy to
8 9	5	mastectomy, length of life to quality of life, and active treatment to refraining from treatment.
10	6	Interviewees also stressed that if patients have a strong preference, they will express it anyway.
11	7	
12	8	3.4 CPG panels' values and preferences
13	9	None of the modules explicitly labelled statements as presenting the CPG panel's values and
14 15	10	preferences that underlie their weighing of the benefits and harms. We found implicit reference to
16	11	CPG panels' preferences, having influenced the development of the recommendation in 15/32
17	12	recommendations (see Box 4). These preferences concerned 9/14 strong recommendations and
18	13	6/18 weak recommendations (see Table 2).
19 20	14	
20	15	>>> Insert Box 4 about here <<<
22	16	
23	17	As described under 3.1, the interviewees sometimes explained discrepancies between the strength
24 25		
25 26	18	of recommendation and the extracted information by the CPG panel's valuation of the outcomes.
27	19	Explanations for the panel members' preferences beyond the evidence were: compliance with daily
28	20	practice; the organisation of care; culture (a preference for radiotherapy seemed more culturally
29	21	and historically determined than evidence-based); and concerns about keeping a good relationship
30	22	between specialties when their treatments compete.
31 32	23	Some interviewees found that CPG panels' preferences underlying the weighing of benefits and
33	24	harms should be made explicit. One interviewee stated that having an external party critically
34	25	reviewing the CPGs before publication would foster this. The panel members often expressed their
35	26	own preference for active treatment versus refraining from (further) treatment or active
36 37	27	surveillance, even at the expense of over-treating a substantial part of the patient population.
38	28	
39	29	Panel member: That is watertight, radiotherapy does have an effect. Not for everyone,
40	30	far from it, but for some. And we cannot sufficiently select for whom it does, so we say,
41	31	give radiation to all.
42 43	32	(Interview 4, about radiotherapy for DCIS patients)
44	33	
45	34	Their motivation was mostly a strong belief in survival gain for a subgroup that cannot be identified
46	35	as of yet. In these instances, panel preferences for active treatment had influenced the balancing of
47	36	benefits and harms, such that a recommendation for active treatment would not be a weak one.
48 49	37	This was argued e.g. for treatment aimed at reducing local recurrence rates without concomitant
50	38	survival gain. Concerning this example, an interviewee argued in one instance that it was preferable
51	39	simply to not include survival as an outcome, as no survival gain was possible given the already high
52	40	survival (Interview 2, about radiotherapy for DCIS).
53 54	41	
54 55	42	Band members but I find it a bit of a bromide to say that DCIS or rather that
56	42 43	Panel member: but I find it a bit of a bromide to say that DCIS, or rather that radiotherapy for DCIS yields no survival benefit and therefore we shouldn't do it. Because
57	44	one cannot improve upon 99 % survival benefit. The important thing is, in which sub-
58	45	groups those recurrences occur that might not be such nice recurrences, that call for a lot
59 60	46	more treatment and the like

60

BMJ Open

1 2		
2	1	(Interview 2, about radiotherapy for DCIS patients)
4	2	(interview 2, about radiotherapy for bels patients)
5 6	3	At the same time, others voiced opinions against over-treatment and pointed out that the paradigm
7	4	in favour of over-treatment to avoid under-treatment is shifting, particularly in patients diagnosed
8	5	by population screening (DCIS, T1 carcinoma in polyp).
9	6	
10 11	7	3.5 Advice about patient involvement in decision-making
12	8	Five modules included in total 20 statements about the patient's role in decision-making (see Box 5).
13	9	Relatively more statements (14) were seen for the weak than for the strong (6) recommendations.
14 15	10	All statements recommended to include the patient's preferences in making the decision except for
15 16	11	two, relating to weak recommendations, that recommended to inform the patient about the trade-
17	12	off. One of the three CPGs included a separate chapter about decision-making, in which it was
18	13	recommended to elicit the preferences of the patient in an SDM process.
19 20	14	recommended to encir the preferences of the patient in an obiti process.
20	15	Interviewees disagreed on the necessity of recommendations about patient involvement in decision-
22	16	making. Several stressed that these statements were included only because the patient
23	17	representative asked for it. Others mentioned that the inclusion was based on the opinion of
24 25	18	individual panel members.
26	19	individual parter members.
27	20	>>> Insert Box 5 about here <<<
28 29	21	
	21	
30 31	22	4. DISCUSSION
30 31 32		4. DISCUSSION Healthcare is increasingly guideline-driven, which promotes quality of care and reduces unwarranted
30 31 32 33	22	
30 31 32	22 23	Healthcare is increasingly guideline-driven, which promotes quality of care and reduces unwarranted
30 31 32 33 34 35 36	22 23 24	Healthcare is increasingly guideline-driven, which promotes quality of care and reduces unwarranted practice variation. But guidelines may be a barrier to SDM if they do not acknowledge the
30 31 32 33 34 35 36 37	22 23 24 25	Healthcare is increasingly guideline-driven, which promotes quality of care and reduces unwarranted practice variation. But guidelines may be a barrier to SDM if they do not acknowledge the preference-sensitive nature of many treatment decisions. (1, 30) The aim of this study was to explore
30 31 32 33 34 35 36 37 38	22 23 24 25 26	Healthcare is increasingly guideline-driven, which promotes quality of care and reduces unwarranted practice variation. But guidelines may be a barrier to SDM if they do not acknowledge the preference-sensitive nature of many treatment decisions.(1, 30) The aim of this study was to explore to what extent CPGs acknowledge preference-sensitive decisions in their recommendations. Our
30 31 32 33 34 35 36 37	22 23 24 25 26 27	Healthcare is increasingly guideline-driven, which promotes quality of care and reduces unwarranted practice variation. But guidelines may be a barrier to SDM if they do not acknowledge the preference-sensitive nature of many treatment decisions.(1, 30) The aim of this study was to explore to what extent CPGs acknowledge preference-sensitive decisions in their recommendations. Our analysis showed that the guidelines involved incomplete and unclear presentation of benefits,
30 31 32 33 34 35 36 37 38 39 40 41	22 23 24 25 26 27 28	Healthcare is increasingly guideline-driven, which promotes quality of care and reduces unwarranted practice variation. But guidelines may be a barrier to SDM if they do not acknowledge the preference-sensitive nature of many treatment decisions.(1, 30) The aim of this study was to explore to what extent CPGs acknowledge preference-sensitive decisions in their recommendations. Our analysis showed that the guidelines involved incomplete and unclear presentation of benefits, harms, and the probabilities thereof. This makes it difficult for the users to judge the
30 31 32 33 34 35 36 37 38 39 40 41 42	22 23 24 25 26 27 28 29	Healthcare is increasingly guideline-driven, which promotes quality of care and reduces unwarranted practice variation. But guidelines may be a barrier to SDM if they do not acknowledge the preference-sensitive nature of many treatment decisions.(1, 30) The aim of this study was to explore to what extent CPGs acknowledge preference-sensitive decisions in their recommendations. Our analysis showed that the guidelines involved incomplete and unclear presentation of benefits, harms, and the probabilities thereof. This makes it difficult for the users to judge the appropriateness of the strength of the recommendation. Further, it may hinder patient engagement
30 31 32 33 34 35 36 37 38 39 40 41	22 23 24 25 26 27 28 29 30	Healthcare is increasingly guideline-driven, which promotes quality of care and reduces unwarranted practice variation. But guidelines may be a barrier to SDM if they do not acknowledge the preference-sensitive nature of many treatment decisions. (1, 30) The aim of this study was to explore to what extent CPGs acknowledge preference-sensitive decisions in their recommendations. Our analysis showed that the guidelines involved incomplete and unclear presentation of benefits, harms, and the probabilities thereof. This makes it difficult for the users to judge the appropriateness of the strength of the recommendation. Further, it may hinder patient engagement in decision-making, which requires that patients are fully informed about the trade-offs. Moreover,
 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 	22 23 24 25 26 27 28 29 30 31	Healthcare is increasingly guideline-driven, which promotes quality of care and reduces unwarranted practice variation. But guidelines may be a barrier to SDM if they do not acknowledge the preference-sensitive nature of many treatment decisions.(1, 30) The aim of this study was to explore to what extent CPGs acknowledge preference-sensitive decisions in their recommendations. Our analysis showed that the guidelines involved incomplete and unclear presentation of benefits, harms, and the probabilities thereof. This makes it difficult for the users to judge the appropriateness of the strength of the recommendation. Further, it may hinder patient engagement in decision-making, which requires that patients are fully informed about the trade-offs. Moreover, patients may be directly accessing the guidelines, and inclusion of this information makes guidelines
 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 	22 23 24 25 26 27 28 29 30 31 32	Healthcare is increasingly guideline-driven, which promotes quality of care and reduces unwarranted practice variation. But guidelines may be a barrier to SDM if they do not acknowledge the preference-sensitive nature of many treatment decisions. (1, 30) The aim of this study was to explore to what extent CPGs acknowledge preference-sensitive decisions in their recommendations. Our analysis showed that the guidelines involved incomplete and unclear presentation of benefits, harms, and the probabilities thereof. This makes it difficult for the users to judge the appropriateness of the strength of the recommendation. Further, it may hinder patient engagement in decision-making, which requires that patients are fully informed about the trade-offs. Moreover, patients may be directly accessing the guidelines, and inclusion of this information makes guidelines also more useful to them. Whether or not clinicians have complete knowledge about all benefits
30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47	22 23 24 25 26 27 28 29 30 31 32 33	Healthcare is increasingly guideline-driven, which promotes quality of care and reduces unwarranted practice variation. But guidelines may be a barrier to SDM if they do not acknowledge the preference-sensitive nature of many treatment decisions.(1, 30) The aim of this study was to explore to what extent CPGs acknowledge preference-sensitive decisions in their recommendations. Our analysis showed that the guidelines involved incomplete and unclear presentation of benefits, harms, and the probabilities thereof. This makes it difficult for the users to judge the appropriateness of the strength of the recommendation. Further, it may hinder patient engagement in decision-making, which requires that patients are fully informed about the trade-offs. Moreover, patients may be directly accessing the guidelines, and inclusion of this information makes guidelines also more useful to them. Whether or not clinicians have complete knowledge about all benefits and harms and their probabilities is questionable, and from an earlier study we know that at least
 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 	22 23 24 25 26 27 28 29 30 31 32 33 34	Healthcare is increasingly guideline-driven, which promotes quality of care and reduces unwarranted practice variation. But guidelines may be a barrier to SDM if they do not acknowledge the preference-sensitive nature of many treatment decisions. (1, 30) The aim of this study was to explore to what extent CPGs acknowledge preference-sensitive decisions in their recommendations. Our analysis showed that the guidelines involved incomplete and unclear presentation of benefits, harms, and the probabilities thereof. This makes it difficult for the users to judge the appropriateness of the strength of the recommendation. Further, it may hinder patient engagement in decision-making, which requires that patients are fully informed about the trade-offs. Moreover, patients may be directly accessing the guidelines, and inclusion of this information makes guidelines also more useful to them. Whether or not clinicians have complete knowledge about all benefits and harms and their probabilities is questionable, and from an earlier study we know that at least many clinicians do not share this information with their patients during the decision making
 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 	22 23 24 25 26 27 28 29 30 31 32 33 34 35	Healthcare is increasingly guideline-driven, which promotes quality of care and reduces unwarranted practice variation. But guidelines may be a barrier to SDM if they do not acknowledge the preference-sensitive nature of many treatment decisions.(1, 30) The aim of this study was to explore to what extent CPGs acknowledge preference-sensitive decisions in their recommendations. Our analysis showed that the guidelines involved incomplete and unclear presentation of benefits, harms, and the probabilities thereof. This makes it difficult for the users to judge the appropriateness of the strength of the recommendation. Further, it may hinder patient engagement in decision-making, which requires that patients are fully informed about the trade-offs. Moreover, patients may be directly accessing the guidelines, and inclusion of this information makes guidelines also more useful to them. Whether or not clinicians have complete knowledge about all benefits and harms and their probabilities is questionable, and from an earlier study we know that at least many clinicians do not share this information with their patients during the decision making process.(14, 15) Complete and clear presentation in CPGs of the benefits and harms help to fill
 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 	22 23 24 25 26 27 28 29 30 31 32 33 34 35 36	Healthcare is increasingly guideline-driven, which promotes quality of care and reduces unwarranted practice variation. But guidelines may be a barrier to SDM if they do not acknowledge the preference-sensitive nature of many treatment decisions.(1, 30) The aim of this study was to explore to what extent CPGs acknowledge preference-sensitive decisions in their recommendations. Our analysis showed that the guidelines involved incomplete and unclear presentation of benefits, harms, and the probabilities thereof. This makes it difficult for the users to judge the appropriateness of the strength of the recommendation. Further, it may hinder patient engagement in decision-making, which requires that patients are fully informed about the trade-offs. Moreover, patients may be directly accessing the guidelines, and inclusion of this information makes guidelines also more useful to them. Whether or not clinicians have complete knowledge about all benefits and harms and their probabilities is questionable, and from an earlier study we know that at least many clinicians do not share this information with their patients during the decision making process.(14, 15) Complete and clear presentation in CPGs of the benefits and harms help to fill knowledge gaps in CPG users, and acknowledge the importance of the information for the trade-offs
 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 	22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37	Healthcare is increasingly guideline-driven, which promotes quality of care and reduces unwarranted practice variation. But guidelines may be a barrier to SDM if they do not acknowledge the preference-sensitive nature of many treatment decisions.(1, 30) The aim of this study was to explore to what extent CPGs acknowledge preference-sensitive decisions in their recommendations. Our analysis showed that the guidelines involved incomplete and unclear presentation of benefits, harms, and the probabilities thereof. This makes it difficult for the users to judge the appropriateness of the strength of the recommendation. Further, it may hinder patient engagement in decision-making, which requires that patients are fully informed about the trade-offs. Moreover, patients may be directly accessing the guidelines, and inclusion of this information makes guidelines also more useful to them. Whether or not clinicians have complete knowledge about all benefits and harms and their probabilities is questionable, and from an earlier study we know that at least many clinicians do not share this information with their patients during the decision making process.(14, 15) Complete and clear presentation in CPGs of the benefits and harms help to fill knowledge gaps in CPG users, and acknowledge the importance of the information for the trade-offs
 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 	22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38	Healthcare is increasingly guideline-driven, which promotes quality of care and reduces unwarranted practice variation. But guidelines may be a barrier to SDM if they do not acknowledge the preference-sensitive nature of many treatment decisions.(1, 30) The aim of this study was to explore to what extent CPGs acknowledge preference sensitive decisions in their recommendations. Our analysis showed that the guidelines involved incomplete and unclear presentation of benefits, harms, and the probabilities thereof. This makes it difficult for the users to judge the appropriateness of the strength of the recommendation. Further, it may hinder patient engagement in decision-making, which requires that patients are fully informed about the trade-offs. Moreover, patients may be directly accessing the guidelines, and inclusion of this information makes guidelines also more useful to them. Whether or not clinicians have complete knowledge about all benefits and harms and their probabilities is questionable, and from an earlier study we know that at least many clinicians do not share this information with their patients during the decision making process.(14, 15) Complete and clear presentation in CPGs of the benefits and harms help to fill knowledge gaps in CPG users, and acknowledge the importance of the information for the trade-offs to be made with the individual patient in preference-sensitive decisions.
 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 	22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39	Healthcare is increasingly guideline-driven, which promotes quality of care and reduces unwarranted practice variation. But guidelines may be a barrier to SDM if they do not acknowledge the preference-sensitive nature of many treatment decisions.(1, 30) The aim of this study was to explore to what extent CPGs acknowledge preference-sensitive decisions in their recommendations. Our analysis showed that the guidelines involved incomplete and unclear presentation of benefits, harms, and the probabilities thereof. This makes it difficult for the users to judge the appropriateness of the strength of the recommendation. Further, it may hinder patient engagement in decision-making, which requires that patients are fully informed about the trade-offs. Moreover, patients may be directly accessing the guidelines, and inclusion of this information makes guidelines and harms and their probabilities is questionable, and from an earlier study we know that at least many clinicians do not share this information in CPGs of the benefits and harms help to fill knowledge gaps in CPG users, and acknowledge the importance of the information for the trade-offs to be made with the individual patient in preference-sensitive decisions.
 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 	22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40	Healthcare is increasingly guideline-driven, which promotes quality of care and reduces unwarranted practice variation. But guidelines may be a barrier to SDM if they do not acknowledge the preference-sensitive nature of many treatment decisions.(1, 30) The aim of this study was to explore to what extent CPGs acknowledge preference-sensitive decisions in their recommendations. Our analysis showed that the guidelines involved incomplete and unclear presentation of benefits, harms, and the probabilities thereof. This makes it difficult for the users to judge the appropriateness of the strength of the recommendation. Further, it may hinder patient engagement in decision-making, which requires that patients are fully informed about the trade-offs. Moreover, patients may be directly accessing the guidelines, and inclusion of this information makes guidelines and harms and their probabilities is questionable, and from an earlier study we know that at least many clinicians do not share this information in CPGs of the benefits and harms help to fill knowledge gaps in CPG users, and acknowledge the importance of the information for the trade-offs to be made with the individual patient in preference-sensitive decisions.

44 the role of value judgements in guideline formulation in palliative oncology. They found that

preferences, such as those for intervening and prolonging life, were not mentioned in the guidelines but had played an important role in determining final recommendations. In line with a study by Alexander et al. (35), it appeared that panel members find it difficult to refrain from providing a clear recommendation in a case of limited or conflicting evidence. CPG panel preferences for active treatment had influenced the way the panel had balanced benefits and harms, such that a recommendation for active treatment would be strong and overtreatment likely. The strong belief in survival gain for a subgroup that cannot be identified as of yet fosters the so-called therapeutic illusion, in which both physicians and patients overestimate the benefits of treatment, since patients are seemingly cured by treatment while they might have had the same outcome without treatment.(36) Rather than routinely resort to active treatment in these instances, the discussion should be opened on how to deal with such uncertainties. Little research is available yet on how best to communicate uncertainty, (37) but this does not relieve us from the obligation to discuss matters honestly with patients. Such openness would contribute to reducing unnecessary treatment, addressing unacceptable variation, and delivering more appropriate, personalised care.(38) Guidelines can facilitate this discussion by acknowledging preference-sensitive decisions, and encouraging users to become more aware of choice and presenting multiple options to patients.

A limitation of the format of GRADE, is that it asks for a dichotomous categorization (weak vs. strong) and a recommendation either for or against. This categorization makes it difficult to explicitly state that multiple options are medically reasonable. Furthermore, information on patient preferences should be more often sought in guideline development. Oncologist experts are invited in guideline panels because of their content expertise, but this involves a risk when more evidence is available for benefits than for harms, and when there is no evidence on patient preferences. Then chances increase that that panel members resort to their own preferences, often favouring active treatment and neglecting harms.(39) The guideline development process, while aiming at achieving EBM, may threaten it by its reliance on expert judgment at the expense of involving patient preferences. GRADE publications accede that panels' judgements of patient preferences often rely on their interactions with patients, but how well such judgements correspond to typical values and preferences is uncertain.

We do not know to what extent our analysis will hold for CPGs from other countries than the Netherlands. Dutch healthcare is likely less paternalistic than that in many other countries, and the Netherlands are leading in the implementation of SDM(40). We therefore expect more discrepancies between evidence and recommendations to arise elsewhere. De Kort et al., (21) analysed a sample of evidence-based oncology guidelines from other countries, and found that recommendations were rarely explained and value judgements were not made explicit either. Further, we do not know if, but have no reason to expect that our findings will be different for other specialties. We urge researchers in other countries and other fields to evaluate their guidelines with preference-sensitivity in mind as well.

An analysis like the one performed runs the risk of subjectivity, as the data extraction and coding requires interpretation. We therefore checked our results with the developers of the guidelines we studied. This provided a validation of our analysis. The aim of this endeavour was to highlight an issue that is a major barrier to patient-centred care and SDM in particular.(41) With the strong

1		
2 3		
4	1	current call for patient involvement, worldwide, it is important to establish to what extent guidelines
5	2	potentially hinder such involvement, and our study may be seen as a first step in that direction.
6	3	
7	4	In sum, our analysis points to a lack of transparency in the CPG development process about benefits
8 9	5	and harms and their probabilities, the preferences of the guideline panel members, and their
10	6	assumptions about patient preferences. Awareness needs to be created among CPG-developers that
11	7	their judgments of the balance of benefits and harms are value-laden, and that variation exists in
12	8	these judgments, among both clinicians and patients. Clear instructions and training to enhance
13 14	9	knowledge and implementation of GRADE might improve the acknowledgement of preference-
14	10	sensitive decisions in guidelines and support shared decision making. This will help avoid what
16	11	McCartney feared in his 2016 Analysis in the BMJ: "there is the danger of guideline
17	12	recommendations being applied to people who do not place the same values on those
18	13	recommendations as their clinician ()".(23)
19 20	14	
21	15	
22	16	
23	17	ACKNOWLEDGEMENTS
24 25	17	
26	18 19	We thank all interviewees for their participation in this study.
27		
28	20	AUTHORS CONTRIBUTION
29 30	21	FRG, AHP, JEAP, and AMS designed the study. FRG, DH, BCMG, GJL and AMS were involved in
31	22	acquisition of the data, FRG and AMS conducted the data extraction. FRG, ML, DH, TA, GJL, AHP, and
32	23	AMS were involved in interpreting the results.
33	24	FRG and AMS wrote the first drafts and final version of the manuscript. JEAP, ML, DH, TA, BCMG,
34 35	25	GJL, and AHP have read the manuscript critically, made improvements to the content and wording of
35 36	26	the work.
37	27	FRG, JEAP, ML, DH, TA, BCMG, GJL, AHP, and AMS all agreed to the final version.
38	28	The corresponding author attests that all listed authors meet authorship criteria and that no others
39	29 30	meeting the criteria have been omitted.
40 41	30 31	
42		
43	32	EXCLUSIVE LICENCE STATEMENT
44	33	The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of
45 46	34	all authors, a worldwide licence to the Publishers and its licensees in perpetuity, in all forms, formats
47	35	and media (whether known now or created in the future), to i) publish, reproduce, distribute, display
48	36	and store the Contribution, ii) translate the Contribution into other languages, create adaptations,
49	37	reprints, include within collections and create summaries, extracts and/or, abstracts of the
50 51	38	Contribution and convert or allow conversion into any format including without limitation audio, iii)
52	39	create any other derivative work(s) based in whole or part on the on the Contribution, iv) to exploit
53	40	all subsidiary rights to exploit all subsidiary rights that currently exist or as may exist in the future in
54	41	the Contribution, v) the inclusion of electronic links from the Contribution to third party material
55	42	where-ever it may be located; and, vi) licence any third party to do any or all of the above.
56 57	43	
58		
59		
60		

Box 1: The GRADE approach and GRADE's proposed role of patient values and preferences in CPG recommendation development:

GRADE offers an approach to rate the certainty in the evidence and strength of recommendations, in which strong and weak (also known as conditional) recommendations are distinguished. Consideration of patient preferences is a crucial step in deciding on the strength of the recommendation. According to the GRADE approach, first, the best estimates of effect for the interventions and the certainty in this evidence (quality of the evidence) is assessed, using up-todate systematic reviews. Further, the CPG panel should consider a number of criteria that influence the strength of recommendations, such as variability or uncertainty in how patients value the main outcomes (both benefits and harms), the balance between benefits and harms, and considerations of resource use, health equity, feasibility and acceptability (from both stakeholder and patient perspective) of an intervention. (26-30) Based on an overall assessment across these criteria, CPG panels reach a conclusion about the direction of their recommendation (for or against the intervention) and the strength of their recommendation: strong or weak. (26) A high level of certainty across the criteria (such as high quality evidence, clear balance between benefits and harms, no uncertainty in patient preferences) allows for strong recommendations. A high level of uncertainty, i.e., preference-sensitive decisions, leads to weak recommendations: there is more than one single best option available, there is important uncertainty or variability in patient preferences, or the benefits and harms are closely balanced. Tension has been shown to occur between adherence to GRADE and the wish to make a strong recommendation out of conviction that a treatment is beneficial, despite the evidence quality or certainty being (very) low.(42)

To guarantee the acknowledgement of patient preferences in the development of recommendations, the GRADE strategy asks to clearly present i) how substantial benefits and harms are, what their balance is, and what the overall certainty of the evidence on these outcomes is, and ii) if there is uncertainty about or variability in how much patients value the important outcomes. (26, 27, 43) In other papers GRADE recommends guideline developers to make transparent and explicit statements iii) about the (variability in) patient values and preferences, as well as CPG panel assumptions of these values and preferences on which decisions on the strength of recommendations are based, in order to be able to judge the applicability of recommendations for decision making with the individual patient. (28, 29)

 Box 2. Examples of textual discrepancies between strength of recommendation and statements in
 other parts of the CPG module

1. Strongly phrased recommendation for adjuvant radiotherapy after lumpectomy in DCIS patients, combined with a statement about the relevance of patient involvement in the decision: <u>Recommendation</u>

"After complete excision of DCIS, radiotherapy of the whole chest wall (with or without boost) is recommended." (Section: Recommendations, module 1)

Statement about patient involvement

"Individual risk assessment and good deliberation with the informed patient determine whether radiotherapy is applied, with or without boost." (Section: Recommendations, module 1)

2. Strongly-phrased recommendation for adjuvant chemotherapy for patients with an MSI colon carcinoma, combined with a statement about very low-quality evidence.

Recommendation

"It is recommended that patients with an MSI carcinoma are offered only fluoropyrimidineoxaliplatin-based chemotherapy." (Section: Recommendations, module 4) <u>Statement about the evidence</u>

"The limited evidence concerning the value of oxaliplatin-based chemotherapy in this group shows no difference compared to patients with MSS tumours, so for patients with stage III MSI tumours, oxaliplatin-based chemotherapy remains recommended for now." (Section: Literature review, module 4)

1 Box 3: Extracted trade-off statements

Trade-off statement for a <u>strong</u> recommendation:

• It is generally agreed upon that a dose of 45–60 Gy in 3 fractions is safe and can achieve good (> 80%) local tumour control. The risk of radiation pneumonitis appears to be acceptable. However, long-term data on the late toxicity of SBRT is lacking, especially for T2 tumours. Evidence pertaining to quality of life is likewise sparse. (Conclusions, module 3a)

Trade-off statements for weak recommendations:

- Additional surgical resection after endoscopic removal of a malignant polyp should always be a balanced decision because of the relative high number needed to treat, for which the patient should always be fully informed about the potential oncologic benefit on the one hand and the risk of complications on the other (Recommendations, module 2a, used for <u>weak</u> recommendations)
- In various case-series, the incidence of local lymph node metastases in T1 colorectal carcinoma varies from 8 to 14 %. ^{654 1082 1259} There is also a large chance that surgical (segmental) resection of the colon has no therapeutic benefits, while being associated with morbidity and even mortality. Hence, it is important to make a well-considered choice for the treatment of malignant polyps." (Section: Literature review, module 2a)
- For high risk malignant colon polyps the oncologic benefit of additional resection should be balanced against the risk of morbidity and possibly even mortality. In this trade-off the age, tumor location, comorbidity of the patient, and the preference of the patient should be taken into account. All patients should be discussed in the multidisciplinary team. (Section: Considerations, module 2a, used for <u>weak</u> recommendations)
- A retrospective subgroup analysis of the MOSAIC studying patients with Stage II colon carcinoma has shown that adding oxaliplatin to a fluoropyrimidine does not convey significant gain in dFS and OS. It seems useful to educate patients with high risk Stage II colon carcinoma about the possible advantages of adjuvant chemotherapy and the concomitant side effects. (Section: literature review, module 2b, used for weak recommendation)]
- Treatment of centrally-located tumours is still under debate, given its high toxicity (Conclusions, module 3a, used for <u>weak</u> recommendation)

3 4	1 Box 4: Examples of CPG panels' va	lues or preferences reflected in the CPG modules	
5 6 7 8 9	CPG statement on which the interpretation of the panel's preference is based.	Description of the identified CPG panel's preference	Concerning what type of recommendation
9 10 11 12	If breast-conserving surgery is not feasible or desirable, there is an indication for mastectomy. (Section: Literature review, module 1)	The panel appears to prefer breast-sparing surgery to mastectomy; mastectomy is considered only when breast-sparing surgery is not feasible or desirable.	2 weak
13 14 15 16 17 18 19 20 21 22 23	DCIS is often discovered based on calcifications on the mammogram that, when biopsied, turn out to be associated with this DCIS. DCIS does not metastasize, and patients with DCIS hence have an excellent prognosis with adequate local treatment. (Section: Introduction, module 1)	The panel prefers local treatment and therefore has a more positive attitude about radiotherapy and a less positive attitude about endocrine therapy for DCIS from the outset. (Supplemental note: no survival benefit has been demonstrated for either radiotherapy or endocrine therapy. It is, however, suspected that a subgroup of the radiotherapy group does indeed have improved survival. Radiotherapy also has an effect on the risk reduction of an invasive recurrence, which appears to be more limited with endocrine therapy. This could be a reason for the more positive attitude toward radiotherapy compared to endocrine therapy)	1 strong
24 25 26 27 28	The risk of radiation pneumonitis seems to be acceptable (Section: Conclusions, module 5)	The panel finds the risk of radiation pneumonitis acceptable. In the literature, this risk is only represented in chance words: the risk is "very low" and "generally low". The reader is shown neither the absolute risk or patient preferences relevant to this trade-off.	1 strong and 1 weak
29 30 31 32 33 34 35 36 37	Radiotherapy hence appears to be effective, considering that without adjuvant radiotherapy the risk of recurrence is expected to be higher and the chance of cure to be lower. (Section: Literature review, module 6)	In case of positive surgical margins, there is a strong recommendation in favour of adjuvant radiotherapy, arising from the assumption that the benefits outweigh the disadvantages. The phrase "appears to be effective" is used, but the guideline does not state the absolute survival gain and does not address side effects, short term or long term. Furthermore, we do not know if patients differ in how they weigh these considerations.	1 strong
38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	2345		

1 Box 5: Examples of phrasings about the patient role

Statements that propose to inform the patient:

- 1. Additional surgical resection after endoscopic removal of a malignant polyp should always be a considered decision, given the relatively high 'number needed to treat', in which the patient must be fully informed about the possible oncological benefit on the one hand and the risk of complications on the other. (Section: Recommendations, module 3)
- 2. It appears worthwhile to inform patients with a high-risk stage II colorectal carcinoma about the possible advantages of adjuvant chemotherapy and the associated side-effects. (Section: Literature review, module 4)

Statements that propose to include the patient's preferences in making the decision:

- 1. Side-effects and effectiveness of both endocrine therapy and radiotherapy should be weighed together with the patient. (Section: Recommendations, module 1)
- **2.** For high-risk malignant colon polyps, the oncological benefit of additional colon resection should always be weighed against the risk of morbidity and even mortality. Age, tumour location, comorbidity, and the patient's preference should be included in this trade-off. (Section: Considerations, module 3)

Localisation	Module	Publication date	Approach	Number of options discussed in recommendations	Strengtl	n of recon	nmendatio	ıs		Role and specialty of interviewees ^{\$}
					In favou	r	Neutral	Against		
		$\mathbf{\wedge}$			Strong	Weak		Weak	strong	
Breast cancer	DCIS	Unpublished concept (27 th February 2017)	GRADE	5	1	0	3	0	1	Surgeon (N=2) Radiotherapist (N=2)
	Endocrine therapy	Unpublished concept (27 th March 2017)	GRADE	11	4	7	0	0	0	None
										IKNL Supervisor (N=1)* Patien representative (N=1)
Colorectal cancer	T1 carcinoma in polyp	16 th April 2014 (version 3)	Evidence-based	3	1	2	0	0	0	Surgeon (N=1) Gastroenterologist (N=1)
	Adjuvant chemotherapy	16 th April 2014 (version 3)	Evidence-based	6	4	2	0	0	0	Oncologist (N=1)
										IKNL Supervisor (N=1)* Patient representative (N=1)
Resectable non- small cell lung cancer	Stereotactic radiotherapy	16 th April 2014 (version 3)	Evidence-based (2011) and Consensus-based (2013)	3	1	1	0	1	0	Radiotherapist (N=3)**
	(Neo) adjuvant radiotherapy	16 th April 2014 (version 3)	Evidence-based (2011) and Consensus-based (2013)	4	1	2	0	0	1	Radiotherapist (N=1)**
										IKNL Supervisor (N=1)

N=3	N=6	N=32	N=12	N=14	N=3	N=1	N=2	IKNL Supervisors N=2; Patient representatives N=2; Radiotherapists N=5; Surgeor N=3; Oncologists N=1; Gastroenterologist N=1
	rlands Comprehensive Cancer O	-						
		ncer and the colorectal carcinoma guidelines about two modules of the NSCLC CPG.						
	otherupist was interviewed one	about two modules of the NSCLC CPG.						

Table 2. Quantitative overview of the results of the CPG analysis

		Strengt	h of recommend	dation
		Strong N (%)	Weak or neutral N (%)	Total N (%)
		14 (44)	18 (56)	32
Trade-offs mentioned	Yes	7 (50)	11 (61)	18 (56)
	No	7 (50)	7 (39)	14 (44)
Patient preferences assessed	Yes	0	0	0
CPG panel's preferences mentioned	Yes, explicitly	0	0	0
	Yes, implicitly	10 (71)	7 (39)	17 (53)
	No	4 (29)	11 (61)	15 (47)
Statements about patient involvement included	Yes, to actively involve the patient	6 (43)	12 (67)	18 (56)
	Yes, to inform the patient	0	2 (11)	2 (6)
	No	8 (57)	4 (22)	12 (38)

REFERENCES

1. O'Connor AM, Legare F, Stacey D. Risk communication in practice: the contribution of decision aids. BMJ. 2003;327(7417):736-40.

2. Burstein HJ, Lacchetti C, Griggs JJ. Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression Summary. Journal of Oncology Practice. 2016;12(4):390-3.

3. Early Breast Cancer Trialists' Collaborative G, Peto R, Davies C, Godwin J, Gray R, Pan HC, et al. Comparisons between different polychemotherapy regimens for early breast cancer: metaanalyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379(9814):432-44.

4. Whelan T, Sawka C, Levine M, Gafni A, Reyno L, Willan A, et al. Helping patients make informed choices: a randomized trial of a decision aid for adjuvant chemotherapy in lymph node-negative breast cancer. J Natl Cancer Inst. 2003;95(8):581-7.

5. Shue J, Karia RJ, Cardone D, Samuels J, Shah M, Slover JD. A Randomized Controlled Trial of Two Distinct Shared Decision-Making Aids for Hip and Knee Osteoarthritis in an Ethnically Diverse Patient Population. Value Health. 2016;19(4):487-93.

6. Stacey D, Hawker G, Dervin G, Tugwell P, Boland L, Pomey M-P, et al. Decision aid for patients considering total knee arthroplasty with preference report for surgeons: a pilot randomized controlled trial. BMC Musculoskeletal Disorders. 2014;15(1):54.

7. Stacey D, Taljaard M, Dervin G, Tugwell P, O'Connor AM, Pomey MP, et al. Impact of patient decision aids on appropriate and timely access to hip or knee arthroplasty for osteoarthritis: a randomized controlled trial. Osteoarthritis Cartilage. 2016;24(1):99-107.

8. Hamelinck VC, Bastiaannet E, Pieterse AH, Jannink I, van de Velde CJ, Liefers GJ, et al. Patients' preferences for surgical and adjuvant systemic treatment in early breast cancer: a systematic review. Cancer Treat Rev. 2014;40(8):1005-18.

9. Pieterse AH, Stiggelbout AM, Baas-Thijssen MC, van de Velde CJ, Marijnen CA. Benefit from preoperative radiotherapy in rectal cancer treatment: disease-free patients' and oncologists' preferences. Br J Cancer. 2007;97(6):717-24.

10. Couet N, Desroches S, Robitaille H, Vaillancourt H, Leblanc A, Turcotte S, et al. Assessments of the extent to which health-care providers involve patients in decision making: a systematic review of studies using the OPTION instrument. Health Expect. 2015;18(4):542-61.

11. Snijders HS, Kunneman M, Bonsing BA, de Vries AC, Tollenaar RA, Pieterse AH, et al. Preoperative risk information and patient involvement in surgical treatment for rectal and sigmoid cancer. Colorectal Dis. 2014;16(2):O43-9.

12. Kunneman M, Branda ME, Hargraves I, Pieterse AH, Montori VM. Fostering Choice Awareness for Shared Decision Making: A Secondary Analysis of Video-Recorded Clinical Encounters. Mayo Clin Proc Innov Qual Outcomes. 2018;2(1):60-8.

13. Kunneman M, Engelhardt EG, Ten Hove FL, Marijnen CA, Portielje JE, Smets EM, et al. Deciding about (neo-)adjuvant rectal and breast cancer treatment: Missed opportunities for shared decision making. Acta Oncol. 2016;55(2):134-9.

14. Kunneman M, Marijnen CA, Rozema T, Ceha HM, Grootenboers DA, Neelis KJ, et al. Decision consultations on preoperative radiotherapy for rectal cancer: large variation in benefits and harms that are addressed. Br J Cancer. 2015;112(1):39-43.

15. Engelhardt EG, Pieterse AH, van der Hout A, de Haes HJ, Kroep JR, Quarles van Ufford-Mannesse P, et al. Use of implicit persuasion in decision making about adjuvant cancer treatment: A potential barrier to shared decision making. Eur J Cancer. 2016;66:55-66.

16. Kunneman M, Stiggelbout AM, Marijnen CA, Pieterse AH. Probabilities of benefit and harms of preoperative radiotherapy for rectal cancer: What do radiation oncologists tell and what do patients understand? Patient Educ Couns. 2015;98(9):1092-8.

Page 23 of 27

BMJ Open

17. Kunneman M, Marijnen CA, Baas-Thijssen MC, van der Linden YM, Rozema T, Muller K, et al. Considering patient values and treatment preferences enhances patient involvement in rectal cancer treatment decision making. Radiother Oncol. 2015;117(2):338-42.

18. Pieterse AH, Kunneman M, Engelhardt EG, Brouwer NJ, Kroep JR, Marijnen CAM, et al. Oncologist, patient, and companion questions during pretreatment consultations about adjuvant cancer treatment: a shared decision-making perspective. Psychooncology. 2017;26(7):943-50.

19. Chong CA, Chen IJ, Naglie G, Krahn MD. How well do guidelines incorporate evidence on patient preferences? J Gen Intern Med. 2009;24(8):977-82.

20. McCormack JP, Loewen P. Adding "value" to clinical practice guidelines. Can Fam Physician. 2007;53(8):1326-7.

21. de Kort SJ, Burgers JS, Willems DL. Value judgements that matter to patients remain implicit in oncology guidelines: an observational study. Neth J Med. 2009;67(2):62-8.

22. Krahn M, Naglie G. The next step in guideline development: incorporating patient preferences. JAMA. 2008;300(4):436-8.

23. McCartney M, Treadwell J, Maskrey N, Lehman R. Making evidence based medicine work for individual patients. BMJ. 2016;353:i2452.

24. Montori VM, Brito JP, Murad MH. The optimal practice of evidence-based medicine: incorporating patient preferences in practice guidelines. JAMA. 2013;310(23):2503-4.

25. Shaneyfelt TM, Centor RM. Reassessment of clinical practice guidelines: go gently into that good night. JAMA. 2009;301(8):868-9.

26. Alonso-Coello P, Oxman AD, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines. BMJ. 2016;353:i2089.

27. Alonso-Coello P, Schunemann HJ, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction. BMJ. 2016;353:i2016.

28. Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, et al. GRADE guidelines:
14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol. 2013;66(7):719-25.

29. Andrews JC, Schunemann HJ, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, et al. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength. J Clin Epidemiol. 2013;66(7):726-35.

30. Stiggelbout AM, Van der Weijden T, De Wit MP, Frosch D, Legare F, Montori VM, et al. Shared decision making: really putting patients at the centre of healthcare. BMJ. 2012;344:e256.

31. Zhang Y, Coello PA, Brozek J, Wiercioch W, Etxeandia-Ikobaltzeta I, Akl EA, et al. Using patient values and preferences to inform the importance of health outcomes in practice guideline development following the GRADE approach. Health Qual Life Outcomes. 2017;15(1):52.

32. Gale NK, Heath G, Cameron E, Rashid S, Redwood S. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. BMC Med Res Methodol. 2013;13:117.

33. Pope C, Ziebland S, Mays N. Qualitative research in health care. Analysing qualitative data. BMJ. 2000;320(7227):114-6.

34. Friese S. Atlas.ti 7 User manual. Berlin: Atlas.ti Scientific Software Development; 2012.

35. Alexander PE, Li SA, Gionfriddo MR, Stoltzfus RJ, Neumann I, Brito JP, et al. Senior GRADE methodologists encounter challenges as part of WHO guideline development panels: an inductive content analysis. J Clin Epidemiol. 2016;70:123-8.

36. Casarett D. The Science of Choosing Wisely--Overcoming the Therapeutic Illusion. N Engl J Med. 2016;374(13):1203-5.

37. Engelhardt EG, Pieterse AH, Han PK, van Duijn-Bakker N, Cluitmans F, Maartense E, et al. Disclosing the Uncertainty Associated with Prognostic Estimates in Breast Cancer. Med Decis Making. 2017;37(3):179-92.

38. Christie B. Catherine Calderwood: champion of "realistic medicine". BMJ. 2016;355:i5455. 39. Ioannidis JPA. Hijacked evidence-based medicine: stay the course and throw the pirates overboard. J Clin Epidemiol. 2017;84:11-3.

40. Coulter A. The global reach of shared decision making 2017 [Available from: https://blogs.bmj.com/bmj/2017/07/13/angela-coulter-the-global-reach-of-shared-decisionmaking/.

41. van der Weijden T, Pieterse AH, Koelewijn-van Loon MS, Knaapen L, Legare F, Boivin A, et al. How can clinical practice guidelines be adapted to facilitate shared decision making? A qualitative key-informant study. BMJ Qual Saf. 2013;22(10):855-63.

42. Alexander P.E. GMR, Li S.A., Bero L., Stoltzfus R.J., Neumann I., Brito J.P., Djulbegovic B., Montori V.M., Norris S.L., Schünemann H.J., Thabane L., Guyatt G.H. A number of factors explain why WHO guideline developers make strong recommendations inconsistent with GRADE guidance. J Clin Epidemiol. 2016;70:111-22.

stro W, Brozek S, frameworks fo. S: GRADE-ADOLOP. Schunemann HJ, Wiercioch W, Brozek J, Etxeandia-Ikobaltzeta I, Mustafa RA, Manja V, et al. 43. GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT. J Clin Epidemiol. 2017;81:101-10.

Standards for Reporting Qualitative Research (SRQR)*

http://www.equator-network.org/reporting-guidelines/srqr/

Page/line no(s).

Title and abstract

Title - Concise description of the nature and topic of the study Identifying the study as qualitative or indicating the approach (e.g., ethnography, grounded	
theory) or data collection methods (e.g., interview, focus group) is recommended	Page 1
Abstract - Summary of key elements of the study using the abstract format of the intended publication; typically includes background, purpose, methods, results,	
and conclusions	Page 2

Introduction

tro	oduction	
	Problem formulation - Description and significance of the problem/phenomenon studied; review of relevant theory and empirical work; problem statement	Page 4
	Purpose or research question - Purpose of the study and specific objectives or questions	Page 4, lines 39- 43

Methods

	Page 4, lines 2
Qualitative approach and research paradigm - Qualitative approach (e.g.,	37
ethnography, grounded theory, case study, phenomenology, narrative research)	Page 5, lines 4
and guiding theory if appropriate; identifying the research paradigm (e.g.,	14
postpositivist, constructivist/ interpretivist) is also recommended; rationale**	Page 7, line 27
Researcher characteristics and reflexivity - Researchers' characteristics that may	
influence the research, including personal attributes, qualifications/experience,	
relationship with participants, assumptions, and/or presuppositions; potential or	
actual interaction between researchers' characteristics and the research	Page 6, lines 3
questions, approach, methods, results, and/or transferability	37
	Page 5, lines 1
Context - Setting/site and salient contextual factors; rationale**	20
Sampling strategy - How and why research participants, documents, or events	Page 5, lines 2
were selected; criteria for deciding when no further sampling was necessary (e.g.,	34
sampling saturation); rationale**	Page 7, lines 5
Ethical issues pertaining to human subjects - Documentation of approval by an	
appropriate ethics review board and participant consent, or explanation for lack	Page 7, lines 8
thereof; other confidentiality and data security issues	10
Data collection methods - Types of data collected; details of data collection	Page 5, line 39
procedures including (as appropriate) start and stop dates of data collection and	page 6, line 31
analysis, iterative process, triangulation of sources/methods, and modification of	Page 7, lines 1
procedures in response to evolving study findings; rationale**	24

Page 5, lines 37; Page 6. Lines 33-

Page 7, lines 22-

Page 5, lines 24-

Page 7, line 45-

Page 7, line 27-

Page 6, line 41 Page 7, line 33-

Page 7, lines 13-

Pages 7, Ine 44--page 11, line 18 Idem (including Boxes and

Page 11, line 22

– page 13, line 6 Page 12, lines

Page 3, lines 12-

Page 3, lines 8-

29-44

14

11

Tables)

page 8, line 4

41

24

25

36

44

17

1 2 3 4 5	Data collection instruments and technologies - Description of instruments (e.g., interview guides, questionnaires) and devices (e.g., audio recorders) used for data collection; if/how the instrument(s) changed over the course of the study
6 7 8 9	Units of study - Number and relevant characteristics of participants, documents, or events included in the study; level of participation (could be reported in results)
10 11 12 13	Data processing - Methods for processing data prior to and during analysis, including transcription, data entry, data management and security, verification of data integrity, data coding, and anonymization/de-identification of excerpts
14 15 16 17	Data analysis - Process by which inferences, themes, etc., were identified and developed, including the researchers involved in data analysis; usually references a specific paradigm or approach; rationale**
18 19 20 21	Techniques to enhance trustworthiness - Techniques to enhance trustworthiness and credibility of data analysis (e.g., member checking, audit trail, triangulation); rationale**
22 23 Res	ults/findings
24 25 26 27	Synthesis and interpretation - Main findings (e.g., interpretations, inferences, and themes); might include development of a theory or model, or integration with prior research or theory
28 29 30	Links to empirical data - Evidence (e.g., quotes, field notes, text excerpts, photographs) to substantiate analytic findings
31	
	cussion
32	Integration with prior work, implications, transferability, and contribution(s) to the field - Short summary of main findings; explanation of how findings and conclusions connect to, support, elaborate on, or challenge conclusions of earlier scholarship; discussion of scope of application/generalizability; identification of unique contribution(s) to scholarship in a discipline or field
32 33 Disc 34 35 36 37 38 39 40 41	Integration with prior work, implications, transferability, and contribution(s) to the field - Short summary of main findings; explanation of how findings and conclusions connect to, support, elaborate on, or challenge conclusions of earlier scholarship; discussion of scope of application/generalizability; identification of
32 33 Disc 34 35 36 37 38 39 40 41 42 43	Integration with prior work, implications, transferability, and contribution(s) to the field - Short summary of main findings; explanation of how findings and conclusions connect to, support, elaborate on, or challenge conclusions of earlier scholarship; discussion of scope of application/generalizability; identification of unique contribution(s) to scholarship in a discipline or field Limitations - Trustworthiness and limitations of findings
32 33 Disc 34 35 36 37 38 39 40 41 42 43	Integration with prior work, implications, transferability, and contribution(s) to the field - Short summary of main findings; explanation of how findings and conclusions connect to, support, elaborate on, or challenge conclusions of earlier scholarship; discussion of scope of application/generalizability; identification of unique contribution(s) to scholarship in a discipline or field Limitations - Trustworthiness and limitations of findings er Conflicts of interest - Potential sources of influence or perceived influence on
32 33 Disc 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49	Integration with prior work, implications, transferability, and contribution(s) to the field - Short summary of main findings; explanation of how findings and conclusions connect to, support, elaborate on, or challenge conclusions of earlier scholarship; discussion of scope of application/generalizability; identification of unique contribution(s) to scholarship in a discipline or field Limitations - Trustworthiness and limitations of findings
32 33 Disc 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48	Integration with prior work, implications, transferability, and contribution(s) to the field - Short summary of main findings; explanation of how findings and conclusions connect to, support, elaborate on, or challenge conclusions of earlier scholarship; discussion of scope of application/generalizability; identification of unique contribution(s) to scholarship in a discipline or field Limitations - Trustworthiness and limitations of findings er Conflicts of interest - Potential sources of influence or perceived influence on study conduct and conclusions; how these were managed Funding - Sources of funding and other support; role of funders in data collection,
32 33 Disc 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50	Integration with prior work, implications, transferability, and contribution(s) to the field - Short summary of main findings; explanation of how findings and conclusions connect to, support, elaborate on, or challenge conclusions of earlier scholarship; discussion of scope of application/generalizability; identification of unique contribution(s) to scholarship in a discipline or field Limitations - Trustworthiness and limitations of findings er Conflicts of interest - Potential sources of influence or perceived influence on study conduct and conclusions; how these were managed Funding - Sources of funding and other support; role of funders in data collection,

Reference:

DOI: 10.1097/ACM.00000000000388

**The rationale should briefly discuss the justification for choosing that theory, approach,

method, or technique rather than other options available, the assumptions and limitations

transferability. As appropriate, the rationale for several items might be discussed together.

O'Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative

research: a synthesis of recommendations. Academic Medicine, Vol. 89, No. 9 / Sept 2014

implicit in those choices, and how those choices influence study conclusions and

BMJ Open

The role of patient preferences in clinical practice guidelines: a multiple methods study using guidelines from oncology as a case

Journal:	BMJ Open
Manuscript ID	bmjopen-2019-032483.R2
Article Type:	Original research
Date Submitted by the Author:	05-Nov-2019
Complete List of Authors:	Gärtner , Fania; Leiden University Medical Center Portielje, Johanneke; Leiden University Medical Center, Clinical Oncology Langendam, Miranda; Academic Medical Center, Clinical Epidemiology, Biostatistics and Bioinformatics Hairwassers, Desiree; Breast Cancer Association the Netherlands Agoritsas, Thomas; University Hospitals of Geneva, Division of General Internal Medicine & Division of Clinical Epidemiology; McMaster University Faculty of Health Sciences, Department of Health Research Methods, Evidence, and Impact Gijsen, Brigitte; Netherlands Comprehensive Cancer Organisation Liefers, Gerrit-Jan; Leids Universitair Medisch Centrum, Surgery; Leids Universitair Medisch Centrum, Pieterse, A.H. ; Leids Universitair Medisch Centrum, Medical Decision Making Stiggelbout, Anne; Leiden University Medical Center
Primary Subject Heading :	Health services research
Secondary Subject Heading:	Communication, Ethics, Evidence based practice, Oncology, Qualitative research
Keywords:	Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, shared decision making, evidence-based medicine, GRADE, patient preferences, choice awareness

SCHOLARONE[™] Manuscripts

1 2		
3	1	The role of patient preferences in clinical practice guidelines: a multiple
4 5	2	methods study using guidelines from oncology as a case
6	2	methous study using guidennes nom oncology as a case
7 8	4	F Gärtner (1) (<u>https://orcid.org/0000-0002-0351-0204</u>), J Portielje (2) (<u>https://orcid.org/0000-0002-</u>
8 9	5	<u>5169-6306</u>), M Langendam (3) (<u>https://orcid.org/0000-0001-9038-3209</u>), D Hairwassers (4), T
10	6	Agoritsas (5,6) (<u>https://orcid.org/0000-0002-6182-9969</u>), B Gijsen (7) (<u>https://orcid.org/0000-0003-</u>
11	7	<u>4578-0293</u>), GJ Liefers (8) (<u>https://orcid.org/0000-0001-7326-8313</u>), AH Pieterse (1)
12 13	8	(https://orcid.org/0000-0001-6395-0052), AM Stiggelbout (1) (https://orcid.org/0000-0002-6293-
14	9	4509)
15	10	
16 17	11	1. Medical Decision Making, Department of Biomedical Data Sciences, Leiden University
18	12	Medical Center, Leiden, The Netherlands
19	13	2. Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands
20 21	14	3. Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam UMC,
22	15	Amsterdam, The Netherlands
23	16	4. Breast Cancer Association The Netherlands (Borstkankervereniging Nederland), The
24 25	17	Netherlands
26	18	5. Division General Internal Medicine, University Hospitals of Geneva, Geneva, Switzerland
27	19	6. Department of Health Research Methods, Evidence, and Impact, McMaster University,
28 29	20	Hamilton, L8S 4K1, Canada
30	21	7. The Netherlands Comprehensive Cancer Organisation (IKNL), Maastricht/Utrecht, The
31	22	Netherlands
32	23	8. Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands
33 34	24	
35	25	Word count: 4797
36	26	
37 38	27	Keywords: EBM, Clinical Practice Guidelines, Shared Decision Making, patient preferences, patient-
39	28	centred care, choice awareness
40	29	
41 42	30	
43	31	Corresponding author:
44 45	32	Corresponding author: AM Stiggelbout, A.M.Stiggelbout@lumc.nl
45 46		
47		
48 49		
49 50		
51		
52 53		
55 54		
55		
56 57		
57 58		
59		
60		
Î		

ABSTRACT (299 words) Objectives: Many treatment decisions are preference-sensitive, and call for shared decision-making, notably when benefits are limited or uncertain, and harms impact quality of life. We explored if clinical practice guidelines (CPGs) acknowledge preference-sensitive decisions in how they motivate and phrase their recommendations. Design: We performed a qualitative analysis of the content of CPGs, and verified the results in semi-structured interviews with CPG panel members. Setting: Dutch oncology CPGs issued in 2010 or later, concerning primary treatment with curative intent. Participants: 14 CPG panel members. Main outcomes: For treatment recommendations from six CPG modules, two researchers extracted: strength of recommendation in terms of GRADE and its consistency with the CPG text; completeness of presentation of benefits and harms; incorporation of patient preferences; statements on the panel's benefits-harm tradeoff underlying recommendation; advice on patient involvement in decision-making. Results: We identified 32 recommendations, 18 were acknowledged preference-sensitive decisions. Three of 14 strong recommendations should have been weak based on the module text. The reporting of benefits and harms, and their probabilities, was sufficiently complete and clear to inform the strength of the recommendation in one of the six modules only. Numerical probabilities were seldom presented. None of the modules presented information on patient preferences. CPG panel's preferences were not made explicit, but appeared to have impacted 15 of 32 recommendations. Advice to involve patients and their preferences in decision-making was given for 20 recommendations (14 weak). Interviewees confirmed these findings. Explanations for lack of information were e.g. that clinicians know the information and that CPGs must be short. Explanations for trade-offs made were cultural-historical preferences, compliance with daily care, presumed role of CPGs, and lack of time. Conclusions: The motivation and phrasing of CPG recommendations do not stimulate choice awareness and a neutral presentation of options, thus hindering shared decision making.

2		
3	1	SUMMARY BOX
4	-	
5	C	Character and limitations of this study
6	2	Strengths and limitations of this study
7		
8	3	• Strength of the study is that we used GRADE for the qualitative analysis of the guidelines, as
9	4	weak recommendations in GRADE reflect preference-sensitive decisions.
10		
11	5	• Strength of the study is the validation of the qualitative analysis of the guidelines in in-depth
12	6	interviews with the guideline developers.
13	7	• Limitation of the study is that we studied oncology guidelines from one country only .
14	8	
15	0	
16	_	
17	9	FUNDING
18		
19	10	This work was supported by the Dutch Cancer Society grant number UL 2015-7615. The funding
20	11	agreement ensured the authors' independence in designing the study, interpreting the data, writing,
21	12	and publishing the report.
22	14	and publishing the report.
23	10	
24	13	COMPETING INTERESTS
25		
26	14	TA and ML are active members of the GRADE working group. BG is employed at The Netherlands
27	15	Comprehensive Cancer Organisation (IKNL), the organization responsible for development of the
28	16	CPGs that were analyzed. e data, writing, and publishing the report.
29		
30	17	DATA SHARING
31	17	
32	10	
33	18	Anonymized transcripts of the interviews and extraction forms (in Dutch) may be shared upon
34	19	reasonable request to the corresponding author.
35		
36	20	
37		
38		
39		
40		
41		
42		
43		
44		
45		
46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		
60		

1 1. INTRODUCTION

Many decisions in healthcare are preference-sensitive, in particular when treatments are burdensome, benefits are limited or uncertain, and harms may impact quality of life.(1) Examples are decisions about adjuvant treatment in oncology (2-4) or about hip or knee arthroplasty for osteoarthritis.(5-7) Research shows that patients as well as clinicians often vary considerably in their evaluation of the balance of benefits and harms. Further, clinicians are not always able to predict their individual patients' preferences for treatments or outcomes of treatment.(8, 9) Shared decision making (SDM) is therefore advocated particularly in preference-sensitive decisions, but is not yet common practice.(10, 11) Clinicians are not prone to fostering choice awareness in their patients, (12, 13) often present treatment options in unbalanced ways, e.g., by overestimating benefits and minimizing harms, (14) or steer in other ways, consciously or unconsciously. (15) Further, numerical probabilities needed to make a trade-off are seldom discussed, (16) and patient preferences infrequently elicited.(17, 18) This raises the question if clinicians perceive these decisions as preference-sensitive? Clinical practice guidelines (CPGs) could play a role in this perception, given the impact they have on what treatment options clinicians present to their patients. While CPGs may use wording that suggests that a decision is preference-sensitive, such as "we suggest" or "clinicians might", rather than "we recommend" or "clinicians should", clinicians may still not fully appreciate the importance of offering more than one option to their patients. It is unknown if recommendations in current CPGs identify preference-sensitive decisions and demand a role for patient preferences in decision making. Two older studies showed that the relevance of preferences of individual patients was not acknowledged in many CPGs.(19, 20) CPG developers often assume "generally accepted" values in developing recommendations, but do not acknowledge this in the phrasing of the recommendation.(21) A request for a more systematic incorporation of patient preferences in CPGs has been expressed repeatedly in high impact journals since the publications of these studies.(22-25) The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) working group -whose approach is nowadays considered the standard in CPG development- has published a framework that acknowledges the integration of patients' values and preferences in the development of CPG recommendations.(26-31) In the GRADE approach, preference-sensitive decisions are reflected in so-called "weak", or "conditional" recommendations. These arise when benefits and harms are closely balanced, evidence is lacking or of uncertain quality, when patients' preferences are expected to vary substantially, but also when no evidence on patient preferences is available, even with moderate or strong evidence of high quality on the benefits of an option. (28) In such situations, GRADE still leads to weak recommendations, assuming that most informed patients would choose the recommended treatment, but a substantial number would not(28, 29, 31) (see Box 1 for a summary of the role that GRADE proposes for patient values and preferences in CPG development).

Box 1: The GRADE approach and GRADE's proposed role of patient values and preferences in CPG recommendation development

GRADE offers an approach to rate the certainty in the evidence and strength of recommendations, in which strong and weak (also known as conditional) recommendations are distinguished. Consideration of patient preferences is a crucial step in deciding on the strength of the recommendation. According to the GRADE approach, first, the best estimates of effect for the interventions and the certainty in this evidence (quality of the evidence) is assessed, using up-to-date systematic reviews. Further, the CPG panel should consider a number of criteria that influence the strength of recommendations, such as variability or uncertainty in how patients value the main outcomes (both benefits and harms), the balance between benefits and harms, and considerations of resource use, health equity, feasibility and acceptability (from both stakeholder and patient perspective) of an intervention. (26-30) Based on an overall assessment across these criteria, CPG panels reach a conclusion about the direction of their recommendation (for or against the intervention) and the strength of their recommendation: strong or weak. (26) A high level of certainty across the criteria (such as high quality evidence, clear balance between benefits and harms, no uncertainty in patient preferences) allows for strong recommendations. A high level of uncertainty, i.e., preference-sensitive decisions, leads to weak recommendations: there is more than one single best option available, there is important uncertainty or variability in patient preferences, or the benefits and harms are closely balanced. Tension has been shown to occur between adherence to GRADE and the wish to make a strong recommendation out of conviction that a treatment is beneficial, despite the evidence quality or certainty being (very) low.(32)

To guarantee the acknowledgement of patient preferences in the development of recommendations, the GRADE strategy asks to clearly present i) how substantial benefits and harms are, what their balance is, and what the overall certainty of the evidence on these outcomes is, and ii) if there is uncertainty about or variability in how much patients value the important outcomes.(26, 27, 33) In other papers GRADE recommends guideline developers to make transparent and explicit statements iii) about the (variability in) patient values and preferences, as well as CPG panel assumptions of these values and preferences on which decisions on the strength of recommendations are based, in order to be able to judge the applicability of recommendations for decision making with the individual patient.(28, 29)

Therefore, a key ingredient for the identification of preference-sensitive decisions is the acknowledgment of values and preferences in the rationale for CPG recommendations. The aim of our study was therefore to explore to what extent CPGs acknowledge preference-sensitive decisions in the way they support and phrase their recommendations. We further wished to assess if the CPGs facilitate the communication of the preference-sensitive nature of these decisions to patients.

1		
2 3	1	
4	1	
5	2	2. METHODS
6 7	3	We performed a qualitative analysis of Dutch oncologic CPGs, which we next verified and refined in
8	4	semi-structured interviews with members of CPG development panels.
9	5	
10	6	2.4. Overlite time and win of CDCs
11 12	7	2.1 Qualitative analysis of CPGs
13	8	2.1.1 Selected CPG modules
14	9 10	We used Dutch oncologic CPGs as a case, because oncology is strongly guideline-driven, decisions
15 16	10	are often preference-sensitive, the guideline development process is organized nationally, and the
17	11	CPGs are open access. The Netherlands Comprehensive Cancer Organisation (IKNL) develops
18	12	guidelines "under responsibility of the most relevant professional or scientific society, usually
19 20	13	following evidence-based methodology" (<u>www.oncoline.nl</u>). We selected three tumour-specific
20	14 15	CPGs, and of each we selected all content of two modules to include in our analysis (i.e., the sections
22		of the CPGs that address specific treatments or patient groups). We selected a convenience sample
23	16 17	of modules for prevalent cancers that we expected to contain at least one preference-sensitive
24 25	17	decision, calling for a weak recommendation. This expectation was based on earlier research from
26	18 19	our group (e.g., (11, 13, 15)), views from the oncology experts on our research team, and/or on the
27	19 20	availability of literature on SDM and decision aids for the treatment in that module. Each of the
28 29	20 21	modules included more than one recommendation.
29 30	21 22	Further criteria for selection of the CPGs and the modules were: published on <u>www.oncoline.nl</u> ,
31	22	issued in 2010 or later, and concerning primary treatment with curative intent. Table 1 presents the
32		CPGs and modules we selected. For the breast cancer CPG, our contact person at the IKNL provided
33 34	24 25	us confidentially with the most recent revision of the two selected modules, which were not yet
35	23 26	published at the time of our analysis. In none of the modules explicit reference was made to GRADE.
36	20 27	2.1.2 Data autraction and analysis
37 38	27	2.1.2 Data extraction and analysis
39	28 29	We assessed if the CPG acknowledges preference-sensitive decisions, and whether the user is to understand the strength of a recommendation, based on the information presented. To this aim we
40	29 30	developed a coding scheme that consisted of the five following themes, based on the GRADE
41	30	framework ((28)).
42 43	51	
44	32	
45	33	<u>1. Strength of recommendations:</u> First, we scored the strength of the recommendation (strongly in
46 47	34	favour/ weakly in favour/ neutral / weakly against/ strongly against a specific option) for each
48	35	treatment option described in the Recommendation section of the CPG. Scoring was solely based on
49	36	the phrasing used in that section The categories strong and weak that we used are in line with
50 51	37	GRADE. We added the 'neutral' category if a weak recommendation for more than one option was
52	38	given.
53	39	
54	40	Next, we assessed whether this strength of recommendation was supported by information
55 56	41	elsewhere in the guideline, including information about the certainty of the evidence, the balance
57	42	between benefits and harms and their probabilities, the variability or uncertainty in how patients
58	43	value the benefits and harms, or the absence of evidence on patient preferences, even with
59 60	44	moderate or strong evidence of high quality on the benefits of an option. If other criteria were
00		

1		
2 3	1	
4	1	provided, we coded these as well. We extracted all information that indicated a discrepancy with the
5	2	strength of recommendation, and scored whether or not textual discrepancies were identified
6	3	(yes/no). We based this on the CPG text, and did not resort to the supporting literature.
7 8	4	
9	5	<u>2. Balance of benefits and harms (trade-offs)</u> : We defined a trade-off as a statement presenting the
10	6	balance of benefits and harms in the treatment decision, ideally based on the probability of benefits
11	7	and harms, the quality of the evidence, and on how much patients value the outcomes. We
12	8	extracted statements about the trade-offs made in the CPG or about the trade-offs to be made in
13 14	9	the clinical encounter with the individual patient (trade-offs made explicit/trade-offs not made
15	10	explicit). We also judged whether the presentation of outcomes was sufficiently complete and clear
16	11	to inform the trade-off (<i>sufficient/insufficient</i>).
17	12	
18 19	13	<u>3. Patient preferences:</u> We assessed if patient preferences had been incorporated (yes/no), and if so,
20	14	how (<i>literature search/data collection by CPG panel/other</i>). Also, we extracted whether explicit
21	15	assumptions were made regarding patient preferences (<i>yes/no</i>).
22	16	ussumptions were made regulating patient preferences (yes/no).
23	17	4. CPG panel's values and preferences: We extracted information about the preferences that
24 25	18	
26		supported the CPG panel's weighing of benefits and harms, and summarized per treatment
27	19 20	recommendation if these preferences were explicitly mentioned (<i>yes/no</i>). This theme does not
28	20	directly originate from the GRADE recommendations. We added it as we encountered statements
29 30	21	suggesting that CPG panel's values and preferences had influenced the development of
31	22	recommendations. <u>Finally, we</u> assessed if the CPGs facilitated discussion of patient preferences for
32	23	weak recommendations, as for the latter "clinicians and other health care providers need to devote
33	24	more time to the process of shared decision making by which they ensure that the informed choice
34	25	reflects individual values".((28))
35 36	26	
37	27	5. Advice on how to involve the patient: We extracted statements that described how to involve an
38	28	individual patient or his/her preferences in the decision making process, and summarized per
39	29	recommendation if such statement was given (yes, actively involving the patient or patient
40 41	30	preferences in the decision making/yes, informing the patient/no advice about patient involvement).
42	31	
43	32	Two coders (FG and AS) independently applied a first draft of the coding scheme to a CPG module
44	33	that would not be included in the final selection. They subsequently discussed the coding process
45	34	and any inconsistencies, and updated the coding scheme. They had not been involved in the
46 47	35	development of any CPG in oncology nor GRADE, and had no existing working relationship with the
48	36	members of the respective CPG panels. The coders independently applied the coding scheme to one
49		
50	37	of the selected modules, and resolved any discrepancies by consensus. Based on this discussion no
51 52	38	further changes were made to the scheme. One researcher (FG) then coded the remaining modules,
52 53	39	and the second checked the extraction and scoring. They discussed any inconsistency between them
54	40	until agreement was reached. Data extracted was analysed descriptively.
55	41	
56	42	
57 58	43	2.2 Semi-structured interviews with CPG developers
58 59	44	2.2.1 Sampling
60		

We or our IKNL contact person invited all panel members involved in the development of the selected modules for participation. Membership and size of the different CPG panels varied, not all were multidisciplinary, and not all included a patient representative. We aimed to interview at least one member of each specialty involved in the development of a module, the patient representative, and the IKNL supervisor of the CPG.. As patient representatives did not participate in this study based on a paid position, the respective patient organizations received an incentive of 100 Euros. The study protocol did not require review from a medical ethics committee as no patients or lay people were recruited. 2.2.2 Data collection In semi-structured interviews, we first checked whether the interviewee agreed with our interpretation of the strength of recommendations, our extraction of the discrepancies found in the CPG text, of the trade-offs, and the completeness and clarity of the presentation of the benefits and harms, of the role of patient preferences, and of the preferences of the CPG panels that supported the recommendations. For the benefits, harms, and trade-offs we asked them how the developers selected which ones to present, and whether the presentation of benefits and harms aimed to facilitate communication in the clinical encounter. Finally, we discussed the function of statements concerning the involvement of patients and their preferences in decision making for the individual patient. We adapted the questions to the specific content of the module to be discussed. For each subsequent interview we added or adapted questions based on earlier interviews. Interviews lasted 30 to 60 minutes, were audiotaped, and transcribed verbatim. One interviewer (FG) trained in qualitative research methods and highly experienced in interviewing carried out all interviews. 2.2.3 Coding and analysis We adhered to the Framework Approach to code and analyse the interviews. (34, 35) The coding scheme was based on the five themes of the CPG analysis described above. First, two researchers (FG and AS) independently familiarized themselves with the data, and coded three interviews deductively, to supplement our coding scheme with any additional emerging themes. Dissimilarities in coding were discussed and codes were adapted based on consensus. Second, one researcher applied deductive coding to all other interviews and refined, and reduced the codes in a process of re-reading and constant comparison of codes. Third, categories of codes were clustered to generate (sub)themes. Steps two and three were performed by one researcher and checked by the second. Inconsistencies in interpretation of the data and formulation of codes and themes were discussed until consensus was reached. Coding was performed using Atlas.ti software.(36) 2.3 Patient involvement The CPG committee involved patient representatives for two modules, and we interviewed these patients. One patient (DH) took part in the writing of the manuscript. The article will be shared with the Netherlands Federation of Cancer Patient Societies NFK. **3. RESULTS** We present the results of the qualitative analysis and the interviews together, structured around the five themes mentioned above. We interviewed 14 CPG panel members: 10 clinicians, two patient representatives, and two IKNL supervisors (Table 1). For one module (adjuvant endocrine therapy in

Page 9 of 27

BMJ Open

1			
2			
3	1	breast cancer), only one of the clinician panel members indicated to have time to participate. After	
4 5	2	an interruption due to a clinical urgency she did not want to resume the interview because she	
6	3	found the questions too critical. Therefore only the IKNL supervisor and the patient panel member	
7	4	were interviewed. Patients were not part of the CPG panel for the NSCLC modules. To illustrate our	
8	5	analyses we add examples of the extractions of the CPG modules in Box 2-5.	
9 10	6		
10	7	3.1 Strength of CPG recommendations	
12	8	In the six modules we identified 32 recommendations, of which 14 were phrased as strong and 18 as	
13	9	weak or neutral. The proportion of weak or neutral recommendations was just over half for all	
14 15	10	modules, except for that on adjuvant chemotherapy for colorectal carcinoma, which had fewer weak	
16	11	recommendations (33%). For five of the recommendations, both strong (three) and weak (one) or	
17	12	neutral (one), we found discrepancies between the strength of recommendation and extracted	
18 19	13	sentences from the module text. Box 2 shows examples of such discrepancies. In two of the strong	
20	14	recommendations, the discrepancy concerned evidence that was limited or of (very) low quality.	
21	15		
22	16	Box 2. Examples of textual discrepancies between strength of recommendation and statements in	
23 24	17	other parts of the CPG module	
25	18		
26			
27 28			
20		1. Strongly phrased recommendation for adjuvant radiotherapy after lumpectomy in DCIS	
30		patients, combined with a statement about the relevance of patient involvement in the decision:	
31		Recommendation	
32 33		"After complete excision of DCIS, radiotherapy of the whole chest wall (with or without boost) is recommended." (Section: Recommendations, module 1)	
34		Statement about patient involvement	
35		"Individual risk assessment and good deliberation with the informed patient determine whether	
36 37		radiotherapy is applied, with or without boost." (Section: Recommendations, module 1)	
37			
39		2. Strongly-phrased recommendation for adjuvant chemotherapy for patients with an MSI colon	
40		carcinoma, combined with a statement about very low-quality evidence.	
41 42		<u>Recommendation</u> <i>"It is recommended that patients with an MSI carcinoma are offered only fluoropyrimidine-</i>	
43		oxaliplatin-based chemotherapy." (Section: Recommendations, module 4)	
44		Statement about the evidence	
45		"The limited evidence concerning the value of oxaliplatin-based chemotherapy in this group shows	
46 47		no difference compared to patients with MSS tumours, so for patients with stage III MSI tumours,	
48		oxaliplatin-based chemotherapy remains recommended for now." (Section: Literature review,	
49		module 4)	
50 51			
52			
53	19		
54 55	20	The CPG panel members confirmed our interpretation of the strength of recommendations. They	
56	21	explained that the three strong recommendations in the case of limited evidence were based on a	
57	22	valuation of the outcomes by the CPG panel (see further under 3.4). One explanation for the	
58	23	discrepancies between the strength of recommendation and the extracted were the differences in	
59 60	24	the handling of low quality evidence between methodologists and clinicians. One clinician described	

1				
2				
3	1	methodologists as being more careful in drawing conclusions, while clinicians incorporate current		
4 5	2	standards of practice in the formulation of recommendations.		
6	3			
7	4	Panel member : I think that it is inherent to making recommendations, where		
8	5	clinicians and methodologists clash. I am currently preparing the revision of the		
9	6	guideline, and what one sees is that we simply clash immediately with the		
10	7	methodologists in the preparation of the revision. Those are very dogmatic in their		
11	8	methodologic thinking. And the problem is, that that does not work, particularly not		
12	9	for the medical literature, so to say. And that is why the GRADE methodology		
13 14	10	explicitly discusses that in their approach, that one can upgrade the recommendation		
14	11	if one agrees as professional group that something should or should not be done.		
16	12	(Interview 10 ,about T1 carcinoma in polyp)		
17	12	(interview 10; about 11 carcinoma in polyp)		
18	13	2.2 Information comparison the holence of hereofite and hermo		
19		3.2 Information supporting the balance of benefits and harms		
20	15	Three of the modules (T1 carcinoma in polyp and adjuvant chemotherapy in colorectal cancer,		
21	16	stereotactic radiotherapy in NSCLC) included explicit trade-off statements (see Box 3). Probabilities		
22	17	of outcomes were mentioned in one of these, but for the benefits only. One trade-off statement		
23 24	18	substantiating a strong recommendation included the presentation of a value judgment, but it was		
25	19	unclear whose values it presented "it is agreed upon that it is safe," and "the risk of radiation		
26	20	pneumonitis seems acceptable".		
27				
28	21	For one of the six modules, adjuvant chemotherapy for colorectal cancer, we rated the report of		
29	22	benefits and harms and their probabilities as sufficiently complete and clear to inform the strength		
30	23	of recommendation. In three modules information was lacking about benefits, in four about harms,		
31	24	and harms were often only presented generically (e.g., "complications", "psychological impact").		
32 33	25	Relative rather than absolute risk reduction was often presented, verbal labels rather than numbers		
34	26	were used to convey risk, e.g., "The chance of eventually preserving the breast is higher if radiation		
35	27	of the breast already takes place after the first excision".		
36		of the breast already takes place after the first excision .		
37	28			
38				
39				
40 41				
41				
43				
44				
45				
46				
47				
48				
49 50				
51				
52				
53				
54				
55				
56				
57				
58				

Box 3: Extracted trade-off statements

Trade-off statement for a strong recommendation:

• It is generally agreed upon that a dose of 45–60 Gy in 3 fractions is safe and can achieve good (> 80%) local tumour control. The risk of radiation pneumonitis appears to be acceptable. However, long-term data on the late toxicity of SBRT is lacking, especially for T2 tumours. Evidence pertaining to quality of life is likewise sparse. (Conclusions, module 3a)

Trade-off statements for weak recommendations:

- Additional surgical resection after endoscopic removal of a malignant polyp should always be a balanced decision because of the relative high number needed to treat, for which the patient should always be fully informed about the potential oncologic benefit on the one hand and the risk of complications on the other (Recommendations, module 2a, used for <u>weak</u> recommendations)
- In various case-series, the incidence of local lymph node metastases in T1 colorectal carcinoma varies from 8 to 14 %. ^{654 1082 1259} There is also a large chance that surgical (segmental) resection of the colon has no therapeutic benefits, while being associated with morbidity and even mortality. Hence, it is important to make a well-considered choice for the treatment of malignant polyps." (Section: Literature review, module 2a)
- For high risk malignant colon polyps the oncologic benefit of additional resection should be balanced against the risk of morbidity and possibly even mortality. In this trade-off the age, tumor location, comorbidity of the patient, and the preference of the patient should be taken into account. All patients should be discussed in the multidisciplinary team. (Section: Considerations, module 2a, used for <u>weak</u> recommendations)
- A retrospective subgroup analysis of the MOSAIC studying patients with Stage II colon carcinoma has shown that adding oxaliplatin to a fluoropyrimidine does not convey significant gain in dFS and OS. It seems useful to educate patients with high risk Stage II colon carcinoma about the possible advantages of adjuvant chemotherapy and the concomitant side effects. (Section: literature review, module 2b, used for weak recommendation)]
- *Treatment of centrally-located tumours is still under debate, given its high toxicity* (Conclusions, module 3a, used for <u>weak</u> recommendation)

Some interviewees found that transparency about the trade-offs in the CPG text could be improved, while others found an explicit mention, including details about benefits and harms and their probabilities, unnecessary. Reasons for the latter were time constraints, the aim to keep the CPG short, the assumption that CPG-users know the balance of benefits and harms, or that the weighting of benefits and harms was acceptable to everyone. One interviewee, e.g., stated that not recommending endocrine treatment in DCIS was "common knowledge" and that "we also could have chosen to just leave out the whole paragraph about this adjuvant therapy, to just not mention it at all." (Interview 15) The interviewees indicated that in none of the modules patients had been involved in the selection of the outcomes described. Some acknowledged that outcomes might be missing, but a substantial number did not regard a complete presentation of outcomes and their probabilities as necessary, using the following arguments: guidelines should be short, harms are assumed to be common knowledge for clinicians or might be presented in other modules, evidence for long-term harms is lacking, and probabilities from the literature are not applicable to the Dutch setting or would only be representative at the hospital level, not at that of the individual clinician (i.e., for mortality due to surgery). Several interviewees were especially reticent to present probabilities in terms of absolute risk reduction, as those percentages would soon be dated, differed between patient groups, or would be too time-consuming to calculate. One stated to have argued to include Numbers Needed to Treat in the CPG, to no avail. Interviewer: and for what reason is the other side of the coin not mentioned in the CPG? You indicated, already, that actually... **Panel-member:** the CPG is mostly written to, what we provide as recommendation towards the patient, for the outcome of treatment. I don't know if the CPG is written at least, I have never interpreted it as such, but I don't know if one should put in the CPG, let's say, what's it called, all risks of treatment. That differs per agent, have different risks. And then the CPG becomes much more extensive. But that is also the baseline knowledge that every oncologist should have. (Interview 7, about adjuvant chemotherapy for colon carcinoma) 3.3 Patient preferences None of the modules stated that evidence about patient preferences had been searched for or elicited. No information was presented about generic patient preferences, or about variation in patient preferences, either from the literature or assumed by the panel. Some interviewees acknowledged that patient preferences may vary and may differ from clinician preferences, and they stressed that the awareness of such variation sometimes motivated a weak recommendation. Reasons not to include information about patient preferences were: time and capacity constraints, the assumption that no evidence exists, or lack of awareness that this information is to be included. Others were reluctant to include information about preference variation, because it could threaten the relationship between specialties (if this information would lead to patients choosing against the generally accepted treatment modality). Numerous assumptions about patient preferences were voiced, such as that patients prefer lumpectomy to mastectomy, length of life to quality of life, and active treatment to refraining from treatment. Interviewees also stressed that if patients have a strong preference, they will express it anyway.

d rence to /32 s and dules Concerning what type of recommendation 2 weak		
rence to /32 s and dules Concerning what type of recommendation 2 weak		
/32 s and dules Concerning what type of recommendation 2 weak		
s and dules Concerning what type of recommendation 2 weak		
dules Concerning what type of recommendation 2 weak		
Concerning what type of recommendation 2 weak		
Concerning what type of recommendation 2 weak		
Concerning what type of recommendation 2 weak		
Concerning what type of recommendation 2 weak		
type of recommendation 2 weak		
recommendation 2 weak		
Istrong		
lstrong		
1 strong		
strong		
attitude about endocrine therapy for DCIS from the outset. (Supplemental note: no survival benefit has been		
1 strong and 1 weak		
strong and 1 weak		
1 strong		

³ 1 As described under 3.1, the interviewees sometimes expl	ained discrepancies between the strength	
4 of recommendation and the extracted information by the	of recommendation and the extracted information by the CPG panel's valuation of the outcomes.	
J	Explanations for the panel members' preferences beyond the evidence were: compliance with daily	
	practice; the organisation of care; culture (a preference for radiotherapy seemed more culturally	
8 5 and historically determined than evidence-based); and co	and historically determined than evidence-based); and concerns about keeping a good relationship	
$\frac{9}{10}$ 6 between specialties when their treatments compete.		
	Some interviewees found that CPG panels' preferences underlying the weighing of benefits and	
12	harms should be made explicit. One interviewee stated that having an external party critically	
13 0 reviewing the CPCs before publication would foster this	reviewing the CPGs before publication would foster this. The panel members often expressed their	
	antial part of the patient population.	
19 13 Panel member: That is watertight, radiotherapy does		
2014far from it, but for some. And we cannot sufficiently s2115give radiation to all.	select for whom it does, so we say,	
21 15 give radiation to un. 22 16 (Interview 4, about radiotherapy for DCIS patients)		
$\frac{1}{23}$ $\frac{1}{17}$		
²⁴ 18 Their motivation was mostly a strong belief in survival ga	in for a subgroup that cannot be identified	
23		
	benefits and harms, such that a recommendation for active treatment would not be a weak one.	
20	This was argued e.g. for treatment aimed at reducing local recurrence rates without concomitant	
29 29 20 22 29		
50	survival gain. Concerning this example, an interviewee argued in one instance that it was preferable	
	simply to not include survival as an outcome, as no survival gain was possible given the already high	
 32 24 survival (Interview 2, about radiotherapy for DCIS). 33 25 		
34 23		
35 26 Panel member: but I find it a bit of a bromide		
	radiotherapy for DCIS yields no survival benefit and therefore we shouldn't do it. Because	
	one cannot improve upon 99 % survival benefit. The important thing is, in which sub-	
	groups those recurrences occur that might not be such nice recurrences, that call for a lot more treatment and the like	
40 31 (Interview 2, about radiotherapy for DCIS patients)		
41 32		
42 22 444 44 44 44 44 44 44 44 44 44 44	eatment and pointed out that the paradigm	
 43 33 At the same time, others voiced opinions against over-tree 44 34 in favour of over-treatment to avoid under-treatment is s 		
45 35 by population screening (DCIS, T1 carcinoma in polyp).	sinting, particularly in patients diagnosed	
46 26		
T/	_	
 48 37 3.5 Advice about patient involvement in decision-makin 49 38 Five modules included in total 20 statements about the n 	-	
50		
39 Relatively more statements (1/1) were seen for the weak	than for the strong (b) recommendations	
51 7		
52 40 All statements recommended to include the patient's pre	ferences in making the decision except for	
All statements recommended to include the patient's pre two, relating to weak recommendations, that recommend	ferences in making the decision except for ded to inform the patient about the trade-	
 All statements recommended to include the patient's pre 40 All statements recommended to include the patient's pre 53 41 two, relating to weak recommendations, that recommended 54 42 off. One of the three CPGs included a separate chapter al 	ferences in making the decision except for ded to inform the patient about the trade- bout decision-making, in which it was	
All statements recommended to include the patient's pre two, relating to weak recommendations, that recommen off. One of the three CPGs included a separate chapter al recommended to elicit the preferences of the patient in a	ferences in making the decision except for ded to inform the patient about the trade- bout decision-making, in which it was	
All statements recommended to include the patient's pre two, relating to weak recommendations, that recommend off. One of the three CPGs included a separate chapter al recommended to elicit the preferences of the patient in a 44	ferences in making the decision except for ded to inform the patient about the trade- bout decision-making, in which it was	
All statements recommended to include the patient's pre two, relating to weak recommendations, that recommen off. One of the three CPGs included a separate chapter al recommended to elicit the preferences of the patient in a	ferences in making the decision except for ded to inform the patient about the trade- bout decision-making, in which it was an SDM process.	

- 1 representative asked for it. Others mentioned that the inclusion was based on the opinion of
 - 2 individual panel members.

Box 5: Examples of phrasings about the patient role

Statements that propose to inform the patient:

- 1. Additional surgical resection after endoscopic removal of a malignant polyp should always be a considered decision, given the relatively high 'number needed to treat', in which the patient must be fully informed about the possible oncological benefit on the one hand and the risk of complications on the other. (Section: Recommendations, module 3)
- 2. It appears worthwhile to inform patients with a high-risk stage II colorectal carcinoma about the possible advantages of adjuvant chemotherapy and the associated side-effects. (Section: Literature review, module 4)

Statements that propose to include the patient's preferences in making the decision:

- 1. Side-effects and effectiveness of both endocrine therapy and radiotherapy should be weighed together with the patient. (Section: Recommendations, module 1)
- **2.** For high-risk malignant colon polyps, the oncological benefit of additional colon resection should always be weighed against the risk of morbidity and even mortality. Age, tumour location, comorbidity, and the patient's preference should be included in this trade-off. (Section: Considerations, module 3)

8 4. DISCUSSION

Healthcare is increasingly guideline-driven, which promotes quality of care and reduces unwarranted practice variation. But guidelines may be a barrier to SDM if they do not acknowledge the preference-sensitive nature of many treatment decisions.(1, 30) The aim of this study was to explore to what extent CPGs acknowledge preference-sensitive decisions in their recommendations. Our analysis showed that the guidelines involved incomplete and unclear presentation of benefits, harms, and the probabilities thereof. This makes it difficult for the users to judge the appropriateness of the strength of the recommendation. Further, it may hinder patient engagement in decision-making, which requires that patients are fully informed about the trade-offs. Moreover, patients may be directly accessing the guidelines, and inclusion of this information makes guidelines also more useful to them. Whether or not clinicians have complete knowledge about all benefits and harms and their probabilities is questionable, and from an earlier study we know that at least many clinicians do not share this information with their patients during the decision making process.(14, 15) Complete and clear presentation in CPGs of the benefits and harms help to fill knowledge gaps in CPG users, and acknowledge the importance of the information for the trade-offs to be made with the individual patient in preference-sensitive decisions.

Furthermore, information on patient preferences or the variation therein, was not included in any of the six modules analysed. If GRADE were to be followed, this lack of evidence on patient preferences should have led to more weak recommendations than seen. Additionally, we found indications that panel members' assumptions about patient preferences as well as their own preferences, determined the recommendations. This corroborates findings of De Kort et al. (21) on the role of value judgements in guideline formulation in palliative oncology. They found that preferences, such as those for intervening and prolonging life, were not mentioned in the guidelines but had played an important role in determining final recommendations. In line with a study by Alexander et al. (37), it appeared that panel members find it difficult to refrain from providing a clear recommendation in a case of limited or conflicting evidence. CPG panel preferences for active treatment had influenced the way the panel had balanced benefits and harms, such that a recommendation for active treatment would be strong and overtreatment likely. The strong belief in survival gain for a subgroup that cannot be identified as of yet fosters the so-called therapeutic illusion, in which both physicians and patients overestimate the benefits of treatment, since patients are seemingly cured by treatment while they might have had the same outcome without treatment.(38) Rather than routinely resort to active treatment in these instances, the discussion should be opened on how to deal with such uncertainties. Little research is available yet on how best to communicate uncertainty, (39) but this does not relieve us from the obligation to discuss matters honestly with patients. Such openness would contribute to reducing unnecessary treatment, addressing unacceptable variation, and delivering more appropriate, personalised care.(40) Guidelines can facilitate this discussion by acknowledging preference-sensitive decisions, and encouraging users to become more aware of choice and presenting multiple options to patients.

A limitation of the format of GRADE, is that it asks for a dichotomous categorization (weak vs. strong) and a recommendation either for or against. This categorization makes it difficult to explicitly state that multiple options are medically reasonable. Furthermore, information on patient preferences should be more often sought in guideline development. Oncologist experts are invited in guideline panels because of their content expertise, but this involves a risk when more evidence is available for benefits than for harms, and when there is no evidence on patient preferences. Then chances increase that that panel members resort to their own preferences, often favouring active treatment and neglecting harms.(41) The guideline development process, while aiming at achieving EBM, may threaten it by its reliance on expert judgment at the expense of involving patient preferences. GRADE publications accede that panels' judgements of patient preferences often rely on their interactions with patients, but how well such judgements correspond to typical values and preferences is uncertain.

We do not know to what extent our analysis will hold for CPGs from other countries than the Netherlands. Dutch healthcare is likely less paternalistic than that in many other countries, and the Netherlands are leading in the implementation of SDM(42). We therefore expect more discrepancies between evidence and recommendations to arise elsewhere. De Kort et al., (21) analysed a sample of evidence-based oncology guidelines from other countries, and found that recommendations were rarely explained and value judgements were not made explicit either. Further, we do not know if, but have no reason to expect that our findings will be different for other specialties. We urge researchers in other countries and other fields to evaluate their guidelines with preference-sensitivity in mind as well.

BMJ Open

An analysis like the one performed runs the risk of subjectivity, as the data extraction and coding requires interpretation. We therefore checked our results with the developers of the guidelines we studied. This provided a validation of our analysis. The aim of this endeavour was to highlight an issue that is a major barrier to patient-centred care and SDM in particular.(43) With the strong current call for patient involvement, worldwide, it is important to establish to what extent guidelines potentially hinder such involvement, and our study may be seen as a first step in that direction.

))

In sum, our analysis points to a lack of transparency in the CPG development process about benefits and harms and their probabilities, the preferences of the guideline panel members, and their assumptions about patient preferences. Awareness needs to be created among CPG-developers that their judgments of the balance of benefits and harms are value-laden, and that variation exists in these judgments, among both clinicians and patients. Clear instructions and training to enhance knowledge and implementation of GRADE might improve the acknowledgement of preference-sensitive decisions in guidelines and support shared decision making. This will help avoid what McCartney feared in his 2016 Analysis in the BMJ: "there is the danger of guideline recommendations being applied to people who do not place the same values on those recommendations as their clinician (...)".(23)

- 22 ACKNOWLEDGEMENTS
- 23 We thank all interviewees for their participation in this study.
- 25 AUTHORS CONTRIBUTION
- FG, AHP, JP, and AMS designed the study. FG, DH, BG, GJL and AMS were involved in acquisition of
 the data, FG and AMS conducted the data extraction. FG, ML, DH, TA, GJL, AHP, and AMS were
 involved in interpreting the results.
 - FG and AMS wrote the first drafts and final version of the manuscript. JP, ML, DH, TA, BG, GJL, and AHP have read the manuscript critically, made improvements to the content and wording of the work.
 - 32 FG, JP, ML, DH, TA, BG, GJL, AHP, and AMS all agreed to the final version.
 - The corresponding author attests that all listed authors meet authorship criteria and that no others
 meeting the criteria have been omitted.
- 49 37 EXCLUSIVE LICENCE STATEMENT
- The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide licence to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the
- 43 Contribution and convert or allow conversion into any format including without limitation audio, iii)
- 44 create any other derivative work(s) based in whole or part on the on the Contribution, iv) to exploit
- 45 all subsidiary rights to exploit all subsidiary rights that currently exist or as may exist in the future in

2 where-ever it may be located; and, vi) licence any third party to do any or all of the above.3

BMJ Open

Localisation	Module	Publication date	Approach	Number of options discussed in recommendations	Strengtl	h of recor	nmendatio	ns		Role and specialty of interviewees ^s
					In favou	r	Neutral	Against		
		$\mathbf{\wedge}$			Strong	Weak		Weak	strong	
Breast cancer	DCIS	IKNL, unpublished concept (27 th February 2017)	GRADE	5	1	0	3	0	1	Surgeon (N=2) Radiotherapist (N=2)
	Endocrine therapy	IKNL, unpublished concept (27 th March 2017)	GRADE	11	4	7	0	0	0	None
										IKNL Supervisor (N=1)* Patier representative (N=1)
Colorectal cancer	T1 carcinoma in polyp	16 th April 2014 (version 3)	Evidence-based	3	1	2	0	0	0	Surgeon (N=1) Gastroenterologist (N=1)
	Adjuvant chemotherapy	16 th April 2014 (version 3)	Evidence-based	6	4	2	0	0	0	Oncologist (N=1)
					(2				IKNL Supervisor (N=1)* Patient representative (N=1)
Resectable non- small cell lung cancer	Stereotactic radiotherapy	16 th April 2014 (version 3)	Evidence-based (2011) and Consensus-based (2013)	3	1	1	0	1	0	Radiotherapist (N=3)**
	(Neo) adjuvant radiotherapy	16 th April 2014 (version 3)	Evidence-based (2011) and Consensus-based (2013)	4	1	2	0	0	1	Radiotherapist (N=1)**
										IKNL Supervisor (N=1)

N=3	N=6	N=32	N=12	N=14	N=3	N=1	N=2	IKNL Supervisors N=2; Patient representatives N=2; Radiotherapists N=5; Surgeon N=3; Oncologists N=1; Gastroenterologist N=1
	rlands Comprehensive Cancer Orga							
		er and the colorectal carcinoma guidelines						
		but two modules of the NSCLC CPG.						

Table 2. Quantitative overview of the results of the CPG analysis

		Strengt	th of recommen	dation
		Strong N (%)	Weak or neutral N (%)	Total N (%)
		14 (44)	18 (56)	32
Trade-offs mentioned	Yes	7 (50)	11 (61)	18 (56)
	No	7 (50)	7 (39)	14 (44)
Patient preferences assessed	Yes	0	0	0
CPG panel's preferences mentioned	Yes, explicitly	0	0	0
	Yes, implicitly	10 (71)	7 (39)	17 (53)
	No	4 (29)	11 (61)	15 (47)
Statements about patient involvement included	Yes, to actively involve the patient	6 (43)	12 (67)	18 (56)
	Yes, to inform the patient	0	2 (11)	2 (6)
	No	8 (57)	4 (22)	12 (38)

REFERENCES

1. O'Connor AM, Legare F, Stacey D. Risk communication in practice: the contribution of decision aids. BMJ. 2003;327(7417):736-40.

2. Burstein HJ, Lacchetti C, Griggs JJ. Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression Summary. Journal of Oncology Practice. 2016;12(4):390-3.

3. Early Breast Cancer Trialists' Collaborative G, Peto R, Davies C, Godwin J, Gray R, Pan HC, et al. Comparisons between different polychemotherapy regimens for early breast cancer: metaanalyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet. 2012;379(9814):432-44.

4. Whelan T, Sawka C, Levine M, Gafni A, Reyno L, Willan A, et al. Helping patients make informed choices: a randomized trial of a decision aid for adjuvant chemotherapy in lymph node-negative breast cancer. J Natl Cancer Inst. 2003;95(8):581-7.

5. Shue J, Karia RJ, Cardone D, Samuels J, Shah M, Slover JD. A Randomized Controlled Trial of Two Distinct Shared Decision-Making Aids for Hip and Knee Osteoarthritis in an Ethnically Diverse Patient Population. Value Health. 2016;19(4):487-93.

6. Stacey D, Hawker G, Dervin G, Tugwell P, Boland L, Pomey M-P, et al. Decision aid for patients considering total knee arthroplasty with preference report for surgeons: a pilot randomized controlled trial. BMC Musculoskeletal Disorders. 2014;15(1):54.

7. Stacey D, Taljaard M, Dervin G, Tugwell P, O'Connor AM, Pomey MP, et al. Impact of patient decision aids on appropriate and timely access to hip or knee arthroplasty for osteoarthritis: a randomized controlled trial. Osteoarthritis Cartilage. 2016;24(1):99-107.

8. Hamelinck VC, Bastiaannet E, Pieterse AH, Jannink I, van de Velde CJ, Liefers GJ, et al. Patients' preferences for surgical and adjuvant systemic treatment in early breast cancer: a systematic review. Cancer Treat Rev. 2014;40(8):1005-18.

9. Pieterse AH, Stiggelbout AM, Baas-Thijssen MC, van de Velde CJ, Marijnen CA. Benefit from preoperative radiotherapy in rectal cancer treatment: disease-free patients' and oncologists' preferences. Br J Cancer. 2007;97(6):717-24.

10. Couet N, Desroches S, Robitaille H, Vaillancourt H, Leblanc A, Turcotte S, et al. Assessments of the extent to which health-care providers involve patients in decision making: a systematic review of studies using the OPTION instrument. Health Expect. 2015;18(4):542-61.

11. Snijders HS, Kunneman M, Bonsing BA, de Vries AC, Tollenaar RA, Pieterse AH, et al. Preoperative risk information and patient involvement in surgical treatment for rectal and sigmoid cancer. Colorectal Dis. 2014;16(2):O43-9.

12. Kunneman M, Branda ME, Hargraves I, Pieterse AH, Montori VM. Fostering Choice Awareness for Shared Decision Making: A Secondary Analysis of Video-Recorded Clinical Encounters. Mayo Clin Proc Innov Qual Outcomes. 2018;2(1):60-8.

13. Kunneman M, Engelhardt EG, Ten Hove FL, Marijnen CA, Portielje JE, Smets EM, et al. Deciding about (neo-)adjuvant rectal and breast cancer treatment: Missed opportunities for shared decision making. Acta Oncol. 2016;55(2):134-9.

14. Kunneman M, Marijnen CA, Rozema T, Ceha HM, Grootenboers DA, Neelis KJ, et al. Decision consultations on preoperative radiotherapy for rectal cancer: large variation in benefits and harms that are addressed. Br J Cancer. 2015;112(1):39-43.

15. Engelhardt EG, Pieterse AH, van der Hout A, de Haes HJ, Kroep JR, Quarles van Ufford-Mannesse P, et al. Use of implicit persuasion in decision making about adjuvant cancer treatment: A potential barrier to shared decision making. Eur J Cancer. 2016;66:55-66.

16. Kunneman M, Stiggelbout AM, Marijnen CA, Pieterse AH. Probabilities of benefit and harms of preoperative radiotherapy for rectal cancer: What do radiation oncologists tell and what do patients understand? Patient Educ Couns. 2015;98(9):1092-8.

Page 23 of 27

BMJ Open

17. Kunneman M, Marijnen CA, Baas-Thijssen MC, van der Linden YM, Rozema T, Muller K, et al. Considering patient values and treatment preferences enhances patient involvement in rectal cancer treatment decision making. Radiother Oncol. 2015;117(2):338-42.

18. Pieterse AH, Kunneman M, Engelhardt EG, Brouwer NJ, Kroep JR, Marijnen CAM, et al. Oncologist, patient, and companion questions during pretreatment consultations about adjuvant cancer treatment: a shared decision-making perspective. Psychooncology. 2017;26(7):943-50.

19. Chong CA, Chen IJ, Naglie G, Krahn MD. How well do guidelines incorporate evidence on patient preferences? J Gen Intern Med. 2009;24(8):977-82.

20. McCormack JP, Loewen P. Adding "value" to clinical practice guidelines. Can Fam Physician. 2007;53(8):1326-7.

21. de Kort SJ, Burgers JS, Willems DL. Value judgements that matter to patients remain implicit in oncology guidelines: an observational study. Neth J Med. 2009;67(2):62-8.

22. Krahn M, Naglie G. The next step in guideline development: incorporating patient preferences. JAMA. 2008;300(4):436-8.

23. McCartney M, Treadwell J, Maskrey N, Lehman R. Making evidence based medicine work for individual patients. BMJ. 2016;353:i2452.

24. Montori VM, Brito JP, Murad MH. The optimal practice of evidence-based medicine: incorporating patient preferences in practice guidelines. JAMA. 2013;310(23):2503-4.

25. Shaneyfelt TM, Centor RM. Reassessment of clinical practice guidelines: go gently into that good night. JAMA. 2009;301(8):868-9.

26. Alonso-Coello P, Oxman AD, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines. BMJ. 2016;353:i2089.

27. Alonso-Coello P, Schunemann HJ, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction. BMJ. 2016;353:i2016.

28. Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, et al. GRADE guidelines:
14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol. 2013;66(7):719-25.

29. Andrews JC, Schunemann HJ, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, et al. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength. J Clin Epidemiol. 2013;66(7):726-35.

30. Stiggelbout AM, Van der Weijden T, De Wit MP, Frosch D, Legare F, Montori VM, et al. Shared decision making: really putting patients at the centre of healthcare. BMJ. 2012;344:e256.

31. Zhang Y, Coello PA, Brozek J, Wiercioch W, Etxeandia-Ikobaltzeta I, Akl EA, et al. Using patient values and preferences to inform the importance of health outcomes in practice guideline development following the GRADE approach. Health Qual Life Outcomes. 2017;15(1):52.

32. Alexander P.E. GMR, Li S.A., Bero L., Stoltzfus R.J., Neumann I., Brito J.P., Djulbegovic B., Montori V.M., Norris S.L., Schünemann H.J., Thabane L., Guyatt G.H. A number of factors explain why WHO guideline developers make strong recommendations inconsistent with GRADE guidance. J Clin Epidemiol. 2016;70:111-22.

33. Schunemann HJ, Wiercioch W, Brozek J, Etxeandia-Ikobaltzeta I, Mustafa RA, Manja V, et al. GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT. J Clin Epidemiol. 2017;81:101-10.

34. Gale NK, Heath G, Cameron E, Rashid S, Redwood S. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. BMC Med Res Methodol. 2013;13:117.

35. Pope C, Ziebland S, Mays N. Qualitative research in health care. Analysing qualitative data. BMJ. 2000;320(7227):114-6.

36. Friese S. Atlas.ti 7 User manual. Berlin: Atlas.ti Scientific Software Development; 2012.

BMJ Open

37. Alexander PE, Li SA, Gionfriddo MR, Stoltzfus RJ, Neumann I, Brito JP, et al. Senior GRADE methodologists encounter challenges as part of WHO guideline development panels: an inductive content analysis. J Clin Epidemiol. 2016;70:123-8.

38. Casarett D. The Science of Choosing Wisely--Overcoming the Therapeutic Illusion. N Engl J Med. 2016;374(13):1203-5.

39. Engelhardt EG, Pieterse AH, Han PK, van Duijn-Bakker N, Cluitmans F, Maartense E, et al. Disclosing the Uncertainty Associated with Prognostic Estimates in Breast Cancer. Med Decis Making. 2017;37(3):179-92.

40. Christie B. Catherine Calderwood: champion of "realistic medicine". BMJ. 2016;355:i5455.

41. Ioannidis JPA. Hijacked evidence-based medicine: stay the course and throw the pirates overboard. J Clin Epidemiol. 2017;84:11-3.

42. Coulter A. The global reach of shared decision making 2017 [Available from: <u>https://blogs.bmj.com/bmj/2017/07/13/angela-coulter-the-global-reach-of-shared-decision-making/</u>.

43. van der Weijden T, Pieterse AH, Koelewijn-van Loon MS, Knaapen L, Legare F, Boivin A, et al. How can clinical practice guidelines be adapted to facilitate shared decision making? A qualitative key-informant study. BMJ Qual Saf. 2013;22(10):855-63.

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Standards for Reporting Qualitative Research (SRQR)*

http://www.equator-network.org/reporting-guidelines/srqr/

Page/line no(s).

Title and abstract

Title - Concise description of the nature and topic of the study Identifying the study as qualitative or indicating the approach (e.g., ethnography, grounded	
theory) or data collection methods (e.g., interview, focus group) is recommended	Page 1
Abstract - Summary of key elements of the study using the abstract format of the intended publication; typically includes background, purpose, methods, results,	
and conclusions	Page 2

Introduction

tro	oduction	
	Problem formulation - Description and significance of the problem/phenomenon studied; review of relevant theory and empirical work; problem statement	Page 4
	Purpose or research question - Purpose of the study and specific objectives or questions	Page 4, lines 39- 43

Methods

	Page 4, lines 2
Qualitative approach and research paradigm - Qualitative approach (e.g.,	37
ethnography, grounded theory, case study, phenomenology, narrative research)	Page 5, lines 4
and guiding theory if appropriate; identifying the research paradigm (e.g.,	14
postpositivist, constructivist/ interpretivist) is also recommended; rationale**	Page 7, line 27
Researcher characteristics and reflexivity - Researchers' characteristics that may	
influence the research, including personal attributes, qualifications/experience,	
relationship with participants, assumptions, and/or presuppositions; potential or	
actual interaction between researchers' characteristics and the research	Page 6, lines 3
questions, approach, methods, results, and/or transferability	37
	Page 5, lines 1
Context - Setting/site and salient contextual factors; rationale**	20
Sampling strategy - How and why research participants, documents, or events	Page 5, lines 2
were selected; criteria for deciding when no further sampling was necessary (e.g.,	34
sampling saturation); rationale**	Page 7, lines 5
Ethical issues pertaining to human subjects - Documentation of approval by an	
appropriate ethics review board and participant consent, or explanation for lack	Page 7, lines 8
thereof; other confidentiality and data security issues	10
Data collection methods - Types of data collected; details of data collection	Page 5, line 39
procedures including (as appropriate) start and stop dates of data collection and	page 6, line 31
analysis, iterative process, triangulation of sources/methods, and modification of	Page 7, lines 1
procedures in response to evolving study findings; rationale**	24

Page 5, lines 37; Page 6. Lines 33-

Page 7, lines 22-

Page 5, lines 24-

Page 7, line 45-

Page 7, line 27-

Page 6, line 41 Page 7, line 33-

Page 7, lines 13-

Pages 7, Ine 44--page 11, line 18 Idem (including Boxes and

Page 11, line 22

– page 13, line 6 Page 12, lines

Page 3, lines 12-

Page 3, lines 8-

29-44

14

11

Tables)

page 8, line 4

41

24

25

36

44

17

1 2 3 4 5	Data collection instruments and technologies - Description of instruments (e.g., interview guides, questionnaires) and devices (e.g., audio recorders) used for data collection; if/how the instrument(s) changed over the course of the study
6 7 8 9	Units of study - Number and relevant characteristics of participants, documents, or events included in the study; level of participation (could be reported in results)
10 11 12 13	Data processing - Methods for processing data prior to and during analysis, including transcription, data entry, data management and security, verification of data integrity, data coding, and anonymization/de-identification of excerpts
14 15 16 17	Data analysis - Process by which inferences, themes, etc., were identified and developed, including the researchers involved in data analysis; usually references a specific paradigm or approach; rationale**
18 19 20 21	Techniques to enhance trustworthiness - Techniques to enhance trustworthiness and credibility of data analysis (e.g., member checking, audit trail, triangulation); rationale**
22 23 Res	ults/findings
24 25 26 27	Synthesis and interpretation - Main findings (e.g., interpretations, inferences, and themes); might include development of a theory or model, or integration with prior research or theory
28 29 30	Links to empirical data - Evidence (e.g., quotes, field notes, text excerpts, photographs) to substantiate analytic findings
31	
	cussion
32	Integration with prior work, implications, transferability, and contribution(s) to the field - Short summary of main findings; explanation of how findings and conclusions connect to, support, elaborate on, or challenge conclusions of earlier scholarship; discussion of scope of application/generalizability; identification of unique contribution(s) to scholarship in a discipline or field
32 33 Disc 34 35 36 37 38 39 40 41	Integration with prior work, implications, transferability, and contribution(s) to the field - Short summary of main findings; explanation of how findings and conclusions connect to, support, elaborate on, or challenge conclusions of earlier scholarship; discussion of scope of application/generalizability; identification of
32 33 Disc 34 35 36 37 38 39 40 41 42 43	Integration with prior work, implications, transferability, and contribution(s) to the field - Short summary of main findings; explanation of how findings and conclusions connect to, support, elaborate on, or challenge conclusions of earlier scholarship; discussion of scope of application/generalizability; identification of unique contribution(s) to scholarship in a discipline or field Limitations - Trustworthiness and limitations of findings
32 33 Disc 34 35 36 37 38 39 40 41 42 43	Integration with prior work, implications, transferability, and contribution(s) to the field - Short summary of main findings; explanation of how findings and conclusions connect to, support, elaborate on, or challenge conclusions of earlier scholarship; discussion of scope of application/generalizability; identification of unique contribution(s) to scholarship in a discipline or field Limitations - Trustworthiness and limitations of findings er Conflicts of interest - Potential sources of influence or perceived influence on
32 33 Disc 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49	Integration with prior work, implications, transferability, and contribution(s) to the field - Short summary of main findings; explanation of how findings and conclusions connect to, support, elaborate on, or challenge conclusions of earlier scholarship; discussion of scope of application/generalizability; identification of unique contribution(s) to scholarship in a discipline or field Limitations - Trustworthiness and limitations of findings
32 33 Disc 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48	Integration with prior work, implications, transferability, and contribution(s) to the field - Short summary of main findings; explanation of how findings and conclusions connect to, support, elaborate on, or challenge conclusions of earlier scholarship; discussion of scope of application/generalizability; identification of unique contribution(s) to scholarship in a discipline or field Limitations - Trustworthiness and limitations of findings er Conflicts of interest - Potential sources of influence or perceived influence on study conduct and conclusions; how these were managed Funding - Sources of funding and other support; role of funders in data collection,
32 33 Disc 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50	Integration with prior work, implications, transferability, and contribution(s) to the field - Short summary of main findings; explanation of how findings and conclusions connect to, support, elaborate on, or challenge conclusions of earlier scholarship; discussion of scope of application/generalizability; identification of unique contribution(s) to scholarship in a discipline or field Limitations - Trustworthiness and limitations of findings er Conflicts of interest - Potential sources of influence or perceived influence on study conduct and conclusions; how these were managed Funding - Sources of funding and other support; role of funders in data collection,

Reference:

DOI: 10.1097/ACM.00000000000388

**The rationale should briefly discuss the justification for choosing that theory, approach,

method, or technique rather than other options available, the assumptions and limitations

transferability. As appropriate, the rationale for several items might be discussed together.

O'Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative

research: a synthesis of recommendations. Academic Medicine, Vol. 89, No. 9 / Sept 2014

implicit in those choices, and how those choices influence study conclusions and